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Abstract 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and 
the most prevalent form of senile dementia, affecting more than 26 million 
people worldwide. The amyloid-!42 peptide (A!42) has been suggested to play 
a central role in the pathogenesis of AD. Although the primary etiologic 
mechanism of AD is unknown, it has a clear association with age. However, is it 
ageing, the slow erosion of biological function, that is the cause of AD; or is 
ageing merely a measure of how long it takes to accumulate toxic levels of A!? 
To distinguish between age-dependent and age-independent effects on the rate 
and extent of AD pathogenesis, an inducible model of A! toxicity was developed 
in the fruit fly Drosophila melanogaster. This is a model system where 
expression of A! peptides can be induced for the first time, or turned off, at 
different ages.  
 
Induced expression of the human Arctic mutant A!42 peptide in Drosophila 
neural tissue resulted in flies with age-dependent locomotor and 
electrophysiology deficits and shortened lifespan. Conditional expression of 
Arctic A!42 at different ages was then used to show that ageing renders flies 
more vulnerable to A!42 toxicity. The results of this thesis also served to 
highlight the technical drawbacks of the GeneSwitch system and the 
complexities of measuring the effect of ageing interventions such as reduced 
insulin signalling and the drug rapamycin on A! toxicity in Drosophila. 
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1.1 Alzheimer’s disease 
1.1.1 Historical perspective and overview 
In 1901, a German psychiatrist and neuropathologist, Alois Alzheimer (1864-
1915), admitted a 51-year-old woman, Auguste D., to the state asylum in 
Frankfurt. She was suffering from an assortment of strange behavioural 
symptoms including short-term memory loss, language deficits, auditory 
hallucinations, delusions, paranoia and aggression. After her death in 1906, her 
brain was sent for examination to the Munich medical school, where Alzheimer 
had moved in 1903 to work under Emil Kraepelin – one of the foremost German 
psychiatrists of the era. With the aid of a new silver staining method developed 
by Max Bielschowsky 4 years earlier, Alzheimer identified two unique lesions in 
Auguste’s brain: amyloid plaques and neurofibrillary tangles.  
 
On the 3rd November 1906, at the 37th meeting of the Society of Southwest 
German Pyschiatrists in Tubingen, Germany, Alzheimer presented the clinical 
and neuropathological features of Auguste’s case and the following year his talk 
was published. Auguste’s condition remained nameless until Kraeplin, writing in 
the eighth edition (1910) of his Handbook of Psychiatry, coined the term 
‘Alzheimer’s disease’. 
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Figure 1.1. A photograph of Auguste Deter. During her time at the Frankfurt 
state asylum she was often recorded saying, ‘I think I have lost myself’. 
 
In over a 100 years since, Alzheimer’s disease (AD) has become the most 
common cause of senile dementia and 7th leading cause of death (www.alz.org), 
currently affecting more than 26 million people worldwide (Brookmeyer et al. 
2007). It is a progressive, genetically heterogeneous and fatal neurodegenerative 
disorder of uncertain etiology, the risk of which dramatically increases in 
individuals beyond the age of 65. With a rapidly ageing population in the 
developed world and increasing life expectancy in the developing world, the 
social and economic burden of AD is set to explode, with some predicting the 
current prevalence to quadruple by 2050 (see Figure 1.2; Ferri et al. 2005; 
Brookmeyer et al. 2007). 
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Figure 1.2. Prevalence of Alzheimer’s disease as a function projected total 
number of cases over time. Figure taken from Ferri et al. (2005). 
 
The disease is broadly categorised into two subtypes: early onset familial AD 
(FAD) and late-onset sporadic AD (see section 1.1.2). Despite the difference in 
age of onset, familial and sporadic AD is clinically and histologically identical, 
characterised by a progressive, global, cognitive decline, involving memory, 
orientation, judgement and reasoning. Typically, the disease starts with insidious 
memory problems, advancing to the terminal stages 8-10 years later, where there 
is complete memory loss of all life-time events together with deficits in verbal 
and motor control. However, definitive confirmation of the disease requires 
histological examination of post-mortem brain tissue and the presence of both 
extracellular amyloid-! (A!) plaques and intraneuronal neurofibrillary tangles 
(NFTs). The neuropathology of AD is covered in more detail in section 1.1.3.  
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Amyloid-plaques have long represented one of the hallmark features of AD. 
However, it took almost 80 years before A! was purified and identified as the 
primary component of meningovascular (blood vessel) amyloid deposits in AD 
and Down’s syndrome (Glenner & Wong. 1984a; Glenner & Wong. 1984b). A 
year later, the same peptide was recognized as the primary component of senile 
(neuritic) plaques isolated from AD brain tissue (Masters & Simms. 1985). 
Around the same time, the microtubule-associated protein tau was identified as 
the main constituent of the NFTs that accumulate inside many neurons and their 
processes in AD brains (Grundke-Iqbal et al. 1986; Kosik & Joachim. 1986; 
Nukina et al. 1986). 
 
Soon after, the gene encoding APP, of which A! is part, was mapped to 
chromosome 21 (Kang et al. 1987). These seminal discoveries marked the 
beginning of the modern era of AD research, paving the way for the discovery of 
AD causative genes, the development of the paradigmatic amyloid cascade 
hypothesis, which accuses A! as main villain in AD, and the subsequent 
engineering of many different transgenic disease models. Unfortunately, 
although much has been learnt from genetic studies of FAD, the precise 
molecular events underlying the initiation and progression of AD remain unclear, 
particularly for sporadic forms of the disease. As a result, no biological markers 
or specific disease modifying treatments for AD are available and current 
therapies are palliative at best. With ageing representing one of major risk factors 
for AD, understanding the link between the ageing process and AD may hold the 
key to successfully treating the disease. 
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1.1.2 Genetics of Alzheimer’s disease 
Genetically, AD is heterogeneous and complex, displaying no single or simple 
mode of inheritance. Rare, early-onset forms of the disease (FAD) account for 
less than 5% of all cases and typically affect patients in their 4th or 5th decade. 
FAD is caused by the inheritance of autosomal-dominant mutations in one of 
three genes: APP (chromosome 21), which encodes the amyloid precursor 
protein; and PSEN1 (chromosome 1) and PSEN2 (chromosome 14) which 
encode the presenillins 1 and 2, respectively. Notably, all these mutations affect 
APP processing and act to either increase the total amount of A!, increase the 
A!42/A!40 ratio or to increase the propensity for A! to aggregate (Table 1).  
Up-to-date information regarding FAD-causing mutations can be found at the 
Alzheimer’s Disease Mutation Database (www.molgen.ua.ac.be/ADMutations). 
 
Mutations in the APP gene were the first to be identified (Goate et al. 1991) and 
to date 37 unique, missense mutations have been discovered in 89 families 
(www.molgen.ua.ac.be/ADMutations). The effect of each APP mutation depends 
in part on its position in the molecule. Mutations found near the N-terminal site 
(beta-secretase cleavage site) of the A! peptide such as the Swedish mutation, a 
double K670M/N671L substitution (Mullan et al. 1992), can result in increased 
A! production (Citron et al. 1992). Mutations within the A! domain, such as the 
Arctic mutation, a Glu22Gly amino acid substitution, typically increase the 
propensity of A! to aggregate (Nilsberth et al. 2001; Murakami et al. 2002) 
Additionally, mutations found near the C-terminus, such as the London mutation, 
a V717I substitution (Goate et al. 1991), result in increased production of A!42 
relative to A!40 (Suzuki et al. 1994; Tamaoka et al. 1994). 
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APP gene dosage can also have an effect. In Down’s syndrome (trisomy 21) 
patients, who have an extra copy of APP, A!42 levels are significantly higher 
(Tokuda et al. 1997) and invariably lead to AD-like pathology. Moreover, in an 
extremely rare example, five familial cases of AD and congophillic amyloid 
angiopathy (CAA), an amyloid disease where A! is deposited in nervous system 
blood vessels, were recently discovered to be a result of duplication of the APP 
locus (Rovelet-Lecrux et al. 2006). 
 
Mutations in APP only account for 1% of all familial cases (Brouwers et al. 
2008). The majority of familial cases are caused by mutations in the genes 
encoding presenilin-1 (PS1) and presenilin-2 (PS2), the two proteins that provide 
the catalytic core of "-secretase. To date, 182 FAD mutations have been 
identified in PS1 and 13 FAD mutations in PS2 
(www.molgen.ua.ac.be/ADMutations). Mutations in PSEN1 and PSEN2 are 
scattered across the protein but typically result in an increase in the A!42/A!40 
ratio. 
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Table 1. Overview of the various FAD-causing mutations and their effects 
on APP processing and the properties of A!. Figure taken from Brouwers et 
al. (2008). 
 
By contrast, sporadic forms of AD, which account for the majority of cases and 
typically affect patients in their 7th decade, have a multifactorial etiology in 
which a wide range of genetic polymorphisms have been identified as 
predisposing factors. The most robust findings are for the gene encoding 
apolipoprotein E, particularly the "4 allele, which has been shown to increase the 
risk of developing sporadic AD (Corder et al. 1993). Conversely, it has been 
shown that the "2 allele may confer some protection (Corder et al. 1994). 
Although the exact mechanism is unclear, there is evidence that ApoE may alter 
A! levels through modulation of "-secretase activity (Irizarry et al. 2004). Many 
other disease-predisposing genetic polymorphisms have been identified 
including: insulin-degrading enzyme (IDE), which plays a role in the catabolism 
of A!; ubiquillin-1 (UBQLN1), which affects intracellular APP trafficking; 
sortilin-related receptor 1 (SORL1); and #2-macroglobin The exact details of 
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these polymorphisms are beyond the scope of this thesis, but a comprehensive 
review can be found in Brouwers et al. (2008). 
 
As with other age-related diseases (cardiovascular diseases, diabetes, cancer and 
so on) sporadic AD is associated with a host of dietary, behavioural and other 
environmental risk factors. Advancing age is the most prominent, with incidence 
in the general population rising from 6% in those over 65 years to 30% in those 
over 85 years (Ferri et al. 2005). Other studies have linked cerebral 
microvascular pathology, such as reduced blood supply to the brain or disrupted 
microvascular integrity in cortical regions, to the development of sporadic AD 
(for review see Farkas & Luiten. 2001). A low education level (Koepsell et al. 
2007), traumatic brain injury (Van den Huevel et al. 2007), depression (Ownby 
et al. 2006), consumption of high-calorie, high-fat diets and a sedentary lifestyle 
have all been highlighted as potential risk factors (Mattson. 2004).  
 
1.1.3 Neuropathological features of Alzheimer’s disease 
Because memory loss is a symptom with many underlying pathologies, definitive 
diagnosis of AD requires post-mortem examination of the brain. 
Macroscopically, AD is characterized by synaptic degeneration and neuron loss 
in the cerebral cortex (the outermost layer of the brain associated with higher-
order functions) and certain sub-cortical regions. This results in gross cortical 
atrophy, particularly in the frontal, parietal and temporal lobes (Figure 1.3). The 
temporal lobes are the location of the hippocampus and the entorhinal cortex, 
two areas critically important in the formation of new memories. Notably, these 
structures are two of the first to suffer damage during AD. Interestingly, there is 
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relative sparing of occipital, and primary motor and sensory regions. The 
ventricular system, cavities in the brain containing cerebrospinal fluid that 
provide mechanical support to the brain, are also frequently found enlarged.  
 
Mere changes in the anatomical structure of the brain are not sufficient for 
diagnosis, since these features are not specific to AD (Mott & Hulette. 2005). A 
definitive diagnosis requires histopathological examination of brain tissue, which 
must contain a sufficient number of senile plaques and neurofibrillary tangles 
(Figure 1.4). 
 
 
 
Figure 1.3. Atrophy of the brain during Alzheimer’s disease. The image on 
the left represents a normal, healthy brain whereas the image on the right 
represents  typical gross changes to the brain in severe AD (image taken from 
www.nia.nih.gov/Alzheimers/Resources/HighRes.htm).  
 
Senile, or amyloid, plaques are extracellular deposits of fibrillar and amporphous 
aggregates of amyloid-beta peptides (A!) (Glenner & Wong. 1984b; Masters et 
al. 1985) that occur principally in a filamentous form, i.e., as star-shaped masses 
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of A! fibrils rich in !-pleated sheet structure (Selkoe. 2001). Senile plaques are 
complicated and heterogeneous lesions ranging between 10-160#m in diameter 
and may either be ‘cored’, with a dense core of fibrillar A! (Figure 1.4a), or 
diffuse (Figure 1.4b). Cored plaques are typically found in limbic structures and 
the association neocortex (outermost part of frontal cortex) and are often neuritic, 
surrounded by dystrophic neurites (degenerated axons and dendrites) and glial 
(reactive astrocytes and active microglia) cellular elements. Much of the fibrillar 
A! found in neuritic plaques is A!42 (Iwatsubo et al. 1994), the slightly longer 
and more hydrophobic form that is prone to aggregation (Jarret et al. 1993). 
However, A!40 has also been shown to co-localise to a lesser extent with A!42 
in plaques, particularly those of the mature type (Iwatsubo et al. 1994; Iwatsubo 
et al. 1995). 
 
Diffuse plaques, commonly referred to as ‘pre-amyloid deposits’, were first 
identified in the late 1980’s (Joachim et al. 1989; Tagliavini et al. 1988)  
following the sequencing of A! and subsequent development of antibodies 
sensitive to endogenous and synthetic A!. Diffuse plaques demonstrate light, 
amorphous A!-immunoreactivity without a clearly fibrillar, compacted centre 
(Figure 1.4b). They are mainly composed of A!42, rather than a mix of A!40, 
as seen in neuritic plaques, and are associated with little or no neuritic dystrophy. 
They are found in areas typical of neuritic plaques (limbic and association 
cortices) but also in areas not clearly implicated in the symptomatology of AD, 
such as the thalamus and cerebellum (Joachim et al. 1989). These observations 
led to the idea, diffuse plaques may represent immature lesions - the beginnings 
in the formation of neuritic, cored plaques. A! deposits can also be found in 
  28 
blood vessel walls, in the form of congophillic amyloid angiopathy (CAA) 
(Figure 1.4c). 
 
 
 
 
Figure 1.4. Neuropathology of AD. Immunohistochemistry with antibodies to 
A!: senile plaques (a), preamyloid deposits (b), and amyloid angiopathy (c). 
Immunohistochemistry for phosphorylated tau in NFTs (d). Figure taken from 
Minati et al. (2009). 
 
Many neurons of the brain associated with plaque pathology are found to contain 
intraneuronal, non-membrane bound bundles of abnormal fibres. These fibres 
consist of pairs of ~10-nm filaments wound in helices, otherwise known as 
paired helical filaments (PHFs). PHFs are themselves composed of insoluble 
fibrillar aggregates of the microtubule-binding protein tau (Grundke-Iqbal. 1986; 
Kosik et al. 1986; Nukina & Ihara. 1986), which is found to be in a 
hyperphosphorylated state (Hanger et al. 1991). These neurofibrillary tangles 
(NFTs) (Figure 1.4d)  are the other defining feature of AD neuropathology and 
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their accumulation in the brain follows a defined pattern as the severity of the 
disease progresses (Braak and Braak. 1991). Initially, they are confined to the 
entorhinal cortex and hippocampus in what is known as Braak and Braak stages 
I-II, before spreading throughout all neocortical association areas during Braak 
and Braak stages III-IV. 
 
It is still unclear how the neuropathological features of AD relate to each other 
and more importantly, to the emergence of cognitive impairments. Memory 
deficits occurring early in the disease process appear to correlate best with 
synaptic loss, prior to overt neuronal loss (Terry et al. 1991) and possibly to the 
number of NFTs (Arriagada et al. 1992). Interestingly, it has been found that the 
number of plaques in the brain correlates weakly with the degree of dementia 
experienced in life (Terry et al 1991; Arriagada et al. 1992). This is exemplified 
by the fact that healthy, cognitively normal humans can have substantial amounts 
of A! amyloid present at death (Katzman et al. 1988; Delaere et al. 1990). These 
observations have been confirmed in transgenic mouse models of AD, where 
overexpression of FAD-associated mutant APP causes memory and cognitive 
deficits prior to the detection of plaque pathology (Mucke et al. 2000; Oddo et 
al. 2003; Billings et al. 2005; Lesné et al. 2008). Furthermore, studies in 
transgenic mice that overexpress APP have indicated that the accumulation of 
insoluble A! is accompanied by minimal neuron loss (Irizarry et al. 1997a; 
Irizarry et al. 1997b) and that the relationship between plaque load and the 
degree of memory impairment is relatively weak (Holcomb et al. 1999; 
Westerman et al. 2002). Following the development of sensitive A! enzyme 
linked immunoabsorbent assays (ELISA), it was found that the degree of 
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dementia in AD correlates much better with the concentration of soluble A! 
species (Lue et al. 1999; Wang et al. 1999). This observation and further studies 
have led to the suggestion; small soluble, oligomeric assemblies of A! are the 
ultimate cause of synaptic dysfunction and memory impairment in early AD (see 
1.1.5) 
 
1.1.4 The origin of A": APP metabolism 
A! peptides are derived from endoproteolysis of the parental amyloid precursor 
protein (APP). APP is a ubiquitously expressed type I transmembrane protein 
with a large, extracellular, glycosylated N-terminus, a single trans-membrane 
domain and a shorter cytoplasmic C-terminus (Kang et al. 1987). The A! region 
is located at the cell surface (or the lumenal side of the endoplasmic reticulum 
(ER) and Golgi membranes) with part of the peptide embedded in the membrane. 
As a consequence of alternative splicing, several isoforms of APP exist, ranging 
in length between 695 and 770 amino acids (Selkoe. 2001). APP751 and APP770 
are widely expressed in non-neuronal cells and neuronal cells (Selkoe. 2001). 
The APP695 isoform however, is the most abundant in neurons (Tanzi et al. 
1987) and differs by the lack of a Kunitz-type protein inhibitor (KPI) sequence in 
its extracellular domain. Interestingly, the relative expression of each APP 
isoform may be important for the development of AD. It has been reported that 
there is a shift in expression from APP695 to KPI-containing APP isoforms in 
AD and that this shift correlates with higher soluble A! levels (Matsui et al. 
2007). 
 
APP is now known to be a member of a larger gene family, the amyloid 
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precursor-like proteins (APLPs), which includes APLP1 and APLP2 in humans, 
the fly homolog Appl (Rosen et al. 1989) and the worm homolog apl-1 (Daigle 
& Li. 1993). All genes in this family encode type 1 membrane proteins with a 
large extracellular domain and short cytoplasmic region and undergo processing 
similar to APP. Notably, only APP contains the sequence encoding the A! 
domain. The biological function of this family, particularly APP, is unclear. 
There is some confusion as to whether APP functions as a bona fide signalling 
receptor and/or adhesion molecule or whether the physiological function derives 
from the proteolytic fragments generated in its metabolism. Either way, APP has 
been implicated in a variety of important roles ranging from cell adhesion and 
cell movement to synaptic plasticity and insulin and glucose homeostasis 
(Review in Jacobsen & Iverfeldt. 2009). Whatever its exact function, APP 
clearly has a subtle role. APP-deficient mice (APP-/-) are viable and fertile, 
displaying only minor abnormalities such as impaired locomotor function and 
gliosis (Zheng et al. 1995). 
 
APP is subject to cleavage by a group of proteases known as alpha-secretase, 
beta-secretase and gamma secretase. The precise identity of the $-secretase is 
unclear but studies have identified several enzymes belonging to the ADAM (A 
disintegrin and metalloproteinase) family of proteases, including ADAM9 
(Koike et al. 1999), ADAM-10 (Lammich et al. 1999) and tumour necrosis 
factor-alpha converting enzyme (TACE)/ADAM-17 (Buxbaum et al. 1998). It 
has been shown in cell culture that endogenous alpha-secretase activity may be 
composed of several ADAM enzymes (Asai et al. 2003). Beta-secretase has been 
identified as a novel transmembrane aspartyl protease, now termed the beta-site 
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APP cleaving enzyme-1 (BACE1) (Vassar et al. 1999). Since mice deficient in 
BACE-1 do not produce any A! (Luo et al. 2001), BACE-1 is thought to be the 
only in vivo protease with clear beta-secretase activity. Interestingly, these mice 
are healthy, fertile and phenotypically normal (Luo et al. 2001), raising the 
potential of BACE-1 inhibition as a viable therapeutic intervention. Gamma-
secretase has been identified as a multi-protein complex consisting an array of 
proteins including presenillin 1 or 2, nicastrin, Aph-1 and Pen-2. The presenillins 
function within this group to provide the catalytic core of the protein (Wolfe et 
al. 1999). 
 
APP can be processed in two ways (Figure 1.5). In the prevalent, non-
amyloidogenic pathway, which precludes A! generation, APP is first cleaved 
within the A! domain by $-secretase, releasing a large N-terminal ectodomain 
(sAPP$) into the extracellular/lumenal medium. Interestingly, sAPPa has been 
reported to have neurotrophic and neuroprotective properties (Furukawa et al. 
1996; Meziane et al. 1998). Following $-secretase cleavage, the resulting 83-
amino acid C-terminal membrane stub (C83) is then cleaved by "-secretase, 
producing a fragment known as p3. P3 is believed to be benign or even 
neuroprotective (p3 is not found in compact amyloid plaques, reviewed in Dulin 
et al. 2008). 
 
The amyloidogenic pathway involves the sequential cleavage of APP by !- and 
$-secretase at the N and C termini respectively and leads to the release of A! 
peptides. APP is first cleaved by !-secretase, releasing sAPP! into the 
extracellular space, leaving a 99-amino-acid C-terminal stub (C99). Unlike the 
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neuroprotective effects of sAPP$, sAPP! appears to have a proapoptotic 
function. Nikolaev et al. (2009) demonstrated that sAPP! can be further 
processed (by a currently unknown protease) to generate an N-terminal 
derivative that binds to the death receptor DR6, resulting in axonal pruning and 
apoptosis during development. 
 
Following beta-secreatase cleavage, C99 is cleaved within the membrane by $-
secretase. Depending on the exact point of cleavage by $-secretase, three 
principal forms of A!, comprising 38, 40 or 42 amino acids, are produced. The 
relative amount of A!42 formed is particularly noteworthy, because this longer 
form of A! is more hydrophobic and far more prone to oligomerise and form 
amyloid fibrils (Jarret et al. 1993) than the more abundantly produced A!40. 
This is particularly exemplified by the fact A!42 is the predominant isoform 
found in both amyloid and diffuse plaques (Iwatsubo et al. 1994). 
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Figure 1.5. Schematic showing amyloidogenic and non-amyloidogenic 
processing of APP. Figure taken from Laferla et al. (2007). 
For many years A! production was considered a pathological event. It was 
thought cleavage of C99 could only occur following some preexisting membrane 
injury – the idea of cleavage occurring within the plane of the membrane was 
unheard of (Selkoe. 2001). Hence, there was much surprise when it was 
demonstrated that A! production is a normal, physiological event as exemplified 
by the detection of A! in cell culture (cells overexpressing APP) (Haas et al, 
1992) and in the brains and human cerebrospinal fluid (CSF) of healthy humans 
throughout life (Seubert et al. 1992; Shoji et al. 1992; Busciglio & Gabuzda. 
1993). 
 
After APP is synthesized in the endoplasmic reticulum (ER), the mature 
glycosylated form of APP in the trans-Golgi network (TGN) is transported to the 
plasma membrane, where it is rapidly processed – the half-life of APP in cell 
culture is typically 45-60 minutes (Selkoe. 2001). Any unprocessed APP can be 
reinternalised into endosomal compartments through clathrin-coated pits 
(Nordstedt et al. 1993), then either recycled back to the cell surface or 
transported to the endosomal/lysosomal system for degradation (Haass et al. 
1992). Theoretically, APP processing could occur in many cellular 
compartments, giving rise to both secreted and intracellular forms of A! (i.e. 
secreted into vesicle lumens). Although it is widely accepted the vast majority of 
A! is secreted, it is suspected the main source of extracellular A! is APP 
processed from an intracellular location such as the ER, TGN and the 
endosomal/lysosomal system rather than the plasma membrane (where the 
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majority of alpha-secretase cleavage is believed to occur (Parvathy et al. 1999). 
In fact, evidence seems to implicate the endosomal/lysososomal pathway as the 
main source of intracellular A!, because this is where the majority of beta- and 
gamma-secretase cleavage of APP occurs, following re-internalisation of APP 
(Pasternak et al. 2004). Morever, the low pH of endosomal/lysosomal pathways 
is optimal for BACE1 cleavage of APP (Laferla et al. 2007) and it has been 
shown that low pH favours A! aggregation (Carrotta et al. 2005). Also, prior to 
extracellular A! deposition, the intracellular pool of soluble A! rises 
substantially in endosomal-lysosomal compartments (Cataldo et al. 2004; 
Takahashi et al. 2004) and remains substantial even in the heavily plaque-laden 
AD brain (Näslund et al. 2000).  
 
1.1.5 The amyloid cascade hypothesis 
Although the exact etiology of AD remains elusive, the amyloid cascade 
hypothesis remains the best-defined and most studied conceptual framework for 
AD. In essence, the amyloid cascade hypothesis proposes that increased 
production or decreased clearance of A!42 peptides is the primary influence 
driving all forms of AD (Hardy and Selkoe. 2002). The hypothesis outlines a 
linear pathological cascade beginning with an increase in A! production and 
accumulation and the formation of soluble A! oligomers. This culminates in a 
series of downstream pathological events including synaptic injury, 
inflammation, oxidative damage and tau dysfunction that in turn result in 
widespread neuronal dysfunction and cell death (see Figure 1.6) 
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Figure 1.6. The hypothetical sequence of pathogenic events leading to AD 
proposed by the amyloid cascade hypothesis. Figure taken from Hardy and 
Selkoe. (2002). 
 
Support for a causal role for A! in AD is overwhelming. The first major piece of 
evidence came from the localisation of the APP gene to chromosome 21 (Kang et 
al. 1987). Since 1969, it had been known that middle-aged patients with Down’s 
syndrome (trisomy 21), invariably develop AD-like pathology (Olson & Shaw. 
1969) and that the amyloid plaques found in these patients are predominantly 
composed of A! (Glenner & Wong 1984a; Masters et al. 1985). Thus, the 
mapping of APP to chromosome 21 was significant because it hinted that the 
extra copy of APP was to blame for the development of AD-like pathology in 
Down’s. Moreover, Down’s patients have higher total levels of A!, as would be 
expected with an extra copy of the APP gene (Tokuda et al. 1997). This 
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relationship was further strengthened by the detection of a rare case of Down’s 
syndrome in which the distal location of the chromosome 21q breakpoint left the 
patient diploid for the APP gene (Prasher et al. 1998). This individual displayed 
no signs of dementia, and amyloid deposition was essentially absent from the 
brain upon death. Conversely but in a similar vein, five familial cases of AD and 
CAA were recently identified to be exclusively the result of duplication of the 
APP locus (Rovelet-Lecrux et al. 2006). 
 
Perhaps the strongest support for the amyloid cascade hypothesis comes from 
genetic studies, which have demonstrated that all FAD causing mutations in 
APP, PS1 and PS2 (for which there are now over 200) either result in increased 
production of A!, increased production of A!42 relative to A!40, or an increased 
propensity for A!42 to aggregate (for details see 1.1.2.). These genetic data are 
supported by the many mouse models of AD that develop A! plaques and exhibit 
memory deficits (covered in more detail in 1.2.1). These transgenic mouse 
models are typically based on overexpression of FAD mutant APP or PS1 (or 
both). Furthermore, similarly designed models in the fruit fly Drosophila and the 
nematode worm Caenorhabditis elegans have demonstrated that APP and A! 
overexpression result in an age-dependent accumulation of A!, neuronal 
dysfunction and increased mortality (see section 1.2.). 
 
Neurofibrillary tangles represents the other major neuropathological hallmark of 
AD yet mutations in tau, the major constituent of NFTs, do not cause AD but 
instead have been linked to frontotemporal dementia (FTD) with parkinsonism 
(Hutton et al. 1998). Moreover, this neurodegenerative disorder is characterized 
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by severe deposition of tau in NFTs in the brain but no deposition of amyloid. 
Thus, the implication is that even the most severe disruptions to tau metabolism 
– profound NFT formation leading to fatal neurodegeneration – are insufficient 
to induce AD pathology. Consequently, it is argued that the wild-type tau NFT 
pathology see in AD must be a consequence of prior changes in A! metabolism, 
rather than a cause of them (Hardy & Selkoe. 2002). This is further supported by 
studies where injection of synthetic A! into the brains of tau transgenic mice 
(Götz et al. 2001) or the co-expression of mutant APP with mutant tau (Lewis et 
al. 2001; Oddo et al. 2003; Santacruz et al. 2005) accelerates tau 
hyperphosphorylation and leads to tangle formation reminiscent of the other 
hallmark lesion that characterises AD. 
 
1.1.6 Framing A" toxicity: rise of the oligomer 
Despite the overwhelming support for the amyloid cascade hypothesis, the 
pathogenic role of A! remains controversial, with two main issues: (1) the exact 
nature of the toxic A! species and (2) whether A! mediates its effects from an 
intracellular or extracellular location.  Originally, when the hypothesis was first 
proposed in the early 90’s, it was believed extracellular A! in the form of 
amyloid plaques represented the major toxic moiety. This was duly supported by 
studies demonstrating that fibrillar forms of A!, as found in plaques, are toxic to 
neuronal cells in culture (Yankner et al. 1990; Busciglio et al. 1992). 
 
Nevertheless, the pathogenic role of A! plaques has been questioned because of 
their presence in healthy, cognitively normal individuals (Katzman et al. 1988) 
and the poor correlation between amyloid load and cognitive impairment in 
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individuals with AD (Terry et al. 1991; Arriagada et al. 1992). This is 
exemplified by the many mouse models of AD that display behavioural deficits 
prior to the detection of plaque pathology (Mucke et al. 2000; Oddo et al. 2003; 
Billings et al. 2005; Lesné et al. 2008). However, proponents of the amyloid 
cascade hypothesis argue that the plaques detected in normal individuals are 
almost exclusively of the diffuse type, which are not associated with surrounding 
neuritic and glial pathology (Hardy & Selkoe. 2002) and that the quantitative 
correlations between histologically determined plaque counts (which are counted 
manually) and cognitive impairment are imprecise and fraught with 
methodological challenges (Haass & Selkoe. 2007).  
 
The advent of A!-specific ELISA, combined with western blotting and mass 
spectrometry has provided a much more precise means of biochemically 
assessing A! levels and has led to the observation that total A! levels, 
particularly soluble A! levels, correlate much better with dementia than does 
plaque count (Lue et al. 1999; Wang et al. 1999). These findings led to the idea 
that soluble oligomers of A!, not monomers or insoluble amyloid fibrils, are the 
primary neurotoxic species in AD (Walsh & Selkoe. 2007). However, the term 
‘soluble oligomer’ casts a wide net, describing any A! species (except 
monomers) that does not pellet following high-speed centrifugation. 
Consequently, there remains much confusion as to which particular species of 
soluble A! oligomer is ultimately responsible for toxicity.  
 
Many groups have generated/isolated synthetic/natural A! oligomers and have 
shown them to be toxic in vitro and in vivo. The list includes secreted dimers and 
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trimers, protofibrils, annular structures, A!-derived diffusible ligands (ADDLs) 
(Lambert et al. 1998) and A!*56, an endogenous dodecameric form of A! 
(Pimplikar. 2009).  
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1.2 Using model organisms to study Alzheimer’s disease 
1.2.1 Transgenic models of Alzheimer’s disease 
With the incidence of AD set to grow, pressure is mounting on the scientific 
community to develop effective treatments. Other age-related diseases such as 
heart disease and cancer can now be effectively treated and in some cases cured, 
whereas treatments of AD, and indeed of other age-related neurodegenerative 
disorders such as Parkinson’s Disease, are palliative at best. In part, this is due to 
a poorer understanding of AD, a consequence of the complexity of the brain and 
its relative inaccessibility, but it is also through a dearth of ‘natural’ disease 
models. For instance, the dog naturally reproduces some features of AD 
including A! cortical pathology, neuronal degeneration and learning and 
memory deficits, but it does not develop neuritic plaques and NFTs (Sarasa & 
Pesini. 2009). Also, although rodents will readily develop cancer, the sporadic 
formation of plaques and NFTs has never been reported (Link. 2005). 
 
Thus, transgenic models of AD have enabled researchers to overcome the lack of 
a convenient natural model. Since the study of AD in humans is 
methodologically and ethically complicated, transgenic animal models of AD 
provide a powerful means to further understanding of AD pathogenesis, to 
identify new biomarkers and to design new treatments. In addition, transgenic 
animal models allow investigation of the early stages of the disease, something 
that is difficult with human post-mortem tissue, which typically reflects the 
terminal stages of pathogenesis (Wentzel and Kretzchimer. 2010). Human 
studies, particularly drug trials, are further complicated by the fact AD patients 
are often suffering from a range of other age-related problems. 
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The aims of developing a transgenic model are to replicate as much of the natural 
human pathology as possible whilst also providing opportunities to test candidate 
compounds and other interventions at all points along the pathogenetic cascade. 
With AD, this is further complicated by disagreement in the literature on exactly 
what the pathogenic cascade is. The amyloid cascade hypothesis remains the 
most widely supported and tested mechanism and has thus formed the basis of 
almost all transgenic models; that is, they are engineered to overproduce A!42. 
This has been achieved either through the overexpression of FAD-associated 
mutant APP (with or without FAD-associated PSEN-1) or via the direct 
expression of A! mini-genes in the nervous system. 
 
The success of a model system depends on the degree of homology at the 
molecular, cellular and tissue level between the human and candidate organism. 
In this light, the most appropriate animal for modelling AD is probably the aged 
primate, but this is all but ruled out on ethical grounds. As a consequence, most 
studies have favoured murine models of AD, mainly because mice are mammals 
and have well-established systems for genetic and other types of experimental 
manipulation and phenotypic characterisation. However, due to various 
limitations of the mouse, there has been a move in recent years towards using 
invertebrate models such as Drosophila melanogaster and Caenorhabditis 
elegans.  
 
These two organisms offer two major advantages: first, experiments can in 
general be conducted much more rapidly than in the mouse and with much larger 
numbers of animals and, second, these invertebrate models organisms can be 
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rapidly screened for with both mutations and chemicals, allowing investigation 
of processes involved in AD from a unbiased perspective, something that is 
challenging in mammalian systems. 
 
Flies and worms are phylogenetically further from humans than are rodents, and 
lack some of the complexity of nervous system and behavioural of mammals as 
well as some biological processes that are likely to play a role in AD pathology 
(e.g. a closed blood circulation). Modelling of some diseases, which affect 
specific tissues that are absent in the invertebrates, such as Cystic fibrosis and the 
lungs, would obviously be inappropriate in invertebrates. However, despite these 
limitations, results of both classic genetic analyses and transgenic manipulation 
of these invertebrates (discussed below) appear to validate their use as model 
platforms for the study of AD. 
 
The production of different transgenic models in a variety of model organisms 
raises the question of which is the ‘right’ model. It is important to emphasise 
that, although each particular model system recapitulates one or various aspects 
of disease, to date, not one has completely reproduced all features of the disease. 
Caution must therefore be taken when making conclusions from any model 
system and these conclusions must be made with an appreciation of other 
systems, and always, above all, to the pathology seen in humans. 
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1.2.2 Transgenic models of AD in Mus Musculus 
The formulation of the amyloid cascade hypothesis in the early 90’s prompted 
many groups to attempt to replicate AD pathology in the house mouse Mus 
musculus by overexpressing human APP (wild-type, FAD associated mutations 
in APP or fragments of A!) under neuron specific promoters. Despite largely 
unsuccessful attempts in the early 1990’s (McGowan et al, 2006) the field has 
grown enormously, and to date, over a dozen different models exist that develop 
amyloid and tangle pathology (for review see McGowan et al, 2006). For the 
sake of brevity, only the most popular models, and those particularly relevant to 
this thesis will be discussed. 
 
The first significant developments were publication of the PDAPP (Games et al. 
1995), followed in subsequent years by the Tg2576 (Hsiao et al. 1996) and 
APP23 (Stürchler!Pierrat et al. 1997) mouse models, currently the most widely 
used amyloidosis models in AD!related research. PDAPP mice overexpress a 
human APP minigene, encoding the FAD-associated V717F mutation (Murrel et 
al. 1991) under the control of the platelet derived growth factor ! promoter 
(PDGF!). Both the Tg2576 mouse and the APP23 mice overexpress a human 
APP minigene, encoding the FAD-associated double Swedish mutation 
(K670M/N671L) (Mullan et al. 1992), under the control of the hamster prion 
protein promoter (PrP) and murine thy-1 promoter, respectively. All these mice 
develop robust age- and brain region specific AD pathology (from 6-9 months in 
PDAPP and APP23, 9 months in Tg2576) including A! deposition in both 
neuritic and diffuse plaques, dystrophic neurites, synapse loss and extensive 
gliosis. Although tau was found in a hyperphosphorylated state in these mice 
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(Games et al. 1995, Hsiao et al. 1996), no NFTs were detected nor was there 
evidence of widespread neuronal loss or brain atrophy.  
 
Mutant APP mice do develop a range of behavioural and cognitive deficits but 
the correlation between specific pathological lesions and memory deficits is 
unclear. Furthermore, the use of subtlely different behaviour and learning 
paradigms makes comparison between different studies difficult. For instance, 
spatial discrimination in PDAPP mice, as tested using a radial arm maze (which 
assesses spatial learning and memory), is impaired at ages between 3 and 10 
months, a period both before and after the development of amyloid deposits (6-9 
months) in this model. However, when using the Morris water maze to assess 
spatial learning and memory, deficits were not observed until 13-15 months, well 
after the emergence of A! deposits (Chen et al. 2000). On one side we have 
emergence of cognitive deficits before plaque pathology, which argues against 
plaques as the primary toxic moiety in AD, whereas in the other case we see 
cognitive deficits emerging after plaque formation. 
 
There is a similar story with Tg2576 mice. It was originally demonstrated that 
these mice develop memory deficits, as assessed by the water maze (Hsiao et al. 
1996) and T-maze (Chapman et al. 1999), by 10 months of age (no deficits were 
observed at 3 months). Since there is no widespread neuronal loss in this model, 
these cognitive deficits are believed to be the result of impaired synaptic 
plasticity (Chapman et al. 1999). However, when assessed over a broader age 
range (4-22 months) Tg2576 mice failed to show any overall correlation between 
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memory function and levels of insoluble A!, although a correlation was observed 
within individual age groups (Westerman et al. 2002).  
 
The discovery of FAD associated mutations in PSEN1 and PSEN2 prompted 
many groups to cross APP mutant mice with mice expressing mutant PSEN 
transgenes (PSAPP mice). PSAPP mice display an increased A!42/A!40 ratio 
and dramatically accelerated A! pathology (compared to the single APP model 
they are respectively based on) and thus support the modifying role of PSEN 
mutations. For example, Holcomb et al (1998) crossed the Tg2576 line with a 
mutant PSEN1 (M146L) transgenic line. The double transgenic progeny 
developed large numbers of fibrillar A! deposits in the cerebral cortex and 
hippocampus far earlier than in their singly transgenic Tg2576 littermates (at 6 
months compared to 9 in Tg2576). Furthermore, these mice showed a selective 
41% increase in A!42 levels, when compared to Tg2576 mice. Interestingly, 
these mice showed cognitive deficits, as assessed using a T-maze, as early as 3 
months; well before A! could be detected (Holcomb et al. 1999).   
 
The major caveat of these particular models however, is the notable absence of 
NFT pathology and widespread neuronal loss. This was partly overcome by the 
development of mutated human tau mice and the subsequent crossing of tau and 
APP (Lewis et al. 2001a). JNPL3 mice over-express a mutant form of tau and 
display marked tangle pathology and neuronal loss. Crossing these mice with 
Tg2576 increased tau forebrain pathology relative to the singly transgenic JNPL3 
mice, suggesting that mutant APP and or A! can influence downstream tau 
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pathology. In another study, A!42 fibrils injected into JNPL3 mice, accelerated 
NFT pathology, further implicating the primacy of A! (Götz et al. 2001). 
 
The most complete mouse model of AD is probably the triple transgenic (3xTg) 
mouse (Oddo et al. 2003). These mice express human APP, encoding the 
Swedish mutation; and human tau with the P301L mutation (like the JNPL3 
mice) in a PSEN1 (M1646V) knockin background. Rather than crossing 
independent mutant mouse lines, two transgenic constructs (mutant APP and tau) 
were microinjected into single!cell embryos from homozygous mutant PSEN1 
mice, thereby preventing segregation of APP and tau genes in subsequent 
generations. In accordance with the amyloid cascade hypothesis, 3xTg mice 
develop A! plaques prior to NFT pathology with a temporal and spatial profile 
equivalent to AD, in addition to inflammation, synaptic dysfunction, and 
cognitive decline. 
 
Of particular relevance to this thesis are transgenic mouse models that directly 
overexpress A! isoforms in the absence of APP processing, since this is the 
favoured approach to modelling AD in Drosophila. LaFerla et al (1995) used a 
strong neuron-specific promoter, neurofilament-light (NF-L), to drive expression 
of murine A!42 in the brains of mice. The construct was engineered so that A! 
would accumulate intracellularly - a decision based on the authors’ belief that A! 
neurotoxicity is mediated from an intracellular location, for which there is now 
much evidence. These mice display extensive neuronal degeneration, suggested 
to be a result of apoptosis; reactive gliosis and a 50% reduction in lifespan. 
However, although some extracellular A! deposits were detected using 
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immunohistochemical techniques, no plaque or tangle pathology was observed in 
these mice. Furthermore, this study did not include a negative control peptide 
such as A!40 or GFP, therefore casting doubt on the specificity of A!42 toxicity 
implied in this model. 
 
McGowan et al (2005) similarly generated mice that express A!42 and A!40 in 
the absence of APP processing. Their approach was slightly different. They used 
cDNAs that expressed fusion proteins between the transmembrane protein BRI, 
which is involved in amyloid deposition in Familial British Dementia (FBD) and 
Familial Danish Dementia (FDD), and human A!40 or A!42. It was previously 
shown that transfection of BRI-A! in cell culture results in high levels of 
expression and secretion of A! peptides, following cleavage of the fusion protein 
(Lewis et al. 2001). The efficient secretion of A! in these mice and the use of 
A!40 are the major differences to the approach taken by LaFerla et al (1995), 
who instead specifically aimed to generate high levels of intracellular A!. 
 
Cleavage of the fused BRI-A! protein in BRI-A!40 and BRI-A!42 mice resulted 
in efficient production and secretion of A!40 and A!42, respectively. Soluble 
fractions of both peptides accumulated with age, quantified using A! sandwich 
ELISA over a period of 3-22 months. However, only BRI-A!42 mice 
accumulated insoluble A!42 and developed compact amyloid plaques, diffuse 
A! deposits and extensive CAA with age. This is despite BRI-A!40 mice having 
significant higher levels (~5-10 fold relative to A!42) of A!40 expression. 
Despite overt amyloid plaque pathology in BRI-A!42 mice, there was no 
evidence of NFT pathology or widespread neuronal loss. Interestingly, 
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endogenous murine A!42 was found to co-localise with human A!42 in a subset 
of plaques. This was further evidence demonstrating that different A! sequences 
can aggregate and form plaques.  
 
More importantly, this study demonstrated that A!42 is essential for amyloid 
deposition in the brain parenchyma and also in vessels. It also provides further 
evidence for the primacy of A!42 toxicity in AD, as posited by the amyloid 
cascade hypothesis. 
 
1.2.3 Transgenic models of AD in Caenorhabditis elegans 
Caenorhabditis elegans or C. elegans are small (~1.2mm), transparent, soil-
dwelling nematode worms first used to study molecular and developmental 
biology by Syndey Brenner in the 1970’s (Brenner. 1974). This invertebrate was 
the first animal for which an entire genome was sequenced (C. elegans 
Sequencing Consortium. 1998) and has recently become one of the most popular 
models organisms to study neurodegenerative disease, as demonstrated by the 
development of numerous transgenic disease models including for Alzheimer’s 
Disease (discussed below), Parkinson’s Disease (Lakso et al. 2003; Ved et al. 
2005; Kuwahara et al. 2006), Huntington’s Disease (Faber et al. 2002), and 
Amyotropic Lateral Sclerosis (Oeda et al. 2001). 
 
C. elegans provide a variety of practical advantages for studying age-related 
neurodegenerative disease. They are cheap and easy to maintain in large numbers 
(on plates of E. coli bacteria on which the worms feed), they have a complete cell 
lineage, a simple well-mapped nervous system, a short development time (egg to 
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adult in three days) and a short lifespan (18 days at 20°C). In addition, they are 
amenable to RNA interference, a technique for down-regulating the expression 
of a particular gene of choice. RNAi involves feeding worms bacteria that 
express double stranded RNA copies of the gene of interest (Carthew. 2001), 
which, once ingested by the worm, interfere with the mRNA transcript of the 
gene thereby preventing translation and expression of the respective protein. 
Bacterial libraries of strains that allow RNAi of all known C. elegans coding 
sequences are available and can be used for genome-wide screens for phenotypes 
of interest.  
 
Models of AD in the worm have been almost exclusively developed and studied 
by the laboratory of Christopher D. Link. Their first model, which was in fact the 
first attempt at modeling AD in an invertebrate, involved expressing a signal 
peptide:human A!42 mini-gene in the body wall muscle of the worm (they used 
the unc-54 promoter which encodes a body-wall muscle myosin) (Link. 1995). 
The expression of the A!42 mini-gene resulted in muscle-associated thioflavin 
S-reactive deposits and a clear progressive paralysis phenotype. Interestingly, 
despite the inclusion of a signal peptide, A! was not secreted in this model. 
Immunoreactive amyloid deposits were only detected inside the muscle (Link. 
2001). Owing to the lack of A! expression in the nervous system, this is perhaps 
a more useful model for the progressive muscle disease Inclusion Body Mitosis 
(IBM), which is associated with the intracellular accumulation of A! (Askanas & 
Engel. 2001) rather than AD.  
 
One concern prior to the development of this worm AD model was that the short 
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lifespan of the worm would not allow enough time for the development of A! 
deposits. On the contrary, this early study demonstrated the A! could rapidly (~2 
days) accumulate into amyloid-like deposits in vivo as well as producing a clear 
and practical phenotype amenable to genetic screens. This model was further 
used to study effects of A! sequence on its propensity to aggregate. Fay et al 
(1998) engineered worms to express wild type and single amino acid variants of 
A!42 in the muscle cell wall. They identified Leu17 and Met35 as key residues 
for in vivo amyloid formation, since their substitution blocked the formation of 
amyloid deposits.  
 
The original Link model (1995) was then later adapted for a temperature-
inducible A! expression system (Link et al. 2003; Drake. 2003), in which A!42 
is only expressed at a non-permissive temperature of 23°C. Movement to the 
higher temperature resulted in increased oxidative stress, evidenced by increased 
protein oxidation, in the absence of A!42 fibril formation (Drake. 2003). Thus, 
this study adds further weight to the notion the toxic species in A! toxicity and 
AD is pre-fibrillar in nature (i.e. soluble oligomers).  
 
1.2.4 Transgenic models of AD in Drosophila melanogaster 
Drosophila melanogaster are the most commonly used species of Drosophila in 
the laboratory. Their use in the modelling of human neurodegenerative disease is 
predominantly based on the inherent presumption that the fundamental aspects of 
cell biology are conserved throughout evolution in higher organisms. This is 
supported by the fact approximately 75% of human disease-related genes have 
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homologs in Drosophila (Reiter et al. 2001), suggesting that molecular 
mechanisms underlying disease in humans may be conserved in the fly. 
 
There are many compelling reasons to studying AD in the fly. The fly brain is 
estimated to have in excess of 300,000 neurons and, similarly to mammals, is 
organized into areas with separate, specialized functions such as learning, 
memory, olfaction and vision. Flies are also highly practical; they have a short 
generation time (10 days), are inexpensive to keep (although, unlike C. elegans 
and mice, they cannot be recovered alive from freezing) and relatively short-
lived. Although one could argue the fly’s maximum lifespan of 50-80 days is 
significantly greater than that of the worm (~18 days), it is still much shorter than 
that of the mouse (2-3 years), making it ideal for studying a progressive age-
related disease such as AD.  
 
In addition, the fly has an unrivalled battery of genetic tools, including a fully 
sequenced genome; an extensive library of mutant stocks including RNA 
interference (RNAi) and knock out (KO) lines; sophisticated transposon based 
methods for gene manipulation; systems for spatial- and temporal-specific 
ectopic gene expression; and balancer chromosomes. Balancer chromosomes are 
unique composed of multiple inversions that prevent recombination, together 
with dominant lethal visible and markers. They allow the maintenance in long-
term culture of lethal or deleterious mutations in heterozygotes, without any 
necessity to set up specific crosses.  
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The combination of such extensive genetic tools and practicality makes the fly 
ideal for genetic screening. A variety of screening methods are available in the 
fly, involving chemical mutagenesis (EMS), genetic deletion kits or mobile 
genetic elements (P-, EP-, GS-elements). Genetic screens are powerful 
experiments providing an unbiased forward genetics approach, which allows the 
discovery of genes or metabolic pathways not immediately apparent in the 
pathogenesis of AD. 
 
1.2.5 Drosophila life cycle 
The Drosophila life history is divided into four distinct morphological phases 
(see Figure 1.7). Periods of growth and development can be easily distinguished 
from sexual maturity and the adult phase. Development time from egg to adult is 
approximately 10 days at 25ºC, although this can change depending on the 
mutant being used. For instance, flies mutant for the insulin receptor substrate 
protein, chico, typically take 12 days to develop whereas mutants lacking the 
Drosophila insulin-like peptides 2,3 and 5 (dilp 2,3-5) can take up to 18 days to 
develop (Grönke et al. 2010).  
  
Once fertile eggs are laid, larvae start to emerge around 24 hours later and then 
enter three distinct stages of growth or instars known as L1, L2 and L3. L1 and 
L2 last for 24 hours each whereas the L3 stage lasts for 48 hours.  During L2 the 
larvae become larger in size and switch from feeding on the surface of the food 
to burrowing down into the food. Feeding can last ~100 hours before larvae leave 
the food medium and crawl up the sides of the vial or bottle to pupariate. The 
pupal period lasts approximately 4 days, during which time pupae undergo 
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metamorphosis before eclosion into adult flies. Adult flies consist almost entirely 
of post-mitotic, fully differentiated cells, with the exception of cells in the gonad 
and some cells in the gut and Malphigian tubule (fly equivalent of the 
mammalian kidney), which continue to divide. 
 
Freshly eclosed flies have shrivelled wings and are pale with a dark spot on their 
abdomen, as a result of their last feed as L3 larvae. Wings expand within an 
hour, followed by pigmentation. Female virgin flies will not mate within the first 
8 hours post-eclosion. After mating, females commence a heavy egg-laying 
period that peaks after 5 days post-copulation. Virgin flies also lay eggs but 
fewer and in a different pattern. 
 
 
Figure 1.7. The Drosophila life cycle. The development of a fertile egg to an 
adult fly over a 10-day period at 25ºC. Following hatching (eclosion), larvae go 
through three instars before reaching pupariation at which time metamorphosis 
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takes place resulting in the emergence of an adult fly. Figure taken from 
FlyMove (http://flymove.uni-muenster.de). 
 
1.2.6 Drosophila nomenclature 
Drosophila melanogaster have four pairs of chromosomes: X; 2nd; 3rd; and 4th. In 
Drosophila sex is determined by the ratio of X to autosomes. Thus, males 
contain a single X and a Y chromosome. For most practical purposes the fourth 
chromosome is ignored because of its relatively small size (it is a fifth of the size 
of any other chromosome).  
 
To fully understand a genetic cross, the specific nomenclature that the geneticists 
uses must be understood. There are a few general rules. When describing a stock 
genes on the same chromosome are separated by a space and genes on 
homologous chromosomes by a slash; a semi-colon separates genes on non-
homologous chromosomes. Wild-type alleles are typically signified by +. Hence, 
a wild-type fly would be written as such: 
 
+/+ ; +/+ ; +/+ ; +/+  
 
If there are no mutations or alterations to a chromosome then generally nothing is 
shown. However, if a cross potentially results in progeny with altered 
chromosomes then + will be used. If the fly is homozygous for a mutation or 
insertion then only one line is usually shown. Gene names are often descriptive 
of the gene function or mutant phenotype such as Curly (curly winged flies) or 
chico (little boy in Spanish), the latter describing the dwarf phenotype of a 
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mutant in a gene encoding the insulin receptor substrate protein. When a gene is 
an orthologue of a gene previously discovered in another organism, a “d” is 
added to the front of the gene name, for example, dFOXO. In addition, the 
genotype, mutant and gene name are always italicized. If the mutant phenotype is 
dominant to the wild-type then the first letter is capitalized, but not when it is 
recessive. 
 
One of the most commonly used stocks in this thesis is: 
 
w1118;UAS-Arctic A!42/+;elavGS/+ 
This stock is therefore homozygous for the w gene in the 1118 background on 
chromosome 1, heterozygous for the UAS-insertion on chromosome 2 and 
heterozygous for the elavGS insertion on chromosome 3.  
 
1.2.7 Modelling AD in the fly 
As has been previously described, AD is characterised by two major 
neuropathological mechanisms, the development of extracellular amyloid-! (A!) 
plaques and intraneuronal neurofibrillary tangles, and fly models of AD can be 
broadly grouped according to these. Thus, Drosophila models of AD typically 
aim to either overexpress A! or tau, respectively. Here, I will largely concentrate 
on models of A! toxicity since the same approach was used to develop an 
inducible model of AD in this thesis. 
 
Modelling A! toxicity in the fly has proved to be challenging because not all the 
components of APP proteolytic processing machinery are conserved. Flies do 
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possess an APP homologue, Appl (Rosen et al. 1989), and like mammalian APP, 
it is expressed specifically in neuronal tissue (Luo. 1990). Interestingly, it has 
been shown that APPL may function as a vesicular receptor for kinesin 1, a 
motor mediating anterograde vesicle trafficking. Flies lacking APPL or 
overexpressing human APP and Drosophila APPL constructs have axonal 
transport defects, which are enhanced by reductions in kinesin 1 expression. 
Moreover, over-expression of the A!-domain-containing APP, but not APPL, 
induced neuronal apoptosis (Torroja et al. 1999a; Gunawardena & Goldstein. 
2001). APPL also been implicated in promoting synaptic formation at the 
neuromuscular junction (NMJ) (Torroja et al. 1999b).  
 
The main problem in modelling A! toxicity is that the equivalent of the A! 
domain in APPL shows low evolutionary conservation with that of mammals 
(Rosen et al. 1989). Furthermore, there is confusion as to whether a functioning 
!-secretase exists in the fly. When using full length human APP695, Fossgreen et 
al (1998) failed to detect any A!, leading them to conclude that the ‘postulated 
!-secretase might somehow be altered in insects or might cleave APP to a non-
detectable extent’. However, Greeve et al (2004) showed that human APP is 
cleaved in the fly, in the absence of human BACE1. Adding fuel to the fire was a 
recent study reporting that APPL could be cleaved by an endogenous !-
secretase-like enzyme, or by human BACE1 to generate A! fragments known as 
dA!. These APPL-derived A! fragments were shown to accumulate, causing 
behavioural deficits and neurodegeneration (Carmine-Simmen et al. 2009).  
On the other hand, Drosophila does definitely possess a functional "-secretase. 
Using a truncated form of human APP (SPA4CT), Fossgreen et al (1998) first 
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demonstrated A! release in flies and fly-tissue culture indicating endogenous "-
secretase activity. 
 
1.2.8 Models of A" toxicity 
Two approaches have been used to work round the lack of endogenous A! 
production in the fly. The first aims to reconstitute the human APP/secretase 
system in the fly, whereas the second directly investigates the downstream 
consequences of A! production. 
 
Greeve et al. (2004) reconstituted the human APP/secretase system in the fly 
eye, by generating flies transgenic for both human APP and human BACE. The 
advantage of this approach is that it makes fewer assumptions about causality, 
allowing investigation into APP processing, in addition to the mechanism of A! 
toxicity. As expected, flies expressing APP and BACE produced A!40 and 
A!42, demonstrating that human BACE appropriately functions in the fly and 
that the endogenous fly Psn gene (single fly homolog of human presenilin) can 
provide the $-secretase activity necessary to produce A!. Interestingly, the 
expression of human APP alone resulted in the production of an A!-like peptide 
containing a 13-amino acid N-terminal extension. In addition, expression of APP 
in the eye alone or in combination with human BACE resulted in an age-related 
degeneration of the retina and the underlying neurons of the optic pathway. Both 
phenotypes were absent when human BACE was expressed alone. The 
introduction of loss-of-function Psn alleles suppressed this APP transgene-
dependent phenotype, and the addition of Psn alleles with FAD-associated 
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mutations enhanced it. This strongly argued that the production of A! was 
responsible for the observed pathology.  
 
Following this study, a number of groups adopted a more focused approach, 
directly overexpressing A! peptides fused to secretion signal peptides, because it 
is believed the majority of A! in humans is eventually secreted. Finelli et al 
(2004) and Iijima et al (2004) generated flies engineered to overexpress human 
A!40 and A!42 mini-genes conjugated to the pre-proenkephalin signal to ensure 
secretion of the peptides.  
 
Expression of A!42 in photoreceptor cells (by using the eye-specific GMR-Gal4 
driver) led to a range of eye abnormalities not seen in multiple A!40 lines (Finelli 
et al., 2004). The severity of the eye-phenotypes was dose-dependent and 
increased with age. Flies solely expressing the GMR driver, aged in parallel, did 
not show any age-dependent rough-eye phenotypes. The rough-eye phenotype is 
a non-progressive, developmental abnormality of the ommatidia that constitute 
the compound eye of the fly. Toxic transgene products may produce a range of 
irregularities in the eye, from subtle misalignments of ommatidia, through fusion 
of ommatidia to the development of necrotic patches. Consequently, the rough 
eye phenotype can be used as a qualitative measure of neurodegeneration  
 
Pan-neuronal expression of A!42 (using the elav-Gal4C155) resulted in a  ~50% 
reduction in life span. Finelli et al (2004) also screened for genetic modifiers of 
the A!42-induced rough-eye phenotype. The screen identified a mutation that up-
regulates expression of nep2, a neprilsyin homolog. Neprilsyin is a plasma-
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membrane bound protein capable of catabolising A!. Appropriate tissue-specific 
expression of this gain of function mutation both decreased A!-dependent eye 
abnormalities and partially rescued the premature death phenotype.  
 
Iijima and colleagues (2004) furthered these studies by measuring behavioural 
phenotypes (olfaction and locomotor ability) as well as neurodegeneration in the 
brain. However, unlike the situation in photoreceptor cells, both A!40 and A!42 
accumulated, although only A!42 flies formed sodium dodecyl sulfate (SDS)-
insoluble aggregates (insoluble A!42 refers to higher order aggregates, fibrils 
etc.). Both A!40 and A!42 lines showed age-dependent olfactory learning 
deficits, but only the A!42 flies demonstrated age-dependent climbing 
phenotypes and shortened lifespan.  
 
Crowther et al (2005) followed with the same direct approach and engineered a 
series of flies overexpressing A!40, wild-type A!42 and the Arctic mutant form 
of A!42 but conjugated to a different secretion signal peptide, Drosophila 
necrotic. The Arctic mutation is a Glu22Gly amino acid substitution that causes 
more rapid protofibril formation with increased neurotoxicity and results in 
early-onset Alzheimer’s disease (Nilsberth et al. 2001; Murakami et al. 2002). 
Expression of these peptides was driven by the pan-neuronal driver elav-
Gal4C155. A!40 was used as a control and over-expression produced no 
survival or climbing phenotypes, consistent with the idea that A!42 represents 
the toxic moiety in AD. On the other hand, expression of A!42 and A!42 
(Arctic) resulted in age-dependent and dose-dependent neurodegeneration, 
reduced longevity and locomotor deficits. Expression of the more aggregation 
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prone A!42 (Arctic) accelerated these phenotypes, consistent with the early-
onset of AD in humans harbouring this mutation. This model was then 
subsequently used to confirm that a modifier of A!42 aggregation, neuroserpin, 
interacts with A!42 in vivo (Kinghorn et al. 2006). 
 
One source of concern regarding these models is whether they are all examining 
the same toxic process. The contribution of intracellular A! in human remains 
controversial and, although the A! peptides were fused to secretion signals, the 
intracellular/extracellular distribution of A! in vivo was not determined. Finelli 
et al (2004) demonstrated that the signal peptide (as used by Iijima et al. 2004) is 
efficiently cleaved from A! in the fly model and showed that in Drosophila S2 
cells the A! transgenes can produce secreted A!. In addition, the suppression of 
A!-dependent phenotypes by nep2 up-regulation suggests A! is secreted in this 
model.  However, Crowther et al (2005), who also used S2 cell lines, claimed 
that, although A!42 correctly entered the secretory pathway, the majority of 
A!42 and all the Arctic A!42 were retained within the cell as a monomer or 
soluble oligomers. This could be attributed to use of a different secretion signal 
peptide. Furthermore, they observed that in brain sections from young transgenic 
flies, A! is initially intracellular and only later are extracellular deposits 
observed. Hence, Crowther et al (2005) used their model as evidence for a role 
of intraneuronal A! aggregation in causing toxicity. 
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1.2.9 Application of Drosophila models of AD 
A major advantage of using invertebrates such as Drosophila is the power to 
perform unbiased genetic screens to identify novel modifiers of AD phenotypes. 
To date, two such screens have been published (Cao et al. 2008; Rival et al. 
2009). Cao et al (2008) searched for modifiers of the rough eye phenotype, 
caused by A! over-expression in the eye of the fly (Finelli et al. 2004). They 
screened for dominant modifiers of the phenotype in a library of flies with 1963 
unique insertions of mobile transposon constructs (EP-elements) that enhance 
expression of neighbouring genes. Rival et al (2009) used a slightly different 
approach. They use EP-like elements to generate up-regulation of a random set 
of genes in flies over-expressing A! in the nervous system, and subsequently 
measured differences in lifespan to look for disease modifiers. 
 
Both screens identified a strong role for the transition metals copper (Cao et al. 
2008) and iron (Rival et al. 2009) amongst genes for vesicle transport, protein 
degradation, stress response and chromatin structure (Cao et al. 2008). The most 
powerful modifying genes in the Rival et al (2009) screen were those encoding 
iron binding proteins such as the heavy and light chains of the iron storage 
protein ferritin. Furthermore, co-expression of heavy chain ferritin with A! in a 
A!-mini gene model (Crowther et al. 2005) suppressed longevity and 
behavioural phenotypes, and reduced oxidative damage, despite an increase in 
the A! load in the brains of these flies. The researchers went further to suggest 
the free-radical generating Fenton reaction therefore might play a role in A! 
toxicity.  
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1.3 Ageing as a risk factor for Alzheimer’s disease 
1.3.1 Ageing and neurodegenerative disease 
Late-onset is the most striking common feature of human neurodegenerative 
disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD) 
Huntington’s disease (HD) (and other polyglutamine diseases) and prion disease. 
In the case of AD and PD, rare individuals that carry familial-associated 
mutations develop the disease in their fifth decade, whereas the sporadic forms 
manifest during the seventh decade of life (Amaducci and Tesco. 1994). HD is a 
familial, monogenic disorder that similarly to other familial neurodegenerative 
disorders onsets during the patients fifth decade. The common pattern of onset 
between these disparate maladies defines ageing as a major risk factor for the 
development of neurodegenerative disease (Amaducci and Tesco. 1994). With 
sporadic AD, the association between ageing and onset could not be clearer – 
beyond the age of 65, the prevalence doubles approximately every 5 years (see 
Figure 1.8). 
 
At this point it will be important to discuss exactly what ‘ageing’ is. The term 
itself is rather vague and can be colloquially used to describe almost any change 
over time, be it a positive, negative or indifferent one. For example, the ageing of 
red wine is believed to improve its quality whereas the hardening of the arteries 
with advancing age can be life threatening. On the other hand some changes such 
as the greying of hair carry no positive or negative ramifications for health. From 
a biological perspective ageing is defined as an intrinsic decline in function 
during adulthood that reduces fecundity and increases the probability of death  
(Partridge. 2010). This decline in function is thought to be the result of 
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accumulation of multiple forms of tissue-specific molecular damage over time. 
Thus, ageing represents a highly complex, multifaceted process. 
 
 
 
Figure 1.8. The prevalence of AD has a function of age. Figure taken from 
Ferri et al. (2005). 
 
Aside from late-onset, neurodegenerative diseases are also defined by the 
aggregation, accumulation and deposition of abberantly folded proteins. As has 
been extensively discussed, A! aggregation is believed to underlie pathology in 
AD. Similarly, PD is caused by aggregation of $-synuclein, whereas in HD, a 
mutated form of the Huntington (Htt) protein, bearing an abnormally long 
polyglutamine (CAG) stretch causes the disease. Furthermore, aggregation of the 
prion protein (PrP) leads to prion disorders. 
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There is now much evidence implicating the soluble oligomeric forms of these 
various proteins as the primary toxic species. The remarkable fact these soluble 
oligomers share a common structure (Kayed et al. 2003) implies that these 
diseases may all share a common pathogenic mechanism. Furthermore, the fact 
these diseases share a common risk factor points towards the ageing process as a 
fundamental aspect of this ‘common pathogenic mechanism’ and ultimately 
raises an important question: why do such different diseases, each with distinct 
underlying pathologies, occur late in life? Is there a causal relationship between 
ageing and protein-mediated neurodegeneration?  
 
One idea suggests that the production and accumulation of toxic aggregates is a 
stochastic process, requiring many years to initiate disease. So in fact, it is not 
ageing per se, that increases the risk of neurodegenerative disease, rather, the 
time it takes for an initially asymptomatic protein to accumulate to toxic levels. 
Alternatively, it has been proposed that the ageing process - the increase in 
neuronal vulnerability and the decline in the cell’s ability to defend against 
protein aggregates – plays an active role in enabling the onset of 
neurodegenerative disease (Cohen et al. 2006). In other words, this theory 
predicts that neurodegeneration, or in the context of this thesis, A!-mediated 
toxicity, is age dependent.  
 
Distinguishing between these two scenarios has been difficult for two reasons. 
Firstly, the development of effective and practical transgenic models of AD has 
only occurred in the last twenty years. Secondly, and more importantly, the 
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ageing process was, until recently, intractable - a kind of genetic ‘black box’. 
This idea was a natural consequence of work on evolution of ageing.  
 
1.3.2 Ramifications of the evolutionary theory of ageing and the 
birth of modern biogerontology 
At first sight ageing requires no special explanation. It is simply a consequence 
of the second law of thermodynamics - biological wear and tear. However, 
despite showing a broad phylogenetic distribution, ageing is not universal. For 
instance, the simple fresh-water animals Hydra were reported to show no 
increases in mortality when assayed over a four-year period (Martínez. 1998). If 
biological wear and tear were the cause of ageing we would expect similar 
organisms to age at roughly similar rates but this is not so. For example, as a 
group, bats live 3.5 times as long as nonflying mammals of the same size 
(Austad. 2005), and within the bat species itself there are huge differences in 
lifespan despite roughly identical body sizes. The rate at which organisms age 
can therefore, evolve. This presents somewhat of an evolutionary paradox and is 
why evolutionary biologists are so fascinated by ageing. According to Darwinian 
theory, natural selection acts to remove deleterious traits from populations 
through the differential survival and reproductive success (fitness) of individuals. 
Ageing is unconditionally deleterious – it results in damage, lowered fertility and 
death- yet is believed no genes have evolved to cause ageing (Partridge. 2010). 
 
Early evolutionary biologists such as Alfred Russel Wallace and August 
Weismann first debated the evolution of ageing in the late 19th century. They 
posited that ageing is an evolved trait for the good of the species, not the 
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individual. They believed ageing removes the old so to increase the fitness of the 
young (i.e. through reallocation of resources). Although a logical explanation, 
this idea has now been discredited. This is because there is little evidence to 
suggest ageing contributes to mortality in the wild (Kirkwood & Austad. 2000). 
In fact, natural mortality is mostly due to extrinsic hazards such as infection, 
predation and accidents. A key realisation was the idea the force of natural 
selection declines with age (Haldane. 1941; Medawar. 1952). Extrinsic hazard 
makes it unlikely for individuals to grow old therefore the greatest contribution 
in creating a new generation comes from the young. This idea is central to 
contemporary evolutionary theory of ageing, which proposes that ageing evolves 
as a side effect, either of pressure of new mutations that reduce fecundity or 
survival probability later in life or of mutations that have beneficial effects in the 
young (Medawar. 1952; Williams. 1957; Partridge & Gems. 2006). These ideas 
led to the assumption that ageing is a non-adaptive, highly polygenic trait, too 
complex for experimental manipulation. The idea single-gene mutations could 
affect ageing was unheard of. 
 
Thus, there was great surprise when Klass isolated the first long-lived mutants in 
C. elegans (Klass. 1983). He himself seemed surprised suggesting it was ‘most 
likely due to reduced caloric intake’ and that lifespan could be controlled in a 
polygenic manner. However, these were later verified and these worms were 
found to have a mutation in the age-1 gene. Kenyon and colleagues (1993) then 
isolated daf-2 mutant worms that exhibited a lifespan double that of wild-type 
worms. It was discovered that these mutations occurred in the dauer formation 
(Daf) pathway and that animals with weak alleles of the daf-2 or age-1 genes 
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could bypass the dauer state and show significant longevity gains that were 
dependent on daf-16 (Kenyon et al. 1993) - a downstream transcription factor. It 
was later determined that the effects of daf-2 are also dependent on another 
downstream target encoded by the hsf-1 gene (Hsu et al. 2003). The mutated 
genes were discovered to encode components of an invertebrate insulin/insulin-
like growth-factor-like signalling (IIS) pathway and mutations in IIS pathway 
components that increase lifespan were soon found in flies and mice. These 
discoveries marked the beginning of the modern biogerontology era and the 
ability to manipulate the rate of ageing experimentally. 
 
1.3.3 Evidence linking ageing and neurodegeneration 
As previously discussed, a major question in the neurodegenerative field 
concerns the nature of the association between ageing and susceptibility to 
protein-mediated toxicity. The discovery of single-gene mutations that extend 
lifespan have allowed this issue to be properly explored. In the age-dependent 
role model of toxicity, one would expect interventions that increase lifespan to 
also rescue protein-mediated toxicity. Increasing evidence is in support of this, 
suggesting that the IIS pathway might be the mechanistic link between ageing 
and protein-mediated toxicity. 
 
The IIS pathway is an evolutionary conserved pathway that is ubiquitous in 
multi-cellular animals (Skorokhod et al. 1999). In fact, it is believed to have 
played a central role in the evolution of multi-cellularity itself (Skorokhod et al. 
1999). The IIS pathway has a multitude of functions, exemplified by studies 
showing that modulation of IIS activity can affect growth, development, 
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metabolic homeostasis, fecundity and, of particular relevance to this thesis, 
lifespan. The role of IIS signalling in regulating lifespan appears to be 
evolutionary conserved since reductions in IIS signalling yield stress-resistant, 
long-lived worms (Kenyon et al. 1993), flies (Tatar et al. 2001; Clancy et al. 
2001; Giannakou & Partridge. 2007) and mice (Blüher et al. 2003; Holzenberger 
et al. 2003).  
 
Several studies performed in C. elegans and mouse models of neurodegenerative 
disease support the role of IIS in mediating toxic protein aggregation. In a worm 
model of Huntington’s disease (HD), it was found that poly-glutamine (polyQ) 
aggregation and toxicity was reduced in age-1 mutants (Morley et al. 2002). This 
protection was dependent on hsf-1 yet this study failed to determine whether IIS 
was acting at the level of protein synthesis or polyglutamine solubility. Cohen et 
al. (2006) similarly demonstrated in a worm model of AD (Link et al. 1995), that 
A! toxicity (as measured by survival and motility) was ameliorated in worms 
treated with daf-2 RNAi. This was also found to be dependent on daf-16 and hsf-
1. 
 
These findings were confirmed in various mouse models of AD, where it was 
shown that deficiencies in IRS-2, neuronal IGF and the neuronal insulin receptor 
delayed mortality and decreased A! accumulation through reduced 
amyloidogenic processing (Freude et al. 2009). This same effect was also seen in 
IRS-2 null mice (Killick et al. 2009) and IGF-1 receptor heterozygous mice 
(Cohen et al. 2009). In the latter study, it was found that reduced IIS resulted in 
fewer amyloid plaques of higher density, which resulted in decreased steady state 
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levels of soluble A! oligomers. This is evidence for the protective effects of 
amyloid formation as a means of removing the toxic soluble oligomers. 
 
One of the other major pathways controlling lifespan is dietary restriction  (DR). 
DR describes a reduction in food intake that falls short of starvation or 
malnutrition and has been shown to extend lifespan in organisms from yeast to 
mammals (for review see Mair & Dillin. 2008). Interestingly, DR delays protein 
mediated toxicity in C.elegans models of poly-glutamine disease and A! toxicity 
(Steinkraus et al. 2008). This was apparently due to a mechanism distinct from 
reduced IIS, which was dependent on hsf-1. Interestingly, in a Drosophila model 
of AD, DR had no effect on neuronal dysfunction but did delay ageing (Kerr et 
al. 2009). 
 
Thus, these studies point towards a strong link between the ageing process and 
protein-mediated toxicity.  
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1.4 Thesis Outline 
The aims of this thesis were to investigate the association between ageing and 
neurodegeneration using a Drosophila model of Alzheimer’s disease. In 
particular, the aim was to determine whether ageing increases the vulnerability to 
A!42-mediated toxicity. This was achieved using a novel inducible model of 
A!42 toxicity to conditionally express A!42 peptides at different ages and by 
using genetic and pharmacological interventions known to extend lifespan. 
  
The specific aims were to: 
 
1) To refine existing fly models of AD with the aim of developing an 
inducible model of A! toxicity and to fully characterise this model using 
well-established markers of toxicity (Chapter 3). 
 
2) To further characterise and exploit the features of this particular model 
system to investigate: a) the dynamics of A!42 toxicity and b) whether 
ageing plays an active mechanistic role in enabling neurodegeneration 
(Chapter 4). 
 
3) To measure the effect of lifespan-extending pharmacological  
(rapamycin, Chapter 5) and genetic interventions (reduced IIS signalling, 
Chapter 6) on A!-mediated toxicity. 
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Chapter 2 Materials and Methods 
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2.1 Drosophila melanogaster stocks 
2.1.1 Wild-type stocks 
The majority of experiments were performed in the wild-type inbred white1118 
(3605), background. However, in some instances the whiteDahomey background 
was used and this has been clearly noted. 
2.1.1.1 white1118 (w1118)  
w1118 was originally obtained from the Bloomington stock centre at Indiana 
University, and has been maintained in bottles containing standard sugar yeast 
medium with overlapping generations on a 12-hour light/dark cycle at 25°C and 
65°C in a controlled temperature (CT) room. w1118 is an inbred isogenic strain 
with white eyes due to a deletion in the sex-linked white gene (w). This strain 
also lacks the intracellular bacterium Wolbachia. 
 
2.1.1.2 whiteDahomey  (wDahomey)  
wDahomey were generated by backcrossing w1118 flies into the outbred Dahomey 
wild-type background. The Dahomey wild-type stock was originally collected in 
1970 in the Republic of Dahomey (now Benin), West Africa, and have since 
been maintained in population cages (measuring 20 x 21 x 30cm) at 25°C at 0% 
humidity under a 12-hour light/dark cycle with overlapping generations. Unlike 
discrete culture, this method has been shown to maintain lifespan and fecundity 
at levels observed with flies freshly collected from the wild (Sgrò & Partridge. 
2001). Flies in population cages had constant access to 12 bottles of standard 
Sugar-Yeast (SY) food medium, with the three oldest bottles being replaced with 
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fresh medium every week. Naturally, Dahomey and wDahomey  strains both carry 
the intracellular bacterium Wolbachia. 
 
2.1.2 GeneSwitch driver stocks 
Two pan-neuronal GeneSwitch drivers were used throughout this thesis. They 
consist of the cloned promoter of the pan-neural ELAV (embryonic lethal, 
abnormal vision) gene upstream of the gene encoding a RU486-dependent 
GAL4-progesterone-receptor fusion protein called GeneSwitch, which can be 
used for spatially and temporally restricted UAS-linked transgene (see UAS-
stocks below) expression (Osterwalder et al. 2001). All drivers were backcrossed 
at least six times into the w1118 and wDahomey genetic backgrounds. 
 
2.1.2.1 elavGS301.2  
This is the original line created by Osterwalder and colleagues and was obtained 
from the Bloomington stock centre. 
 
2.1.2.2 elavGS 
This is a more potent line (see results section 3.2.2) derived from the original 
elavGS301.2 line. Latouche et al (2007) generated this line to develop an adult-
onset Drosophila model of spinocerebellar ataxia (SCA) (Latouche et al. 2007) 
and it was obtained as a generous gift from Dr H. Tricoire (CNRS, France).  
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2.1.3 UAS-stocks 
All UAS stocks contain a GAL4 binding site or Upstream Activating Sequence 
(UAS) upstream of the transgene. All UAS lines were backcrossed at least six 
times into the w1118 and wDahomey genetic backgrounds. 
 
2.1.3.1 UAS- Arctic A!42  
This strain encodes the human A!42 peptide 
(MASKVSILLLLTVHLLAAQTFAQDAEFRHDSGYEVHHQKLVFFA 
EDVGSNKGAIIGLMVGGVVIA) fused to a secretion signal peptide from the 
Drosophila necrotic gene (Crowther et al. 2005). This mutant form of A!42 
contains the FAD-associated Arctic mutation (Glu22Gly) that leads to rapid 
aggregation of the peptide and early-onset AD (Nilsberth et al. 2001).  
 
2.1.3.2 UAS-A!40  
This strain encodes the human A!40 peptide 
(MASKVSILLLLTVHLLAAQTFAQDAEFRHDSGYEVHHQKLVFFA 
EDVGSNKGAIIGLMVGGVV) fused to the same a secretion signal peptide as 
above.  
 
Both UAS stocks were obtained as kind gift from Dr D. Crowther (University of 
Cambridge, UK) and were previously used to develop a Drosophila model of AD 
(Crowther et al. 2005). 
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2.1.3.3 UAS-lacZ 
This strain encodes the product of the E. coli lacZ gene, !-galactosidase. !-
galactosidase catalyses the hydrolysis of a variety of !-galactosides including 
CPRG that is used in this thesis (see section 2.4.9). This is one of the most 
extensively used reporter strains in Drosophila research. UAS-lacZ flies were 
obtained form the Bloomington stock centre at Indiana University. 
 
2.1.4 chico1/CyO 
These flies are heterozygous for a null mutation in the Drosophila insulin 
receptor substrate gene, chico, which is a component of the IIS pathway. chico1 
was maintained in a heterozygous state over a chromosome 2 balancer carrying 
the dominant CyO marker. Thus, the majority of flies in this stock had curly 
wings, although a small proportion were homozygous for chico1.  
 
chico1 homozygotes are sterile, less than half the size of wild-type flies, owing to 
fewer and smaller cells, (although they do have higher lipid levels) and exhibit 
an increase in median and maximum lifespan (Böhni et al. 1999; Clancy et al. 
2001). These flies were obtained as a kind gift from Ivana Bjedov, who acquired 
them from Ersnt Hafen. They were backcrossed at least 6 times into the wDah 
background. 
 
2.1.5  wDah; Sp/CyO; TM6B/Mkrs 
This stock carried multiple balancers on the 2nd and 3rd chromosomes and was 
obtained from the Bloomington stock centre at Indiana University. 
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2.2 Food media 
2.2.1 Sugar yeast (SY) medium 
SY medium contained per litre: 100g autolysed Brewer’s yeast powder (MP 
Biomedicals, Solon, OH, USA), 50g sucrose (Tate and Lyle Sugars, London, 
UK), 10g agar (Sigma-Aldrich, UK), 30ml nipagin (100g/L methyl 4-
hydroxybenzoate in 95% ethanol) (Clariant UK Ltd, Pontypridd, UK), 3ml 
propionic acid (Sigma-Aldrich, UK) and distilled water to 1 litre. Nipagin and 
Propionic acid were added as preservatives and anti-fungal reagents. 
 
To prepare the medium 700ml of distilled water and 15g of agar were mixed in a 
saucepan and brought to the boil. The sugar and yeast were then added and 
mixed thoroughly. The mixture was then returned to the boil and the heat 
removed. Once the food had settled, the remaining 170ml of water were added 
and the mixture was left to cool. Following cooling to 60°C, both the nipagin and 
propionic acid were added.  
 
The medium was dispensed into glass vials or glass bottles (see  
Figure 2.1) in aliquots of 7ml and 70ml respectively using a motorized pump. 
SY medium was left to solidify and dry overnight. The vials or bottles were then 
plugged with cotton wool and stored at 4°C for no longer than 3 weeks. 
 
It is important to note glassware was used for stock maintenance whereas plastic 
vials were used for all experiments involving drug-based SY mediums (see 
below). This was necessary to prevent contamination of the communal glassware 
(which is autoclaved, washed and recycled after each use). Plastic vials were 
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disposed of immediately after use. To prevent any contamination of the pumping 
apparatus, drug based SY medium was manually dispensed using 1L plastic 
‘ketchup bottles’ at ~3ml a vial.  
 
 
 
Figure 2.1. A photograph of the glassware and plasticware used for stock 
maintenance and experiments: a) UK half-pint glass bottle containing 70ml SY 
b) plastic vial containing ~3ml SY and c) glass vial containing 7ml SY. 
 
2.2.2 RU486 (RU) SY 
A 100mM RU working stock was made by dissolving RU powder in 95% 
ethanol at a concentration of 43mg/ml. 2ml of this 100mM stock was then added 
to 998mL SYA, prior to dispensing, to give a final concentration of 200#M RU 
per litre. To obtain other RU SY concentrations, the volume of RU working 
stock was changed accordingly (e.g. 1ml in 1L to give a final concentration of 
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100#M or 4ml in 1L to obtain a final concentration of 400#M). For control food 
(-RU), the equivalent volume of ethanol alone was added. All concentrations of 
RU SY medium, including -RU, were dispensed into plastic vials at ~3ml per 
vial. 
 
It is important to note that RU486 is a synthetic steroid with antiprogestational 
effects. It is commercially used with the name of Mifeprex to give abortions in 
the case of unwanted early pregnancies. The usual dose for terminating 
pregnancy is 200mg, however it has been reported that a dose of 1mg/kg of body 
weight can have effects on uterus implantation and the absorption of 300ug/kg 
can severely disrupt the estrus cycle. Thus, RU SY must be dispensed under a 
fumehood and be clearly labelled when drying or in storage. 
 
2.2.3 Rapamycin SY 
1g of rapamycin (LC Laboratories) was dissolved in 100% ethanol and vortexed. 
2.4ml were then added to a final volume of 600ml SY medium (+/- RU), prior to 
dispensing, to give a final concentration of 200#M. For rapamycin-free control 
food (-rapa), the equivalent volume of ethanol alone was added. All 
concentrations of rapamycin SY medium, including -rapa, were dispensed into 
plastic vials at ~3ml per vial. 
 
2.2.4 Grape juice medium 
Grape juice medium consisted of 500ml distilled water, 25g agar, 300ml grape 
juice, 50ml extra water and 21ml nipagin (100g/L). Water and agar were first 
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brought to the boil, at which point all the grape juice was added. The mixture 
was then returned to the boil and allowed to cool. Once below 60°C, the extra 
water (used to rinse the cylinder containing the residual grape juice) and nipagin 
were both added. The medium was then poured into small or large petri dishes, 
otherwise known as grape plates (Figure 2.3). Grape plates were used during 
standard larval density preparations to promote and track egg laying. 
 
 
 
 
Figure 2.2. Photograph of grape plates used to easily track and identify egg 
laying. On the plate in the right of the image eggs are visible around the 
circumference of the plate. A globule of yeast paste is also visible in the middle 
of the plate. 
 
2.3 Fly husbandry and culturing 
2.3.1 Stock maintenance 
All stocks were maintained at 18°C or 25°C on a 12 hour light/dark cycle at 
constant humidity (65%) on SY medium. Stocks were maintained in glass, half-
pint UK milk bottles or glass-shell vials (Figure 3.1). Stocks at 18°C were 
transferred to fresh medium roughly every 4 weeks, whereas stocks at 25°C were 
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transferred every 10 days. Stocks were transferred or ‘tipped’ from old 
bottles/vials to fresh ones by quickly banging the flies into the fresh bottle/vial, 
with the aid of a funnel to prevent any flies escaping. In some instances light 
CO2 anesthesia was used to confirm the phenotype of the stock or to select a 
standard number of flies to transfer to a fresh bottle. 
 
2.3.2 Distinguishing males and females 
The sex of flies can easily be distinguished, while anaesthetised with CO2, under 
a light microscope. Males are generally smaller than females and have a rounder 
abdomen that is dark dorsally compared with the striped tip of the female 
abdomen (Roberts. 1998). These differences are so clear that one can often tell 
the difference with the naked eye, especially with the abdomen. However, both 
shape and colour may be deceptive in newly eclosed flies. When in doubt, males 
were unambiguously identified by the presence of sex combs, a row of thick dark 
bristles on the tarsus on the first pair of legs (Roberts. 1998). Males and females 
were sorted with the use of a fine paintbrush on a CO2 pad to avoid any structural 
damage. 
 
2.3.3 Virgin Collection 
For all experimental crosses it was essential to use virgin females. This is 
because mated females store sperm in the ventral receptacle and spermatheca. 
This stored sperm is sufficient to enable females to lay up to 100 eggs per day for 
many days in ideal conditions (Roberts. 1998). Because males and females 
emerge from the same bottle, brother-sister mating can occur potentially 
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confusing the results of crosses. Using virgin females therefore ensures crosses 
produce progeny at expected Mendelian ratios. 
 
Female Drosophila will not mate within 8 hours after eclosion at 25°C. Thus, the 
following routine was followed to ensure successful virgin collection. First, 
bottles with emerging flies were emptied first thing in the morning, preferably 
before lights on (when flies are more likely to start emerging). It was extremely 
important to remove all flies, particularly those stuck on the side of the bottle. A 
paintbrush was used to scrape any rogue males off the sides. Alternatively, the 
cotton plug (the site of most pupation in a bottle) was removed and placed in a 
fresh bottle. This prevented flies getting stuck in the old ‘churned’ medium. 
Females were then collected at the end of the day/within 8 hours and stored at a 
density of 10-20 virgins per vial.  Virgin flies can be distinguished by their pale 
body colour and the presence of a dark spot or meconium in the gut, visible 
through the ventral abdominal wall. It is important to use very light CO2 
anaethesia, or preferably ice anaethesia, when sorting virgin females since excess 
CO2 exposure can cause visible bloated abdomens, which often results in 
premature death. Males were either disposed or stored at a density of 25 males 
per vial. Collection bottles were kept at 18°C overnight to slow the rate of 
eclosion until the morning, from when the bottles were brought back to 25°C. 
This cycle was repeated until the desired number of virgins was collected. 
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2.3.4 Standard larval density 
Maintaining standard density in larvae is important since larval density can affect 
longevity (Priest & Mackowiak. 2002). Since longevity was used as a surrogate 
marker of A! toxicity throughout this thesis, it was essential to control for this. 
Furthermore, overcrowding of larvae results in smaller flies. The size of a fly can 
negatively affect negative goeotaxis, another marker of disease used in fly AD 
models, since smaller flies have to effectively climb farther than normal sized 
flies. To ensure standard larval density, the following technique developed by 
Kennington and Clancy (2001) was used when setting up all experimental 
crosses. 
 
To rear flies at a constant density, crosses were set up in plastic population cages 
at a virgin female:male ratio of 2:1. Each cage contained a single petri-dish 
containing grape juice medium, otherwise known as a grape plate (see grape 
juice medium), supplemented with live yeast paste. Larger cages also included a 
vial of water plugged with a damp cotton bud, to provide humidity. Flies were 
left to lay eggs for a maximum of 22 hours. It was often necessary to carry out a 
‘pre-lay’ whereby the plates were supplemented with lots of yeast paste to 
encourage sufficient egg laying. After a sufficient number of eggs were laid the 
eggs were washed off with phosphate buffered saline (PBS) into a Falcon tube 
with the aid of a paintbrush. Eggs were allowed to settle and the remaining 
supernatant was poured off. Using a Gilson pipette, 20µl of the eggs were 
aspirated from the solution and squirted into 200ml glass bottles containing 70ml 
SYA medium, typically resulting in a standard density of 300-350 eggs per bottle 
(Kennington. 2001). 
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2.4 Experimental procedures 
2.4.1 Once-mated females 
For all experiments, flies were raised at a standard density on 70ml of standard 
SY medium in 200mL glass bottles. Flies emerging over a 24-hour period were 
transferred to fresh bottles for a period of 48 hours following eclosion. This 
ensured all females had mated at least once. Once-mated females were then 
sorted into vials (at a density necessary for the specific experiment) and the 
males discarded. Once-mated females were used for experiments for two key 
reasons. Because I decided to use the ‘in-food’ RU486 delivery approach, it was 
essential for flies to feed to induce UAS-transgene expression. Since females are 
known to feed at a higher level than males, using females ensured UAS-
transgene would be more robust owing to a higher rate of RU486 ingestion. 
 
Females were once-mated mainly for practical reasons. Having them one-mated 
was a means of standardising the female population, which was especially 
important when assaying behavioural phenotypes and survival. Virgins are 
thought to live twice as long as mated females (Smith. 1958) possibly due to 
higher egg production and the cost of mating in mated flies, both from physical 
damage and the transfer of seminal fluid from males, which has been shown to 
reduce lifespan (Trevitt and Partridge. 1991). Contrastingly, overexposure to 
males can shorten lifespan (Fowler and Partridge. 1989). Thus, using once-mated 
females ensured the female population was fairly homogenous rather than an 
assortment of virgins and mated females. Furthermore, it was more practical to 
collect mated females rather than virgins since strict timings did not need to be 
adhered to. 
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2.4.2 Lifespan assay 
Once-mated females were transferred to experimental plastic vials containing 
~3ml of SYA medium (with or without specified drug where applicable) at a 
density of 10-15 flies per vial. Flies were transferred to fresh food every 2-3 
days, at which point, deaths or censors were scored. Dead flies were typically 
motionless with curled legs and shriveled bodies. A record was made of any dead 
flies carried over into the fresh vial. Censored flies included those that escaped 
during transfer, that had been accidentally damaged (eg. crushed between the 
cotton wool and vial) or any that were stuck to the food. Data are presented as 
survival curves and statistical comparisons of survival were performed using log-
rank tests. 
 
2.4.3 Proboscis-extension assay during undisturbed conditions 
For undisturbed observations of feeding, 7-day-old mated flies of the same sex, 
were transferred to new food at a density of 5 per vial on the evening before the 
assay. Vials were coded and placed in a randomised order in rows on viewing 
racks at 25ºC overnight. The assay occurred with minimal noise and physical 
disturbance to the flies. To avoid recording disturbed fly feeding behaviour, 30 
minutes was allowed between the arrival of the observer and commencement of 
the assay.  
 
Observations were performed ‘‘blind’’ the next day for 90 minutes, commencing 
one hour after lights-on. In turn, each vial was observed for approximately 3 
seconds during which the number of flies feeding was noted. A feeding event 
was scored when a fly had its proboscis extended and touching the food surface 
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while performing a bobbing motion. Once all vials in the experiment had been 
scored in this way, successive rounds of observations were carried out in the 
same way for the whole 90 minutes of the assay, which, depending on the size of 
the experiment meant that each vial was observed once every 2 to 5 minutes. At 
the end of the assay, the vial labels were decoded and the feeding data expressed 
as a proportion by experimental group (sum of scored feeding events divided by 
total number of feeding opportunities, where total number of feeding 
opportunities = number of flies in vial*number of vials in the group*number of 
observations). For statistical analyses, comparisons between experimental groups 
were made using log rank test. 
 
2.4.4 Negative geotaxis (climbing) assay 
Negative geotaxis is a commonly assessed behaviour in Drosophila that is used 
as a proxy measure of neuronal dysfunction. It is an innate escape response 
mechanism elicited by banging flies to the bottom of a container; the flies 
respond to the mechanical stimulation by climbing up the container wall.  
 
Once-mated females were transferred to plastic vials containing ~3ml of SYA 
(+/-drug) medium at a density of 15 flies per vial. 3 vials of 15 flies were 
typically set up per genotype/condition. Climbing ability was then assayed every 
2-3 days post-drug treatment. All assays were performed blind at the same time 
of day and under constant conditions (25°C, no humidity, no CO2 exposure prior 
to assay). Flies were moved to the CT room at least an hour prior to the 
beginning of each assay to allow the flies to adjust to changes in the 
environment. 
  87 
For the assay, 15 adult flies were transferred to a vertical column (25cm long, 
1.5cm diameter) with a conic bottom end (i.e. a 25ml pipette, see Figure 2.4) 
tapped to the bottom of the column, and their subsequent climb to the top of the 
column was analysed. Flies reaching the top and flies remaining at the bottom of 
the column after a 45s period were counted separately, and three trials were 
performed at 1 min intervals for each experiment. A 45s training tap was 
performed before each trial. Scores recorded were the mean number of flies at 
the top (ntop), the mean number of flies at the bottom (nbottom) and the total 
number of flies assessed (ntotal). The Performance Index (PI) was calculated as 
0.5(ntotal + ntop – nbottom)/ntotal. Data are presented as the mean PI ± SEM 
obtained in three independent experiments for each group, and analysis of 
variances (ANOVA) and post hoc analyses were performed using JMP 7.0 
software. 
  88 
 
 
 
 
 
 
Figure 2.3. A photograph of the apparatus used for climbing assays. a) 25ml 
pipette assay and b) plastic vial assay. In the 25ml pipette assay the number of 
flies reaching the top, middle (area between top and bottom) and remaining at the 
bottom were scored after 45s. With the vial assay, the number of flies reaching 
the 5cm (labelled on vial) was recorded after 18s.   
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2.4.5 Giant Fibre System (GFS) electrophysiology1  
Recordings from the giant fibre system (GFS) of once-mated female flies were 
made as described in (Allen et al. 1999). Flies were anaesthetized by cooling on 
ice and secured in wax, ventral side down, with the wings held outwards. A 
tungsten earth wire (ground electrode) was placed into the abdomen; tungsten 
electrodes were pushed through the eyes and into the brain to deliver a 40 V 
pulse for 0.03ms using a Grass S48 stimulator. Recordings were made from the 
tergotrochanteral muscle (TTM) and contralateral dorsal longitudinal muscle 
(DLM) using glass microelectrodes (resistance: 40–60 M). The electrodes were 
filled with 3M KCl and placed into the muscles through the cuticle. Responses 
were amplified using Getting 5A amplifiers (Getting Instruments, USA) and the 
data digitized using an analogue-digital Digidata 1320 and Axoscope 9.0 
software (Axon Instruments, USA). For response latency recordings, at least 5 
single stimuli were given with 5s rest periods between each stimulus; trains of 10 
stimuli, at either 100, 200 or 250 Hz, were given with a 5s rest interval between 
each train. 
 
2.4.6 Preparation of flies for molecular biology 
Once-mated females were transferred to plastic vials containing ~3ml of SYA 
(+/- drug) medium at a density of 15-25 flies per vial and 5 vials per condition. 
Flies were transferred to fresh food every 2-3 days until the desired age. Flies 
were then transferred, under ice anaesthesia, from the vial to a 1.5ml eppendorf, 
snap frozen in liquid nitrogen and stored at-80°C. The majority of molecular 
                                                
1 All electrophysiology work was carried by H. Augustin. 
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work exclusively used fly heads. To decapitate the flies, the eppendorf was 
dipped in liquid nitrogen and then shaken vigorously, shearing the heads from 
the intact abdomen and thorax. The heads were then sorted from the bodies using 
a custom-made sieve. Once separated, the heads were immediately used or snap 
frozen in liquid nitrogen and stored at -80°C. However, repeated freeze/thaw 
cycles were generally avoided. 
 
2.4.7 RNA extraction, cDNA synthesis and Quantitative-PCR (Q-
PCR) 
Total RNA was extracted from 20–25 fly heads (at least three independent head 
extraction per genotype) using Trizol (GIBCO) according to the manufacturer’s 
instructions. The concentration of total RNA purified for each sample was 
measured using an eppendorf biophotometer. To prevent amplification of 
contaminating genomic DNA, 1mg of total RNA was subjected to DNA 
digestion using DNAse I (Ambion). This was necessary because the A! primers 
were designed within one exon (because the UAS-A! mini-gene was so small) 
and therefore off-target genomic DNA could serve as a template for PCR 
amplification.  
 
DNase treated RNA samples were then subject to reverse transcription using the 
Superscript II system (Invitrogen) with oligo (dT) primers. To evaluate the level 
of genomic DNA in my RNA samples, reverse transcription was performed in 
the absence of reverse transcriptase (negative control). Amplification of this 
sample during Q-PCR represented the level of genomic DNA contamination. 
This was found to be neglibile. Q-PCR was performed using the PRISM 7000 
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sequence-detection system (Applied Biosystems), SYBR Green (Molecular 
Probes), ROX Reference Dye (Invitrogen), and Hot Star Taq (Qiagen, Valencia, 
CA) by following manufacturers’ instructions. cDNA was amplified using two-
pairs of PCR primers, one specific to UAS-A!42/A!40 and a second set specific 
to the endogenous control RP49. The primers for the A!42 and A!40 transgenes 
were directed to the 5’ end and 3’ end of the A! coding sequence: forward 
GATCCTTCTCCTGCTAACC; reverse CACCATCAAGCCAATAATCG. The 
RP49 primers were as follows: forward ATGACCATCCGCCCAGCATCAGG; 
reverse ATCTCGCCGCAGTAAACG. Cycle numbers were optimised for each 
primer set to ensure the reaction was within the linear range and each reaction 
terminated before reagents became limiting.  
 
A! expression levels were quanitified using the relative standard curve method 
(Broughton et al. 2005) and normalised to RP49 (to control for variation in the 
amount and quality of RNA between different samples). Standard curves were 
prepared for both A! and RP49. For each experimental sample, the amount of 
A! and RP49 was determined from the relevant standard curve. Then, each A! 
amount was dividied by the respective RP49 amount to obtain a normalised A! 
value. This value was then expressed relative to a normalised calibrator sample 
(this division removed any units). In most instances this was the normalised A! 
amount in the negative w1118 control. Therefore, A!42 expression levels were 
presented as normalised expression levels relative to w1118. 
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2.4.8 Total, soluble and insoluble A"42 quantification 
To extract total A!42, five fly heads (per replicate) were homogenised in 50#l 
GnHCl extraction buffer [5M Guanidinium HCl, 50mM Hepes pH 7.3, protease 
inhibitor cocktail (Sigma, P8340) and 5mM EDTA], centrifuged at 21,000 g for 
5 min at 40C, and the cleared supernatant retained as the total fly A!42 sample. 
Alternatively, soluble and insoluble pools of A!42 were extracted using a 
protocol adapted from previously published methods (Burns et al. 2003): 200 fly 
heads were homogenised in 200µl tissue homogenisation buffer [250mM 
sucrose, 20mM Tris base, 1mM EDTA, 1mM EGTA, protease inhibitor cocktail 
(Sigma)] then mixed further with 200µl DEA buffer (0.4% DEA, 100mM NaCl 
and protease inhibitor cocktail). Samples were centrifuged at 135,000g for 1 hour 
at 4°C (Beckman OptimaTM Max centrifuge, TLA120.1 rotor), and supernatant 
retained as the soluble A!42 fraction. Pellets were further resuspended in 400µl 
ice-cold formic acid (70%), and sonicated for 2 % 30 sec on ice. Samples were re-
centrifuged at 135,000g for 1 hour at 4°C, then 210 µl of supernatant was diluted 
with 4ml FA neutralisation buffer (1M Tris base, 0.5M Na2HPO4, 0.05% NaN3) 
and retained as the insoluble, formic acid-extractable A!42 fraction. 
 
Total, soluble or insoluble A!42 content was measured in Arctic A!42 flies and 
controls using the hAmyloid !42 ELISA kit (HS) (Millipore). Total A!42 
samples were typically diluted 1:10 or 1:100, and soluble versus insoluble A!42 
samples diluted 1:10 in sample/standard dilution buffer, then ELISA performed 
according to the manufacturer’s instructions. Protein extracts were quantified 
using the Bradford protein assay and the amount of A!42 in each sample 
expressed as a ratio of the total protein content (pmoles/g total protein). Data are 
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expressed as the mean pmol A!42/g total protein ± SEM obtained in at least 
three independent experiments for each genotype. ANOVAs and post-hoc 
analyses were performed using JMP 7.0 software. 
 
2.4.9 Liquid !-galactosidase quantitative assay 
Whole flies were weighed (see 2.4.12) then homogenised in assay buffer (50mM 
K2HPO4, 1mM MgCl2.6H2O) in 96-square well blocks (Qiagen S block) with 2 
flies per well. After spinning down, 15µl of homogenate was extracted and added 
to a flat-bottomed 96-well plate containing 30µl chlorophenol red-b-D-
galactopyranoside (CPRG). Hydroloysis of CPRG by !-galactosidase turns the 
yellow substrate solution yellow to a dark red product. Plates were then mixed 
and allowed to develop in the dark at 25°C for 1 hour. 180µl MilliQ water was 
then added to each well and mixed. Absorption was then immediately measured 
at 574nm. Data are presented as the mean arbitary !-gal activity +/- SEM (n = 8-
10) and were compared using Student’s t-test.  
 
2.4.10 35S-methionine incorporation assay 
This assay was used to measure the rate protein translation and was adapted from 
a previously used method (Bjedov et al. 2010) for the use with fly head extracts. 
SY medium was first supplemented with 100µCi 35S methionine/ml of food 
(American Radiolabeled Chemicals 1mCi/37MBq ARS0104A)  
 
15 flies were transferred to each vial containing 1ml radioactive SY medium. 
After three-hours of feeding, flies were transferred to non-radioactive SY for 
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30min in order to purge any undigested radioactive food from the intestines. 
Flies that were in contact with the radioactive food for 1 minute were used as a 
background control. Flies were then decapitated using liquid nitrogen and the 
heads were homogenized in 200µM 1% SDS and heated for 5 minutes at 95°C. 
At this stage aliquots were taken and mixed with 3ml scintillant. These samples 
represented the total radioactivity in fly head homogenates prior to protein 
extraction.  
 
Samples were then centrifuged for 2x5 mins at maximum speed and supernatant 
retained. Proteins were precipitated by the addition of the same volume of 20% 
cold TCA (10% TCA final concentration) and incubated for 15 minutes on ice. 
Samples were then centrifuged at 16,000 g for 15 minutes, the pellet washed 
twice with acetone and then resuspended in 200µl of 4M guanidine-HCl. 
Samples (100µl) were mixed with 3ml of scintillant (Fluoran-Safe 2, BDH) and 
radioactivity counted in a liquid scintillation analyzer (TriCarb 2800TR, Perkin 
Elmer), with appropriate quench corrections. At the same, time the earlier total 
fly head homogenate samples were also measured. Measurements were 
normalized to total protein for each sample, as determined using the Bradford 
assay. Data are presented as the mean translation index ± SEM (n = 4) and were 
compared using Student’s t-test. 
 
The translation index was calculated as followed:  
 
(TCA protein cpm/total cpm)/#g protein per sample.  
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2.4.11 Bradford assay 
This assay was used to measure the total protein content in whole and head fly 
samples. BioRad reagent (5x) [Bio-Rad protein assay reagent, Bio-Rad 
Laboratories (UK) Ltd, Hemel Hempstead] was first diluted 1/5 in dH20. 200µl 
was then added per well in a flat-bottomed 96-well plate. 2µl of sample was then 
added to each well. Plates were then mixed and absorbance was measured at 
595nm. Absolute protein concentrations were determined using known volumes 
of bovine serum albumin (BSA) as a standard. 
 
2.4.12 Weight analysis 
Body weight of individual female flies (N = 10) was measured with a precision 
scale (range 0.001 – 10mg). Flies were reared at standard larval density and were 
age-matched (typically two-days post eclosion) before weighing. Data are 
presented as the mean mg wet weight per fly +/- SEM (n = 10). Means were 
compared using Student’s t-test. 
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Chapter 3 Development and characterisation of 
an inducible model of Alzheimer’s Disease 
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3.1 Introduction 
Over the past several years, there has been a move towards using invertebrate 
models such as Drosophila to investigate a host of neurodegenerative diseases, 
including Alzheimer’s disease (AD) (reviewed in Lu & Vogel. 2009). Although 
murine models remain the most popular, they often fail to recapitulate all of the 
pathological features associated with the disease, and the behavioural phenotypes 
can be laborious to characterise (Westerman et al. 2002). Moreover, the relative 
time and expense of modelling AD in the mouse permits little flexibility in 
experimental design. These issues combined with the relative practical 
advantages of Drosophila (see section 1.2.4) the power and speed to perform 
large, unbiased experiments – have led to the development and application of 
many fly models of AD.  
 
As has been previously described, AD is characterised by two major 
neuropathological mechanisms, the development of extracellular amyloid-! (A!) 
plaques and intraneuronal neurofibrillary tau tangles, and fly models of AD can 
be broadly grouped according to these. Because of the hypothesised causative 
role of A! in AD pathogenesis, the aim of many groups has been to overexpress 
A! peptides in fly neurons either by reconstituting the human APP/secretase 
system (Greeve et al. 2004) or by directly overexpressing wild-type and mutant 
A! as secreted peptides of different lengths (eg. 1-40 and 1-42) (Finelli et al. 
2004; Iijima et al. 2004; Crowther et al. 2005). In either case, overexpression of 
A!42 but not A!40 caused neurodegeneration in a dose-dependent and age-
dependent manner, reduced longevity, and caused locomotor deficits. All these 
features were associated with the progressive accumulation of A!42, replicating 
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a key feature of the human disease and further strengthening the validity of the 
fly as a model system. In addition, all three A! mini-gene models (Finelli et al. 
2004; Iijima et al. 2004; Crowther et al. 2005) displayed clear phenotypes in the 
absence of amyloid-like deposits of A!, demonstrating that neuronal dysfunction 
and neuronal loss in Drosophila do not require the presence of !-amyloid 
plaques – a feature also demonstrated in worm and various mouse models. 
 
The GAL4/UAS system represents the most widely used system for generating 
spatially restricted transgene expression in Drosophila, and it has been used to 
restrict expression of key AD disease genes to the fly nervous system. It is a 
bipartite system consisting of the yeast transcriptional activator GAL4 and its 
target sequence, the Upstream Activating Sequence or UAS (Brand and 
Perrimon. 1993). Essentially, any line showing tissue-specific expression of 
GAL4 can be used to drive similar tissue-specific expression of any cloned gene 
of interest (effector gene) that is fused to a promoter carrying a UAS. In practice, 
this involves crossing the appropriate GAL4 line to a second line carrying the 
UAS-effector fusion. This produces F1 individuals that carry both constructs and 
express the transgene in a spatially restricted manner as determined by the GAL4 
promoter. In the case of modelling AD, the pan-neuronal elav-GAL4 or eye-
specific GMR-GAL4 drivers have been used to drive either UAS-APP/UAS-
BACE or UAS-A! transgenes. An example of the use of the GAL4/UAS system 
to model AD is shown below (Figure 3.1). 
 
  99 
 
 
 
Figure 3.1. A schematic representation of the Crowther et al (2005) A! mini-
gene model and the GAL4/UAS system. Driver lines expressing the 
transcriptional activator GAL4 under control of the neuron-specific elav 
promoter (elavGAL4) are crossed to flies expressing an Arctic A!42 transgene 
fused to a GAL4-binding upstream activation sequence (UAS-Arctic A!42). 
A!42 peptides are therefore expressed in the same cells where GAL4 is present. 
 
A major drawback of the GAL4/UAS system when modelling age-related 
neurodegenerative disease is that it does not provide any temporal control over 
transgene expression. This is because most promoters and enhancers that drive 
GAL4 expression are active at multiple stages of development. This raises the 
issue of whether the phenotypes seen in fly AD models actually represent 
developmental defects brought on by toxic A!42 overexpression. For instance, 
Crowther et al (2005) observed a rough-eye phenotype, a commonly described 
mild developmental abnormality of the corneal lens of the compound eye, in all 
flies expressing A!42 peptides but not A!40.  
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Ideally, it would be much better to express A! peptides, for the first time, in the 
adult-fly to better replicate the natural progression of the disease in humans (i.e. 
pathology is not present at birth). The advent of inducible transgene systems has 
provided a means of circumventing this problem, allowing spatial and temporal 
control over transgene expression. Conditional systems use an environmental 
stimulus, such as light, temperature or a drug, to activate expression of a target 
gene. Therefore, one can choose when in the life cycle to turn transgene 
expression on and off by adding or removing the stimulus. A further advantage is 
that experimental and control groups are genetically identical - produced from 
the same cross and sharing the same developmental conditions. Ideally, the only 
variable during an experiment should be the absence or presence of the stimulus. 
 
A variety of different conditional systems exist in Drosophila. The use of heat 
shock promoters has proved to provide temporal control but these promoters are 
limited because of their lack of tissue-specificity. Other approaches have 
included light-induced activation of caged GAL4 (Cambridge et al. 1997) and 
the use of tetracycline-dependent ‘tet-off’ (Bello & Resendez-Perez. 1998; 
Stebbins 2001) or ‘tet-on’ (Bieschke et al. 1998) transactivation systems, which 
are based on binding of the tetracycline operator (tetO) sequences (upstream of 
target gene), either by the tetracycline repressor protein (tetR) in the absence, or 
by a mutant tetracycline repressor (rTA) in the presence, of tetracycline or 
derivatives such as doxycycline. 
 
Although the ‘tet-on’ and ‘tet-off’ systems have proven to be effective, they do 
not take advantage of the huge library of pre-existing UAS lines, therefore 
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requiring new tetR or rTA drivers and tetO responsive fly stocks to be generated. 
The GeneSwitch system, on the other hand, is compatible with pre-existing UAS 
lines. Essentially, it is an extension of the GAL4/UAS system, permitting spatial 
and temporal control with a RU486-dependent GAL4-progesterone-receptor 
fusion protein called ‘GeneSwitch’ (Osterwalder et al. 2001; Roman et al. 2001). 
With this system, transgene expression can be initiated at any time, simply by 
adding the drug, mifepristone (RU486) to the fly food before feeding. Once 
activated, GeneSwitch mediated transgene expression can be turned off by 
shifting animals to RU486-free food. 
 
In this chapter I set out to develop a novel adult-onset model of AD in the fruit 
fly Drosophila melanogaster by using the inducible GeneSwitch system to 
spatially and temporally restrict the expression of human A! peptides in fly 
neurons, for the first time in adult flies. A! expression, following induction, was 
first confirmed and characterised. The effect of A! overexpression was then 
measured and profiled with the use of established markers of neuronal function 
and toxicity. The overall aim in developing this model was to investigate the 
direct consequences of A! production, in the absence of APP processing or 
endogenous A! production, exclusively in the adult fly, thereby bypassing any 
potential developmental defects. 
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3.2 Results 
3.2.1 Development of the model 
To establish the model, a pan-neuronal elav GeneSwitch (elavGS) driver line 
(Osterwalder et al. 2001) that has been previously used to develop an adult-
onset, Drosophila model of spinocerebellar ataxia (SCA) (Latouche et al. 2007) 
was used to direct expression of a UAS-Arctic A!42 mini-gene (Crowther et al. 
2005) both spatially and temporally, to neurons in the adult fly (Figure 3.2) The 
Arctic mutation, which causes early-onset familial AD (FAD) in humans, 
encodes a Glu22Gly amino acid substitution within the A! domain that increases 
the propensity of the peptide to aggregate (Nilsberth et al. 2001; Murakami et al. 
2002). Expression of the Arctic mutant form of A!42 is more toxic to flies than 
wild-type A!42 (Crowther et al. 2005). Thus, the decision to overexpress Arctic 
A!42 was made to ensure a robust phenotype could be detected. A UAS-A!40 
line (Crowther et al. 2005) was used as a control for over-expression of non-
toxic forms of A! in fly neurons, since this form of the peptide has previously 
been shown to have no detrimental effect in flies (Finelli et al. 2004; Iijima et al. 
2004; Crowther et al. 2005).  
 
Notably, because the same UAS-A! lines were used, this model can be 
effectively viewed as an extension of the Crowther et al (2005) A! mini-gene 
model. To reiterate, this model investigated the downstream consequences of A! 
production (rather than APP processing) by overexpressing A! peptides fused to 
the Drosophila netrotic secretion signal peptide under the control of the pan-
neuronal driver elav-GAL4C155. In this study expression of A!42 and Arctic 
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A!42 resulted in age-dependent and dose-dependent neurodegeneration, reduced 
longevity and locomotor deficits, with the Arctic mutation accelerating these 
phenotypes. In addition, it was reported that much of the A!42 and all of the 
Arctic A!42 were retained within the cell as monomers or SDS-resistant 
oligomers in Drosophila S2 cells. Similarly in the brain tissue of young flies A! 
was first found to accumulate intracellularly, only later forming extracellular 
non-amyloid deposits. These deposits resembled the diffuse plaques found in 
human AD. So in some ways, this model system better represents the effects of 
intraneuronal A!42-mediated toxicity. 
 
To generate flies for use in experiments, parental flies were crossed as follows: 
UAS-ArcticA!42/UAS-ArcticA!42 males were crossed to female elavGS/elavGS. 
The decision to use female elavGS was mainly practical – the reciprocal cross 
would have been equally valid. However, as it was necessary to cross elavGS to 
many different UAS-lines, using elavGS females minimised the time and media 
required for collecting virgins. Adult-onset expression in neurons was then 
induced in UAS-Arctic A!42/+;elavGS/+ once-mated female progeny by adding 
RU486 to SY medium, typically at two-days post eclosion (Figure 3.2). The 
same crossing scheme applied when using other UAS-lines and driver lines in 
experiments described below. 
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Figure 3.2. A schematic representation of the GeneSwitch-UAS expression 
system. The GeneSwitch system, a modified version of the GAL4/UAS system 
permits spatial and temporal control of transgene expression with a RU486-
dependent GAL4-progesterone-receptor fusion protein called ‘GeneSwitch (GS) 
(Osterwalder et al. 2001). Driver lines expressing the transcriptional activator 
GeneSwitch under control of the neuron-specific elav promoter (elavGS) are 
crossed to flies expressing an Arctic A!42 transgene fused to a GAL4-binding 
upstream activation sequence (UAS-Arctic A!42). In the absence of the activator 
mifepristone (RU486; -RU), the GeneSwitch protein is expressed in neurons but 
remains transcriptionally silent, so that Arctic A!42 is not expressed. Following 
treatment with RU486 (+RU; red) the GeneSwitch protein is transcriptionally 
activated, binds to UAS and thus mediates expression of A! peptide (purple) 
specifically in fly neurons. With this system, UAS-linked transgene expression 
can be initiated at any time, by adding RU486 to SY medium prior to feeding. 
Likewise, expression can be switched off by removal of RU486 from the SY 
medium. 
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3.2.2 Characterisation of elavGS induction kinetics 
Before establishing the AD model, it was necessary to characterise the kinetics of 
the elavGS driver. The elavGS driver line was derived from the elavGS302.1 
strain, originally published by Osterwalder et al (2001), and has been reported to 
induce relatively higher levels of expression, equal to that obtained with the 
constitutive elavC155-GAL4 line (Latouche et al. 2007) used in previous fly 
models of AD (Iijima et al. 2004; Crowther et al. 2005). However, because this 
information was not published, it was important to validate and further 
characterise the driver before adopting it for use in modelling AD. Driver 
kinetics were characterised using a UAS-lacZ reporter construct accompanied 
with quantitative !-galactosidase (!-gal) liquid assays. !-galactosidase activity 
was therefore used as a proxy of gene expression. Because the half-life of !-gal 
and A! were likely to differ, this characterisation was merely to get a quick 
evaluation of the efficacy of the new driver. 
 
Homozygous elavGS or elavGS302.1 females were crossed with homozygous 
UAS-lacZ males. Adult-onset neuron expression of !-galactosidase was then 
induced in UAS-lacZ/+;elavGS/+ or  UAS-lacZ/+;elavGS302.1/+ female 
progeny by adding RU486 to SY medium.  
 
To assess the immediate short-term response of the driver lines to RU486, !-
galactosidase activity was measured in UAS-lacZ/+;elavGS and UAS-
lacZ/+;elavGS302.1 flies treated with 200#M RU486 from two-days post 
eclosion. !-galactosidase activity was then measured up to 48-hours into 
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treatment. Non-RU-treated controls (-RU) were also assayed for each genotype 
at every time point (Figure 3.3). 
 
 
Figure 3.3. Induced !-galactosidase activity with elavGS and elavGS302.1. 
!-galactosidase assays were performed on once-mated, female UAS-
lacZ/+;elavGS/+ and UAS-lacZ/+;elavGS302.1/+ flies treated with +RU 
(200#M) and –RU (0#M) from two-days post eclosion for 4, 8, 12, 24 and 48 
hours. Data are presented as the mean arbitrary !-gal activity/mg wet weight +/- 
SEM (n = 5 for each group). Activity levels between treatments were compared 
within each genotype and between genotypes using Student’s t-test.  
 
!-galactosidase activity levels were significantly higher in elavGS flies, when 
compared to elavGS302.1 and non-RU-treated controls, following 8, 12, 24 and 
48 hours of induction (p<0.01 in all cases, Student’s t-test). Activity levels 
significantly higher than the –RU controls were first detected after 8-12 hours in 
elavGS (p<0.01, Student’s t-test), and after 12-24 hours in elavGS302.1 (p<0.01, 
Student’s t-test). 4 hours induction did not significantly increase !-galactosidase 
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activity in either line, highlighting a minimum period of RU treatment necessary 
for induction. Interestingly, a low level of !-galactosidase activity in the absence 
of RU486 (-RU) was also observed at all timepoints. This basal activity did not 
significantly change over the 48-hour period and it did not differ between elavGS 
and elavGS302.1 flies. Nonetheless, it indicated there was a significant, albeit 
low, basal expression of the UAS-transgene in the absence of RU486.  
 
3.2.3 Arctic A"42 expression can be induced in adult Drosophila 
neurons 
The first goal in establishing the inducible model was to confirm RU treatment 
could induce Arctic A!42 expression in the adult neurons. This was assessed by 
measuring A!42 mRNA and protein levels in the heads of UAS-Arctic 
A!42/+;elavGS/+ flies chronically treated with RU486 (+RU) from two-days 
post eclosion. mRNA and protein expression levels were measured four- and 21-
days into RU486 treatment using RT-PCR and A!42-specific sandwich ELISA, 
respectively (Figure 3.4). Non-RU-treated (-RU) UAS-Arctic A!42/+;elavGS/+ 
flies were used as a control for expression in the absence of inducer. In addition, 
A!40 mRNA and protein levels were assayed in UAS-A!40/+;elavGS/+ flies at 
both timepoints.  
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Figure 3.4. Adult-onset induction of Arctic A!42 peptide in fly neurons. 
Arctic A!42 and A!40 mRNA (relative to w1118 controls) and protein levels were 
quantified at four days and 21 days into-RU486 treatment. Data are presented as 
means +/- SEM (n = 4 for each group) and were analysed by Student’s t-test (* = 
P<0.01). 
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A!42 transcripts were clearly elevated in RU-treated UAS-Arctic 
A!42/+;elavGS/+ flies in comparison with untreated (-RU) flies at four-days 
(P<0.01, Student’s t-test) and 21-days (P<0.01, Student’s t-test).  Moreover, 
A!42-specific sandwich ELISA confirmed that A!42 protein was elevated in 
RU-treated flies compared to untreated (-RU) control flies at both timepoints 
(p<0.01, Student’s t-test) and that the level of protein increased from four-days to 
21-days of age (p<0.01, Student’s t-test). The increase in A!42 protein by 21-
days contrasted with a significant decrease in A!42 mRNA over the same period 
(P<0.01, Student’s t-test). The decline in A!42 mRNA expression could have 
been attributable to a decline in RU consumption, an idea consistent with the 
reduction in feeding behaviour with age previously reported for wild-type flies 
(Wong et al. 2009). The relatively higher A!42 protein levels at 21-days 
indicated a significant accumulation of the Arctic A!42, despite a reduction in 
A!42 mRNA. Again, as in the case when driving UAS-lacZ, A!42 mRNA and 
protein transcripts were both detected in the absence of RU486, indicating a 
slight leak in the control of expression. At the transcript level, leakiness was 
constant; evident by the fact A!42 mRNA levels in untreated flies (-RU) did not 
change over time. However, A!42 protein levels did increase over the same 
period (P<0.05, Student’s t-test), indicating that A!42 protein was accumulating 
in uninduced flies, albeit at a very low level relative to RU-treated flies. 
 
A!40 transcripts were also elevated in UAS-A!40/+;elavGS/+ flies treated with 
RU at both timepoints (P<0.01, Student’s t-test). At day 4, A!40 mRNA levels 
were significantly lower than A!42 levels (P<0.01, Student’s t-test) but by day 
21 these levels were equivalent. Similarly to A!42-expressing flies, A!40 
  110 
mRNA levels decreased from four-days to 21-days. This result is in keeping with 
the idea of reduced RU486 ingestion over time. Unsurprisingly, no A!40 was 
detected in the A!42-specific ELISA, highlighting the specificity of this 
particular assay kit. 
 
3.2.4 Induced Arctic A"42 protein rapidly aggregates in adult 
neurons 
Next, I assessed the state of aggregation of A!42 protein in the mutant flies by 
separating soluble and insoluble protein fractions from fly head extracts. Soluble 
A! is defined as any species that does not pellet and is retained in the supernatant 
following high-speed centrifugation. At day 15, when the first signs of pathology 
were observed in UAS-Arctic A!42/+;elavGS/+ flies (see climbing data below), 
most of the A!42 had accumulated in an insoluble form (Figure 3.5), consistent 
with the aggregation-promoting effects of the Arctic mutation. Interestingly, all 
the A!42 in non-RU-treated flies was found in a soluble state.  
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Figure 3.5. Arctic A!42 peptide in the adult Drosophila neurons was mostly 
in an insoluble state. In the absence of the RU486 (-RU) a negligible amount of 
soluble protein was observed at day 15. Following treatment with RU486 (+RU; 
red) the A! peptide expression was seen in both soluble and insoluble fractions, 
with a significant proportion observed in the insoluble fraction. Data are 
presented as means +/- SEM (n = 3) and were analysed by Student’s t-test. 
P<0.01 when mean protein levels of soluble and insoluble fractions of A!42 
expressing flies (+RU) were compared. 
 
3.2.5 Over-expression of Arctic A"42 peptide in adult neurons 
increases mortality and induces neuronal dysfunction in Drosophila, 
without evidence of neuronal cell loss 
Previously published studies have shown that constitutive expression of Arctic 
A!42 peptide in fly neurons significantly shortens lifespan, induces behavioural 
impairments and causes neuronal death (Finelli et al. 2004; Iijima et al. 2004; 
Crowther et al. 2005). To determine whether adult-onset expression of Arctic 
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A!42 peptide in neurons causes similar phenotypes, I examined survival, and 
neuronal and behavioural dysfunction in UAS-Arctic A!42/+;elavGS/+ flies. 
 
First, the effect of Arctic A!42 over-expression on lifespan was measured by 
treating UAS-Arctic A!42/+;elavGS/+ and UAS-A!40/+;elavGS/+ flies with 
200#M RU from two days-post eclosion and recording their survival (Figure 
3.6). Flies maintained on SY medium containing no RU (-RU) were used as 
controls. Induced expression of Arctic A!42 in adult neurons significantly 
shortened median lifespan by about 50% in comparison to non-RU-treated 
controls (P<0.0001, log rank test). Induced expression of A!40 did not shorten 
lifespan at all when compared to non-RU-treated UAS-A!40/+;elavGS/+ flies (P 
= 0.48, log rank test). This demonstrated a specific lifespan-shortening effect of 
Arctic A!42 compared to the A!40 form of the peptide. Interestingly, the leaky 
expression previously detected in non-RU-treated UAS-Arctic A!42/+;elavGS/+ 
flies did result in a slight reduction in lifespan, when compared to UAS-
A!40/+;elavGS/+ treated flies (P<0.01 for both comparisons, log rank test). 
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Figure 3.6. Expression of Arctic A!42 specifically in adult neurons 
shortened lifespan. Survival curves are depicted and data were compared using 
the log-rank test. Median lifespans are: 33 days for Arctic A!42 +RU, and 66 
days for Arctic A!42 –RU, A!40 –RU and A!40 +RU. Log rank tests: Arctic 
A!42 +RU vs Arctic A!42-RU (P<0.0001), A!40 –RU versus A!40 +RU (P = 
0.48), Arctic A!42 –RU versus A!40 –RU/+RU (P<0.01).   
 
 
To determine whether adult-onset expression of the Arctic A!42 peptide caused 
neuronal toxicity, neuronal function was analysed directly, by recording 
electrophysiological responses of the Drosophila giant fibre system (GFS) and 
indirectly, by measuring negative geotaxis (climbing ability). 
 
The GFS is a neural circuit that mediates the fly’s escape response (Allen et al. 
2006). Stimulation of the giant fibre neuron in the brain results in depolarisation 
of the tergotrochanteral (TTM) jump muscle and the dorsal longitudinal flight 
muscle (DLM). Placement of stimulating electrodes in the giant fibre neuron and 
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recording electrodes in the TTM or DLM allows one to measure the response 
latency – the time taken for a given stimulation to generate depolarisation of the 
muscle. The electrophysiological responses of the GFS were measured to directly 
examine the response of neuronal function to Arctic A!42 (Figure 3.7). GFS 
activity was measured in UAS-Arctic A!42/+;elavGS/+ flies treated with 200#M 
RU486 from two days post-eclosion at day 16 and day 28 into treatment. Giant 
fibres (GF) were stimulated via electrodes inserted inside the compound eye, and 
post-synaptic potentials recorded in the TTM and DLM. Parameters measured 
were the latency from GF stimulation to muscle response and the stability of the 
response to high frequency stimulation. At day 16, response latencies in the 
TTM, DLM and the TTM to high frequency stimulation were comparable 
between UAS-Arctic A!42/+;elavGS/+ flies on +RU and -RU. However, at day 
28, expression of Arctic A!42 peptide significantly increased the response 
latency measured in both the TTM and DLM, and inhibited the stability of the 
TTM response to high frequency stimulation (at 100, 200 and 250 Hz) in 
comparison to untreated control flies (see figure for statistics). This indicated a 
progressive neuronal dysfunction following adult-onset induction of Arctic 
A!42, with young flies exhibiting no dysfunction in the GFS, while older flies 
showed obvious defects in response to both a single stimulus and to high-
frequency stimuli. 
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Figure 3.7. Arctic A!42 peptides induced progressive, adult-onset neuronal 
defects in Drosophila. (a) A schematic illustration of the Drosophila giant fibre 
system [GFS; adapted from Allen et al. (2006)]. Giant fibres (GFs; blue) relay 
signals from the brain to the thoracic musculature via mixed electrochemical 
synapses with the motorneurons (TTMn, red) of the tergotrancheral muscle 
(TTM; left), and the peripherally synapsing interneuron (PSI; green), which 
subsequently forms chemical synapses with the motorneurons (DLMn; orange) 
of the dorsal longitudinal muscles (DLM; right). Note only one of the TTMn 
  116 
axons is shown exiting the nervous system and contacting the muscle on the left 
hand side and one set of the DLMns and corresponding neuromuscular junctions 
are depicted on the right hand side. GFS activity was measured in UAS-Arctic 
A!42/+;elavGS/+ at (b) 16 days and (c) 28 days post-RU486 treatment; 
parameters measured were the latencies from GF stimulation to muscle response 
(response latency DLM and TTM) and the stability of the response to high 
frequency stimulation at 100, 200 and 250 Hz (high frequency stimulation TTM). 
Data are presented as the mean response +/- SEM (n = 8) and were analysed by 
Student’s t-test, at each time point, on log-derived data. *P<0.05, **P<0.01 
comparing response latency or response to high frequency stimulation of UAS-
ArcA!42/+;elavGS/+ +RU flies to -RU controls at 28 days post-induction. Note: 
H. Augustin performed all electrophysiology work. 
 
As a behavioural, indirect measure of neuronal dysfunction, locomotor activity 
was assessed using a negative geotaxis (climbing) assay. Numerous labs have 
demonstrated that negative geotaxis declines with age in wild type flies (Cook-
Wiens and Grotewiel. 2002). However, flies expressing A! peptides show a 
further decline in climbing ability (Iijima et al. 2004; Crowther et al. 2005).  
 
Negative geotaxis was measured in UAS-ArcA!42/+;elavGS/+ and UAS-
ArcA!40/+;elavGS/+ flies treated with  200#M RU486 from two-days post-
eclosion (Figure 3.8). Non-RU-treated flies from both genotypes were used as 
controls. As stated earlier, Drosophila display an age-related decline in climbing 
behaviour, and this was apparent in the non-RU-treated and UAS-
ArcA!40/+;elavGS/+ +RU control flies. However, flies expressing Arctic A!42 
displayed a reduced negative geotaxis in comparison to their -RU control flies 
and the A!40 +RU and -RU flies from day 14 onwards (P<0.05, two-way 
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ANOVA). The climbing behaviour of the Arctic A!42 flies had declined to a 
level by ~ day 12 that was reached by the control flies only by day 28. 
 
 
 
 
 
Figure 3.8. Expression of Arctic A!42 peptides in the adult fly nervous 
system caused locomotor dysfunction. Climbing ability of UAS-
ArcA!42/+;elavGS/+ and UAS-A!40/+;elavGS/+ flies on + and - RU486 SY 
medium was assessed at the indicated time-points. Data are presented as the 
average performance index (PI) +/- SEM (n = 3, number of flies per group = 39-
45) and were compared using two-way ANOVA and Tukey’s honestly 
significant difference (HSD) post-hoc analyses. The PI of UAS-Arctic 
A!42/+;elavGS/+ +RU flies to that of untreated and A!40 over-expressing 
controls was significantly lower from day 14 onwards (P<0.05 all timepoints, 
two-way ANOVA). 
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To assess whether the effects of induced Arctic A!42 over-expresion on lifespan, 
neuronal function and locomotor function resulted from neuronal death, neuronal 
loss was quantified at day 21 in UAS-Arctic A!42/+;elavGS/+ treated with + and 
– RU from two-days post eclosion.  Interestingly, there was no evidence of 
neuronal loss in the brains of flies overexpressing A!42 peptide (Figure 3.9). 
 
 
 
Figure 3.9. Neuronal cell loss was not evident in flies over-expressing Arctic 
A!42 peptide in adulthood. Cell loss was quantified at day 21 in UAS-Arctic 
A!42/+;elavGS flies, fed with + or – RU from two-days post-eclosion. Flies 
were maintained at 27ºC and neuronal loss was quantified by counting the 
number of cell bodies per brain hemisphere. Cell bodies were counted double 
blind. Data are presented as the means +/- SEM (n = 7 per genotype). No 
significant difference in the number of cell bodies was observed when comparing 
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+RU and –RU (Student’s t-test). This work was a collaborative effort with Dr. 
Oyinkan Sofola. 
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3.3 Discussion 
3.3.1 Induction with the GeneSwitch system is robust but declines 
with age 
First and foremost, the results in this chapter reaffirm that the GeneSwitch 
system is an effective platform for inducing UAS-transgene overexpression in 
the adult fly. Induction was achieved by dissolving the inducer, RU486, in SY 
media (prior to dispensing and polymerisation) at a final concentration of 200#M 
or ~86ug/ml (method developed by Giannakou et al. 2004). It is interesting to 
note that other delivery methods have been used, such as adding RU486-
supplemented yeast paste to the food (Hwangbo et al. 2004) or adding a single 
drop of RU486 solution to soak into the food (‘on-food’ method) (Ford et al. 
2007). All delivery methods have been shown to be effective in inducing 
expression (Poirier et al. 2008), with the ‘on food’ method considered the most 
dose-responsive and consistent between genders (Poirier et al. 2008). Despite 
this, I decided to use ‘in food’ delivery because it was the most practical (when 
preparing many vials of SY) and because gender differences in expression were 
not important, since only females were used. Furthermore, dissolving RU486 
into the food ensured the flies were given no choice between drug and drug-free 
food when feeding. 
 
The ‘in-food’ method proved to be rapid and robust. In UAS-lacZ/+;elavGS/+ 
flies significant beta-gal activity (compared to uninduced levels) was detected 8-
12 hours following RU exposure. Similarly, elevated A!42 transcript and protein 
levels were detected after two-days of RU treatment (although this may have 
been sooner if earlier timepoints were assayed). This kinetic data agrees with 
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other studies where induction was detected 5 hours (Osterwalder et al. 2001) and 
one-day (Poirier et al. 2008) following RU exposure. The disparity in the 
induction times is probably a reflection of the different protocols, drivers and 
delivery methods used. For instance, Ostweralder et al (2001) used larvae bathed 
in RU486, whereas Poirier et al (2008) used the ‘on-food’ delivery method. In 
any case, the issue here is not the differences in the response time to RU486 but 
the obvious sensitivity of the GeneSwitch system to different protocols. Thus, 
these differences highlighted the necessity to keep drug dose and delivery 
consistent between experiments. 
 
The results in this chapter also demonstrate that the level of expression driven 
with elavGS declines over time. There was a significant decline in A!42 and 
A!40 mRNA expression from four-days to 21-days of age. This was most likely 
due to a reduction in the amount of RU486 ingested as feeding behaviour has 
been shown to decrease with age in Drosophila melanogaster (Wong et al. 
2009). This is an inevitable drawback of using the in-food delivery method. 
Direct injection of a known concentration of RU486 solution into each individual 
fly might offer the best way of avoiding this problem but it is not practical for 
large experiments. 
 
Temporal variation in transgene expression with the GAL4/UAS system is 
common and has been seen with standard GAL4 (Seroude. 2002) and 
GeneSwitch drivers (Poirier et al. 2008). Interestingly, Poirier et al (2008) 
observed a steady increase in gene expression, using beta-gal activity as a proxy 
measure of UAS-lacZ expression, with the elavGS302.1 driver in female flies. 
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Although this may appear to contradict the data discussed above, it does agree 
with the protein data, which also indicated an increase in A!42 expression over 
time. However, using protein expression as a proxy of gene expression is flawed 
because protein perdurance can bias data interpretation. Extremely stable 
proteins might imply gene expression was constant or increasing, when in fact,  
transcripts were decreasing (as in the case of the inducible model). Beta-gal and 
Arctic A!42 are incredibly stable, and in the latter’s case, aggregation-prone 
proteins. Thus, the relative perdurance of A!42 protein likely explains the 
opposite movement of A!42 mRNA and protein expression levels over time.  
 
3.3.2 Transgene expression in the absence of RU486 is a feature of 
the GeneSwitch system 
A key criterion for any conditional system is the absence of expression in the 
absence of the inducer (control group). The results in this chapter demonstrate 
that the GeneSwitch system is not truly conditional. !-gal activity and A!42 
mRNA and protein expression was evident in non-RU-treated control UAS-
lacZ/+;elavGS and UAS-Arctic A!42/+;elavGS/+ flies, respectively. Because 
whole fly homogenates were used in the !-gal assay, it is possible that !-
galactosidase present in the fly’s gut bacteria were contributing to this signal. 
This agrees with that observation that uninduced !-gal activity did not change 
over time (48 hours). However, in the case of A!42 expressing flies, there was 
no other possible source of the human A!42 peptide. In non-RU-treated flies, 
A!42 expression was clearly evident at the transcript and protein level. Although 
A!42 transcript levels did not change between the two timepoints assayed, there 
was an accumulation of A!42 protein.  
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Expression in the absence of RU486 seems to be a common and unavoidable 
feature of the GeneSwitch system. In the original work by Osterwalder et al 
(2001), very low expression of reporter genes was detected in the absence of 
RU486. Furthermore, this feature has been observed in many studies since 
(Giannakou et al. 2007; Ford et al. 2007; Poirier et al. 2008). The problem of 
‘leaky’ expression in the non-RU-treated control groups raises the question of 
whether GeneSwitch is really suitable for the development of conditional, adult-
onset models of age-related disease as outlined in this chapter. I think the answer 
to this question is a resounding ‘yes’. The leakiness of the GeneSwitch system 
does render it unsuitable for studying the effect of gene expression at a specific 
timepoint (e.g. during L1 phase) since it would be difficult to determine if any 
effects were due to expression at the specified timepoint or leaky expression at 
some other timepoint. However, in the case of modelling AD the main concern 
was whether the induced and leaky domains of expression would overlap, and 
whether the leaky expression was below the threshold required for toxicity. In 
the first instance, leaky expression was very low relative to induced levels and 
secondly, had no effect on climbing ability and only a slight effect on lifespan. In 
any case, the comparisons made in this chapter and the remainder of this thesis 
were always relative to the non-RU-treated controls rather than the wild-type 
background. 
 
3.3.3 The inducible AD model in relation to other fly models of A"42 
toxicity 
This study extended the characterisation of fly AD models by examining the 
effect of A"42 expression exclusively in adulthood by using the inducible 
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GeneSwitch system. Since there are a large number of pre-existing models of AD 
in the fly, particularly models of A!42 toxicity, it will be relevant to discuss the 
findings of this chapter in relation to other models of AD in the fly.  
 
Induced over-expression of the Arctic A!42 peptide in adult fly neurons led to a 
marked reduction in lifespan, neuronal dysfunction, as seen directly in the GFS, 
and behaviourial impairments. On the other hand, induced over-expression of the 
A!40 peptide had no effect on these phenotypes. These findings are in agreement 
with previously reported studies (Finelli et al. 2004; Iijima et al. 2004; Crowther 
et al. 2005). Of particular interest to this thesis are comparisons between the 
inducible model and the Crowther model since they both used the same UAS-
reagents. In general, the phenotypes presented in this model were much less 
severe. For instance, Crowther et al (2005) reported that flies expressing one 
copy of the UAS-Arctic A!42 transgene had a median lifespan of six-days at 
29°C, and were completely immobile by two-days post eclosion. Compare this 
with 33 days and 25 days respectively, in this model. Furthermore, Crowther et 
al (2005) observed a marked rough eye phenotype (mild developmental 
abnormality of the corneal lens of the compound eye) at eclosion. With this 
model, a rough eye phenotype was never observed at any age during experiments 
 
These striking differences are most likely a consequence of the extreme 
experimental conditions used by Crowther et al (2005). Apart from the 
quantification of neuronal loss (Figure 3.9), all experiments in this chapter were 
carried out at 25°C, whereas in the comparative study flies were raised and 
maintained at 29°C. This was to ensure high levels of transgene expression. 
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Drosophila are ectotherms, which means they are too small to regulate their own 
temperature and are thus forced to adopt ambient temperature. In Drosophila, 
lowered temperature increases lifespan entirely by lowering the slope of the 
mortality trajectory, with no effect on the initial mortality rate (Mair et al. 2003). 
In other words, lowering the temperature decreases the rate of ageing in 
Drosophila. This explains why flies expressing A!42 in the inducible model 
were longer lived. This is exemplified by the fact even w1118 wild-type flies had a 
median lifespan of 20 days in the Crowther study. Furthermore, since negative 
geotaxis is also a function of ageing, the difference in experimental temperature 
underpins the relatively slower decline in negative geotaxis seen in these results.  
 
Interestingly, when Crowther et al (2005) performed lifespan assays at 25°C 
rather than 29°C, flies with one copy of UAS-Arctic A!42 exhibited a median 
lifespan of 10 days. This is still significantly shorter than the results seen in this 
chapter. This difference cannot be due to differences in temperature. It is 
possible that expression with the elavc155 driver is much greater than that with 
elavGS and RU486. Alternatively, this could be due to the accumulation of 
A!42-mediated damage during the development process. The latter point 
certainly fits in with the fact Crowther et al (2005) observed a marked rough eye 
phenotype at eclosion, which was absent in flies from this study. Further studies, 
directly comparing the expression levels and their consequences on lifespan and 
negative geotaxis would be useful in exploring this issue. 
 
Although the phenotypic characterisation of the inducible model paralleled other 
reports, there was one major difference; no neuronal loss was observed in the 
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brains of flies over-expressing A!42. This finding contrasts with previous reports 
that flies over-expressing Arctic A!42, using the constitutive neuronal driver, 
elavc155, develop vacuoles (Iijima et al. 2004; Crowther et al. 2005). These 
contrasting results could be reconciled if neuronal loss upon A!42 over-
expression is a consequence of developmental abnormalities in the Drosophila 
brain or if neuronal loss represents an end-stage event in response to A!42 
toxicity, since vacuolation has been reported only under the most extreme 
conditions of expression, age and temperature, while neuronal toxicity in these 
models is already apparent under less stringent conditions (Crowther et al. 2005). 
Importantly, these findings agree with those of other studies demonstrating that 
neuronal loss is generally not evident in murine models of amyloidosis, such as 
in mice transgenic for the amyloid precursor protein (McGowan et al. 2006). 
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Chapter 4 Testing the interaction between 
ageing and AD using an inducible model of AD 
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4.1 Introduction 
One of the major unresolved questions in AD research and the neurodegenerative 
field in general, asks why does neurodegeneration occur late in life? More 
specifically, why do totally distinct disorders, defined by different sets of clinical 
and neuropathological descriptors, share similar temporal emergence patterns 
(Cohen & Dillin. 2008)?  
 
The mechanisms linking protein aggregation and the appearance of disease to 
age remain to be identified. One possibility is that protein aggregation is a 
stochastic process requiring many years to accumulate to toxic levels, so that 
neurons would start to lose function when toxic proteins reach a certain threshold 
concentration. Another suggestion is that the duration of exposure or cumulative 
exposure to a pathogenic protein is what leads to neuronal dysfunction. This 
would lead to the prediction that the total length of exposure, or the area under 
the curve of toxic protein concentration over time, would predict the age at 
which neuronal function starts to decline. A third possibility is that the ageing 
process itself increases vulnerability of neurons to protein toxicity, so that a fixed 
exposure is more likely to lead to dysfunction  in old age (Cohen et al. 2006). All 
of these factors could be important – they are not mutually exclusive. 
 
One approach to investigating the mechanisms leading to late-onset 
neurodegeneration is to alter the rate of ageing in transgenic animal models of 
AD to see whether these interventions ameliorate pathology. Modulating ageing 
in model organisms can be achieved in many ways: genetically, via the 
downregulation of evolutionary conserved nutrient-sensing pathways such as the 
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IIS or TOR pathway; pharmacologically, with drugs such as rapamycin and 
resveratrol; or with dietary restriction. All these interventions have been shown 
to extend lifespan, and remarkably, have all been shown to suppress pathology in 
a range of AD disease models (for review see Douglas & Dillin. 2010). 
Collectively, these studies support an active role for the ageing process in the 
development of neurodegenerative disease. 
 
An alternative approach to investigating the mechanisms leading to late-onset 
neurodegeneration is to induce expression of a toxic protein to different levels, or 
for different lengths of time and at different ages, to disentangle the mechanisms 
at work. This approach differs in that it makes no assumptions about the ageing 
process and what genes or pathways may be important in modulating it. Rather, 
it aims to measure effect the effect of normal physiological ageing. If ageing 
were to play an active mechanistic role in enabling neurodegeneration then one 
would expect that standardised exposure of older neurons to a toxic protein 
would lead them to develop pathology at a faster rate, or to a greater extent, than 
young neurons. In the few studies that have addressed this issue, older organisms 
have been found to be more vulnerable. Brewer et al., (1998) isolated neurons 
from embryonic, young and old-aged rat hippocampus and exposed them to toxic 
A! fragments (25-35). Toxicity as measured by cell death was found to be age, 
dose and time-dependent. The maximum toxicity in cells treated for 1 day with 
25 #M A! (25-35) was 16%, 24% and 33% for embryonic, young and old cells 
respectively. In another study, Guela et al., (1998) demonstrated that aged rhesus 
monkeys are more vulnerable to injected plaque-equivalent concentrations of 
fibrillar A! when compared to young rhesus monkeys, which developed no 
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pathology at all. However, these two studies used either extracellular application 
of A! fragments or microinjection of fibrillar A! to induce toxicity at different 
ages, a drawback of which is that it makes assumptions about the nature of A! 
toxicity. Moreover, these studies may not truly reflect the human disease since it 
is increasingly believed that intracellular (Laferla et al. 2007), soluble oligomers 
of A! are pathogenic (Walsh & Selkoe. 2007), rather than extracellular, fibrillar 
forms of the peptide. A more accurate model of the disease process may, 
therefore, be achieved by inducing protein expression using conditional 
transgenic systems, so that A! originates intracellularly and aggregates under 
physiological conditions.  
 
This approach was used  in the preceding chapter, whereby  expression of the 
FAD-associated Arctic A!42  isoform was induced in adult neurons of the fruit 
fly Drosophila melanogaster. Induction of A!42 in young adult flies resulted in 
age-dependent locomotor and electrophysiology deficits and shortened lifespan. 
The aim of this chapter was to further characterise the flexibility of the inducible 
AD model with the overall aim of investigating the effect of ageing as a risk 
factor for A! toxicity. First, the dynamics of Arctic A! expression with the 
elavGS-UAS system were evaluated. I then sought to exploit these dynamics to 
investigate the role of ageing in response to A!42-mediated toxicity. In particular 
I aimed to induce Arctic A!42 expression at progressively later ages in adult fly 
neurons and then measure the time to develop, and extent of, known markers of 
toxicity such as survival.  
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4.2 Results 
4.2.1 Dynamics of Arctic A"42 transcript and protein expression 
using the elavGS-UAS system 
I previously characterised an adult-onset fly model of Alzheimer’s disease, 
generated by expressing the Arctic A!42 peptide under the control of an RU486-
inducible pan-neuronal driver. In the current study I aimed to investigate the 
effects of standardised A!42 induction on toxicity at different ages, and so it was 
important to firstly understand the dynamics of transgene and protein expression 
and repression using this inducible system.  
 
My previous study demonstrated that Arctic A!42 is expressed, at both the RNA 
and protein level, within four days following induction with RU486. A!42 RNA 
expression declined with age, most likely reflecting a lower intake of the inducer 
RU486 due to an age-dependent reduction in feeding behaviour (Wong et al. 
2010). A!42 protein levels, however, increased with age, either reflecting a time-
dependent accumulation of the peptide or an age-dependent reduction in protein 
turnover. This suggests that both the concentration of RU486 and the length of 
induction would need to be controlled for in order to standardise the level of 
A!42 expression at varying ages. 
 
It was first necessary to confirm RU486 removal represses UAS-transgene 
expression with the GeneSwitch system. This was assessed in two ways. First, as 
in the previous chapter, !-galactosidase activity was used as a proxy for gene 
expression. UAS-lac/+;elavGS/+ flies were treated with 200#M RU486 from 2-
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days post-eclosion for seven days, and then transferred to RU486-free food SY 
food for 4, 12, 24 and 48 hours. Flies maintained on –RU486 and +RU486 for 
the entirety of each experiment were used as controls (Figure 4.1). 
 
Figure 4.1. The effect of RU486 removal on !-galactosidase activity. Liquid 
!-galactosidase assays were carried out on once-mated female UAS-
lacZ/+;elavGS flies. Flies were exposed to +/- RU486 at day 2 for 7 days, and 
then transferred to –RU486 1.0 SY food for 4, 12, 24 and 48 hours. Data are 
presented as means +/- SEM (n = 5 for each condition). *P<0.05 comparing beta-
gal activity in flies switched to –RU486 for 48 hours to flies maintained on 
+RU486 (Student’s t-test) 
 
In chapter 3 it was shown that application of RU486 led to a significant increase 
in transgene expression (using beta-gal activity as a proxy for gene expression) 
within 8-12 hours. The kinetics of repression were much slower. A significant 
drop in !-galactosidase activity was only seen 48 hours (P<0.01, Student’s t-test) 
after the switch to –RU486. This drop only amounted to a 40% reduction in beta-
gal activity. Thus, these results highlighted a difference in the kinetics of 
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induction and repression with the GeneSwitch system and were in agreement 
with other studies reporting a relatively slower suppression of GFP expression 
following RU486 removal (Osterwalder et al. 2001). This difference could have 
been attributable to the perdurance of !-galactosidase. Therefore, to fully assess 
repression dynamics in the context of modelling AD, switch off experiments 
were performed using Q-PCR to profile the level of Arctic A!42 mRNA 
following RU486 removal. 
 
UAS-Arctic A"42/+;elavGS/+ flies were treated with 200µM RU486 from two-
days post-eclosion for 7 days, and then transferred to RU486-free SY. In contrast 
to the !-galactosidase data, Arctic A!42 transcript returned to baseline, un-
induced levels within 24 hours of RU486 removal (Figure 4.2). Thus, at the 
transcript level repression is rapid. On the other hand, no significant reduction in 
Arctic A!42 protein concentration was observed over several weeks following 
removal of RU486 under similar induction conditions (see below; Figure 4.8). 
These data suggest that, although A!42 production could be rapidly switched-off 
using the GeneSwitch system, the Arctic A!42 peptide was highly resistant to 
degradation in these flies.   
 
 
 
 
 
 
 
  134 
 
Figure 4.2. Removal of RU486 results in a robust decline in UAS-Arctic 
A!42 mRNA expression. Arctic A!42 mRNA expression levels in the heads of 
UAS-Arctic A!42/+;elavGS/+ once-mated females treated with 200#M RU486 
from two-days post eclosion for one-week. mRNA levels were assayed at 2-days 
prior to RU486 treatment (day 2), at the end of RU486 treamtment (day 9) and 
24hrs (day 10), 48hrs (day 11) and a week (day 16) following the switch to 
RU486-free food. *P<0.05 when comparing the level of Arctic A!42 mRNA at 
day 9 to all other timepoints (ANOVA). 
 
4.2.2 A!42-mediated toxicity correlates with total Arctic A!42 
concentration in young flies 
As A!42 peptide concentration accumulates with age, I next investigated the 
relationship between the length of induction, at a given age, and the extent of 
toxicity in the fly. UAS-Arctic A!42/+;elavGS/+ once-mated females were 
treated with 200#M RU486 SY from two-days post eclosion before being 
switched back to RU486-free SY at progressively later ages. This ‘switch-on, 
switch-off’ regime will be from hereon in known as a RU486 pulse. Flies were 
‘pulsed’ for two, four and seven days, as outlined below (Table 2) and 
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subsequently assayed for A!42 protein expression (Figure 4.3), negative 
geotaxis (Figure 4.4) and survival (Figure 4.5). Flies maintained chronically on 
–RU486 and 200#M RU486 media were used as negative and positive controls, 
respectively.  
  
Treatment Day switched-on Day switched to –RU 
-RU n/a n/a 
+2d RU 2 4 
+4d RU 2 6 
+1wk RU 2 9 
+RU (chronic) 2 n/a 
 
Table 2. The various RU486 pulses used in switch-off experiments. Note that 
these days are ‘post-eclosion and that all flies were treated with RU486 at the 
same age (2-days post-eclosion). 
 
A!42 protein levels increased in correlation with the length of RU486 treatment 
(Figure 4.3). Hence, at the protein level A!42 appeared to accumulate with 
longer periods of transgene expression, possibly as a consequence of the high 
stability of the peptide. An increase in RU486 exposure also correlated with 
enhanced negative geotaxis (Figure 4.4) and shortened lifespan (Figure 4.5). 
Chronic, one-week and four-day RU486 treatments produced significant declines 
in climbing ability compared to untreated controls (60%, 50% and 29% 
respectively). However, two-day treated flies displayed an ageing-related decline 
that did not differ from controls (Figure 4.3), suggesting that this induction 
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condition was below the threshold to cause neuronal dysfunction in response to 
A!42.  Similarly, chronic RU486 treatment produced the largest (56%), and two-
day treatment the smallest (11%), reduction in median lifespan compared to non-
RU-treated controls (Figure 4.5). As this two-day pulse was sufficient to induce 
a reduction in lifespan, it suggests that survival was more sensitive to changes in 
RU486 exposure time than climbing ability.  
 
Since the Arctic A!42 peptide was highly resistant to degradation for up to three 
weeks following ‘switch-off’ of RNA production (see below; Figure 4.8), 
varying the length of RU486 exposure may be viewed as inducing a dose-
response to A!42 at a given time. This data, therefore, indicated that inducing 
A!42 expression in young flies leads to pathogenic phenotypes later in life that 
are dependent on the dose of A!42. These findings were important because they 
indicated that to induce the equivalent level of toxicity at different ages it would 
be necessary to induce the same Arctic A!42 dose at those ages. 
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Figure 4.3. Total A!42 protein load increases with RU486 exposure time. 
Total Arctic A!42 protein levels were quantified at the end of each RU486 pulse 
in UAS-Arctic A!42/+;elavGS females. Data are presented as the mean total 
Arctic A!42 concentration (pmoles/g total protein) +/- SEM (n = 3 for each 
group). Total Arctic A!42 protein levels were significantly different between all 
treatments. *P<0.05 when comparing highlighted treatment with preceding e.g. 
+1wk RU versus +4d RU (Student’s t-test). 
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Figure 4.4. Locomotor dysfunction increases with RU486 exposure time. 
Climbing ability of UAS-ArcA!42/+;elavGS/+ females pulsed with RU486 for 
2,4 and 7 days was assessed at the indicated time-points. Flies maintained on –
RU486 (-RU) and 200#M RU486 (+RU chronic) were used as negative and 
positive controls, respectively. Data are presented as (a) the average performance 
index (PI) +/- SEM (n = 3, number of flies per group = 39-45) over time and (b) 
the average total negative geotaxis/area under the curve (PI*days) +/- SEM (n = 
3) *P<0.05 when comparing total negative geotaxis between the indicated 
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groups, n.s. represents non-significant differences between groups (Student’s t-
test). 
 
 
 
 
Figure 4.5. Mortality increases with RU486 exposure time. Survival curves of 
UAS-Arctic A!42/+;elavGS/+ females pulsed with 200#M RU486 from two-
days post-eclosion for 2, 4 and 7 days before being transferred to non-RU-treated 
SY. Flies permanently maintained on –RU486 (-RU) and 200#M RU486 (+RU 
chronic) were used as negative and positive controls, respectively. Median 
lifespans are as follows: 62 days for –RU, 55 days for +2d RU, 52 days for +4d 
RU, 45 days for +1wk RU and 27 days for +chronic RU. All survival curves 
were significantly different from each other (P<0.001, log rank test). 
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4.2.3 The challenges of measuring the effect of ageing on Arctic 
A"42-mediated toxicity 
To assess the effects of age on the vulnerability of flies to A!42, I aimed to 
induce toxicity at progressively later ages and then to measure the delay to, and 
extent of, resultant pathological phenotypes. Although survival and negative 
geotaxis are useful surrogate markers of A!42 toxicity, they are also directly 
affected by ageing and this presented a technical challenge for such 
investigations. It was important that at all ages of induction RU486 treatment 
resulted in phenotypes that were significantly different from their respective 
untreated controls, with induction at a time-point prior to the onset of ageing-
related decline. However, the ages of induction needed to be far enough apart to 
resolve any effect of the ageing process. Consequently two to five and 20 days 
post-eclosion were selected as young and old flies respectively, although these 
labels are somewhat arbitrary and serve only to highlight the difference in age. 
Since survival appeared to be more sensitive to alterations in the level of A!42 
as described above, I continued to use this as a marker of toxicity for subsequent 
studies. 
 
4.2.4 Arctic A"42 transcript expression equalisation in young and 
old flies 
My first attempt at inducing equivalent levels of Arctic A!42 protein toxicity 
was largely unsuccessful. To induce an equivalent level of Arctic A!42-mediated 
toxicity, I first sought to equalise Arctic A!42 mRNA expression between young 
(5d) and old (20d) UAS-Arctic A!42/+;elavGS/+ flies. As RNA expression 
declines with age, most likely reflecting a lower intake of RU486 due to reduced 
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feeding behaviour, and protein levels increase with age, in correlation with the 
length of the induction period, I hypothesised that A!42 expression could be 
normalised at different ages by regulating both of these parameters. In particular 
I predicted that a relatively higher dose of RU486 would be required to induce 
equivalent levels of expression in older flies to compensate for reduced food 
intake.  
 
To ascertain what combination of RU486 doses in young and old flies would 
result in equivalent transgene expression levels 5-day and 20-day old UAS-Arctic 
A!42/+;elavGS/+ flies were treated with a range of RU486 concentrations (0-
200#M) for one week. At the end of treatment, Arctic A!42 mRNA levels in fly 
heads were quantified by Q-PCR (Figure 4.6). Hence, the data below represents 
transcripts levels at the end of the RU treatment, i.e. day 12 and day 27 
respectively. 
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Figure 4.6. Arctic A!42 mRNA expression equalisation in young and old 
flies. (a) Arctic A!42 mRNA expression levels (calculated relative to w1118) in 
the heads of UAS-Arctic A!42/+;elavGS/+ once-mated females treated with 0, 
50, 100 and 200#M RU486 for one week from 5-days and 20-days post-eclosion, 
as measured by Q-PCR. (b) A!42 mRNA expression levels were equivalent in 5 
day-old and 20 day-old UAS-Arctic A!42/+;elavGS/+  flies treated with 50#M 
and 200#M RU486, respectively (this data represents a replicate of the 
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concentrations used in (a). Data are presented as means +/- SEM (n = 5 for each 
group). Data were compared using Student’s t-test.  
 
RU486 treatment in both young and old flies resulted in Arctic A!42 mRNA 
overexpression at all doses. In both groups transcript levels were significantly 
higher at all concentrations, when compared to their respective age-matched non-
RU-treated (0#M RU) controls (P<0.05). This indicated that doses as low as 
50#M RU486 were sufficient to induce expression. 
 
As has been observed previously, mRNA transcripts were detected in non-RU-
treated controls, however these were negligible and did not accumulate with age. 
At all doses, Arctic A!42 mRNA expression was higher in young flies when 
compared to old (P<0.05 for all doses). This was consistent with a reduced 
feeding behaviour in older flies. 
 
Comparisons within each age group revealed that expression correlated with 
RU486 dose but to varying degrees. There was no significant difference in Arctic 
A!42 mRNA levels in young flies treated with 100#M and 200#M RU486, 
although they were significantly higher than levels using 50#M RU (P<0.05, 
Student’s t-test). When comparing doses in older flies, no significant difference 
was found between 50#M and 100#M RU486 but levels were significantly 
higher in 200#M RU486-treated flies.  
 
When comparing doses between young and old flies, equivalent levels of A!42 
mRNA were seen using RU treatments of 50#M and 200#M, respectively 
(Figure 4.6b). Notably, these were the only two conditions across age where 
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expression was equivalent. The fact a higher dose was required to generate the 
same level of expression in older flies fitted nicely with the original prediction 
that higher doses could compensate reduced feeding behaviour. 
 
4.2.5 Ageing increases A!42 peptide accumulation and toxicity 
when Arctic A!42 transgene expression is normalised between 
young and old flies 
Next I measured the effect of normalised Arctic A!42 gene expression on 
lifespan as a measure of toxicity at different ages (Figure 4.7). 5 day-old (young) 
and 20 day-old (old) UAS-Arctic A!42/+;elavGS/+ flies were respectively pulsed 
with 50#M and 200#M RU486 for one week, before switching back to RU486-
free food. Un-treated flies were used as controls as this had a negligible effect on 
lifespan (see Figure 3.6). Despite expressing the same level of A!42 mRNA at 
the end of their respective RU treatments (Figure 4.6b), only older-induced flies 
displayed a shortened lifespan in response to A!42-mediated toxicity (Figure 
4.7). However, to determine whether this was due to an age-dependent increase 
in neuronal vulnerability, it was important to establish whether Arctic A!42 
protein levels were also equivalent between young and old flies. 
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Figure 4.7. A!42 transcript equalisation reduces lifespan in old flies only. 
Survival curves of once-mated female UAS-Arctic A!42/+;elavGS/+ flies 
conditionally (one-week RU pulse) treated with 50#M, and 200#M from 5-days 
and 20-days post-eclosion, respectively. Median lifespans: 60 days for -RU, 58 
days for 5d +50 RU, and 53 days for 20d +200 RU. Log rank tests and p values: -
RU versus 5d+50 RU (p = 0.18), -RU versus 20d +200 RU (p<0.0001).  
 
Again flies were pulsed with RU486 for one week under the RNA equalisation 
conditions described above for young and old flies. Flies were frozen for protein 
extraction at the end of the one-week pulse (0d) and one, two and three weeks 
following the switch-off of transgene expression to assess the perdurance of 
A!42 peptide. A!42 peptide levels were measured by ELISA and normalised at 
each age of induction to their respective non-RU486-treated controls (Figure 
4.8), since the peptide accumulates with age even in un-induced flies (see Figure 
3.4b). Considerable levels of Arctic A!42 peptide were detected in both young 
and old-induced flies, but no significant reduction in A!42 was seen for up to 
three weeks following the switch to RU486-free food in either age group (Figure 
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4.8). This suggested that the Arctic A!42 isoform is highly resistant to 
degradation. Of further interest, A!42 levels were significantly higher in old-
induced compared to young-induced flies at all timepoints assayed (P<0.05, 
Student’s t-test). A greater concentration of A!42 peptide could, therefore, 
explain the relatively increased mortality observed upon induction in old flies. 
 
 
 
Figure 4.8. Arctic A!42 transcript equalisation has differential effects on 
protein expression in young and old flies. Arctic A!42 protein levels in the 
heads of once-mated female UAS-Arctic A!42/+;elavGS/+ flies conditionally 
treated (one week RU pulse) with 50#M and 200#M RU from 5-days and 20-
days post-eclosion as quantified by A!42-specific sandwich ELISA. Arctic A!42 
protein levels were assayed immediately after the pulse (0d) and up to 3 weeks 
following the switch to -RU. Data are presented as means +/- SEM (n = 4 for 
each group). Groups were compared using Student’s t-test. 
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Hence, at the protein level A!42 appears to accumulate faster in aged flies. Since 
mRNA levels were equivalent in old and young flies under these conditions, and 
protein turnover has been shown to decline with age in several organisms 
(Rattan. 1996), I hypothesised that this difference in Arctic A!42 peptide level 
was due to age-dependent effects on protein synthesis or degradation. As a 
measure of the rate of translation, 35S-methionine incorporation was assessed in 
in 5 day-old and 20-day old UAS-Arctic A!42/+;elavGS/+ flies (Figure 4.9).  
35S-methionine incorporation was significantly lower in older flies indicating a 
reduced rate of translation. An increase in protein synthesis was, therefore, 
unlikely to explain the accumulation of A!42 peptide in old flies. Hence, it was 
possible that the rate of degradation of A!42 was reduced with age and may have 
accounted for the higher levels of the peptide observed following induction in 
old flies.  
 
Together this data suggested that the ageing process enhances the accumulation 
of A!42, possibly by altering the rate of protein degradation, and that this 
increased level of the peptide exacerbates toxicity in older flies. However, to 
measure the vulnerability of older neurons to protein toxicity it would be 
necessary to control for changes in the rate of protein turnover with age.  
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Figure 4.9. Protein translation decreases with age. 35S-methionine 
incorporation in UAS-Arctic A!42/+;elavGS/+ flies conditionally treated with 
50#M and 200#M RU486 for one week from 5-days and 20-days post-eclosion, 
respectively. Data are presented as mean +/- SEM (n = 5 for each group). Groups 
were analysed using Student’s t-test (*P<0.05). 
 
4.2.6 Ageing increases neuronal vulnerability to equivalent 
concentrations of Arctic A!42 peptide in young versus old flies  
As the concentration of A!42 peptide induced differed greatly between young 
and old flies (Figure 4.8), and the toxic response to the peptide at a given age 
appeared to be dose-dependent (Figure 4.3), I aimed to obtain a more direct 
measure of the effects of ageing upon neuronal vulnerability to A!42 by 
inducing a standard concentration of the peptide at different ages. I first 
optimised conditions to induce equivalent levels of Arc A!42 peptide in young 
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and old flies using an unbiased approach where UAS-Arctic A!42/+;elavGS flies 
were treated to a range of RU486 concentrations (25-400#M RU) for varying 
exposure times (four days to two-weeks) from 5, 20 and 30 days of age, 
representing young, middle and old-aged flies, respectively (Figure 4.10). An 
extra induction at 30-days was included to increase the odds of finding 
equivalent expression and to provide more options when comparing the toxicity 
response. 
 
At the end of the induction period A!42 was measured at the protein level, by 
ELISA (Figure 4.10), in order to control for age-dependent differences in 
mRNA expression and protein turnover.  
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Figure 4.10. Arctic A!42 protein expression levels with age following 
conditional RU486 treatments. Arctic A!42 protein levels in the heads of UAS-
Arctic A!42/+;elavGS/+ once-mated females maintained on a variety of RU486 
SY food concentrations (25#M-400#M) for 4-days, 1-week and 2-weeks from 5-
days, 20-days and 30-days post-eclosion. Prior to RU486 treatment flies were 
maintained on RU486-free food. Arctic A!42 protein levels were quantified at 
the end of each treatment using A!42-specific sandwich ELISA. Data are 
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presented as means +/- SEM (n = 5 for each group). Please note the change in 
scale in each graph. Groups and conditions were compared using Student’s t-test. 
 
As expected, A!42 expression was dependent on the RU486 dose and exposure 
time. Hence, the largest doses with the longest exposures resulted in the highest 
levels of expression. Interestingly, within this range of RU486 concentrations 
and exposure times, there seemed to be no plateau effect on the level of Arctic 
A!42 expression. However, it is possible that induction periods greater than 2 
weeks would not yield higher levels of expression.  Expression levels were 
typically higher in younger flies and, as would be expected with a decline in 
feeding behaviour, invariably lowest in the oldest induced flies (30d). 
Furthermore, older flies seemed less sensitive to changes in RU486 dose.  
 
Differences in the level of expression between different groups were not the 
main concern at this point. In fact, what was really interesting were the 
treatments that showed minimal or no difference in UAS-Arctic A!42 levels 
across age. These treatments were as follows: (1) a one week pulse of 200 #M 
RU in five-day versus 20-day old flies, (2) a one week pulse of 100 #M RU in 
20-day old flies versus 200 #M RU in 30-day old flies and (3) a two week pulse 
of 100 #M RU in five-day old flies versus 200 #M RU in 20-day and 30-day old 
flies.  The four-day induction treatments were not of interest since they produced 
the lowest levels of Arctic A!42 whereas I required high levels of equivalent 
expression to ensure a robust phenotype. 
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Arctic A!42 toxicity was then profiled by measuring survival under the 
conditional RU486 treatment conditions described in (1) (Figure 4.12), (2) 
(Figure 4.13) and (3) above (Figure 4.14). Although negative geotaxis is a more 
apt measure of Arctic A!42 toxicity since it indirectly measures neuronal 
dysfunction, survival was shown to be more sensitive to changes in Arctic A!42 
toxicity. Thus, survival was used to assay Arctic A!42 toxicity because it was 
more likely to resolve subtle differences in ageing effects. Furthermore survival 
can be measured, by definition, over a fly’s entire lifespan whereas climbing 
ability in control flies is significantly reduced by 30-40 days. It was important I 
could see a relative difference between experimental and control flies. 
 
Two outcomes of this experiment were predicted:  
 
1) Ageing does not increase the vulnerability to Arctic A!42 toxicity (Figure 
4.11a) 
In this instance, the time-to-death of of young and old-aged flies in response to 
equivalent Arctic A!42 expression would be the same. The survival from the 
start of RU486 treatment would not be significantly different (the survival curves 
would overlap). In other words, Arctic A!42 would take the same time to exert 
its effects in young and old flies. 
 
2) Ageing increases vulnerability to Arctic A!42 toxicity (Figure 4.11b) 
If older flies were more vulnerable to the same level of Arctic A!42 toxicity, 
then these flies would be theoretically unable to ‘withstand’ the proteotoxicity 
for as long as younger flies. Thus, older flies would exhibit reduced survival (in a 
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normal survival curve). This might occur if the effects of ageing were large since 
older flies are much more likely to die of natural causes. More probable would be 
the scenario where older flies showed an increased time-to-death following 
RU486 treatment 
 
 
Figure 4.11. Hypothetical plots illustrating the possible effects of ageing on 
Arctic A!42 toxicity. (a) Expected survival from RU486 treatment (expressed as 
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a % of control flies) when ageing has no effect. (b) Expected survival from 
RU486 treatment if ageing rendered flies more vulnerable to Arctic A!42 
toxicity. 
 
Equivalent levels of A!42 peptide expression were again confirmed at the end of 
the induction period in young-induced and older-induced flies (Figure 4.12a). 
A!42 peptide was stable one week after switch-off of transgene expression, 
further confirming the resistance of the peptide to degradation. In both five-day 
and 20-day treated flies, survival was reduced relative to non-RU-treated controls 
indicating that Arctic A!42 was toxic when induced at both ages (Figure 4.12b). 
This amounted to a 12% reduction in median lifespan in five-day treated flies 
and a 7% reduction in median lifespan in 20-day treated flies, when compared to 
non-RU-treated controls. The difference in survival between five-day and 20-day 
treated flies was significant (P<0.05, log rank test). This implied that younger 
flies were more vulnerable to Arctic A!42 since they exhibited a relatively 
reduced survival compared to older flies. However, this interpretation did not 
take into account the fact that younger flies were exposed to Arctic A!42 for 
longer. Although RU486 was removed after one week in both 5-day and 20-day 
treated flies, it was likely that peptide remained in the fly due to its high stability. 
Therefore, we plotted survival as a function of the time from RU486 treatment 
(Figure 4.12c), from day five and day 20 respectively.  
 
This analysis revealed that older day-20-treated flies were significantly shorter 
lived from the time of RU486 treatment than younger day-5-treated flies, with 
median lifespans of 45 days and 58 days, respectively. However, the median 
survival for non-RU-treated flies from 20-days and five-days was 50 days and 65 
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days respectively. This demonstrated that flies treated with RU486 at 20-days 
have a reduced survival simply because they are older or ‘closer to death’. 
Therefore, the survival of both experimental groups were normalised to the 
survival of their respective non-RU treated controls at every timepoint (Figure 
4.12d). This generated a new plot that represented the survival of each treatment 
expressed as a % of their respective non-RU-treated control survival. This 
provided a means of controlling for Arctic A!42 independent effects on survival 
and it also prevented a bias in data interpretation – because older flies are more 
likely to die than younger flies, the reduced time to death of older flies could be 
misinterpreted as an increase in vulnerability to Arctic A!42. Interestingly, this 
normalisation step had little effect on the data. The normalised survival of day-20 
treated flies was still reduced when compared to flies treated at day-five (P<0.05, 
Wilcoxin rank test) (Figure 4.12d). This demonstrated that at a fixed 
concentration, Arctic A!42 protein was more toxic when induced in older flies 
compared to younger flies.  
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Figure 4.12. Older flies are more vulnerable when comparing the effect of 
equalised Arctic A!42 expression in 5-day and 20-day treated flies. UAS-
Arctic A!42/+;elavGS/+ once-mated females were conditionally treated with 
200#M RU486 (RU) from 5-days and 20-days post-eclosion for one week only, 
and were maintained on -RU prior to and following the RU pulse. (a) Arctic 
A!42 protein expression levels were equivalent (non-significantly different) 
when quantified at the end of each RU pulse (0) and 1 week after the switch to –
RU (1). Data expressed as mean +/- SEM (n = 5 for each group). Means 
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compared using Student’s t-test. (b) Survival curves of conditionally treated flies. 
Median lifespans are: 69 days for -RU, 61 days for 5d +200 RU and 64 days for 
20d +200 RU. Log rank test and p values:  -RU versus 5d+ 200 RU (p<0.0001), -
RU versus 20d +200 RU (P<0.0001) and 5d +200 RU versus 20d +200 RU (p = 
0.043). (c) These curves represent the survival or time-to-death of conditionally 
treated flies from the first day of RU treatment i.e. 5-days and 20-days, 
respectively. Median lifespans are: 65 days for –RU from 5-days, 50 days for –
RU from 20-days, 58 days for 5d +200 RU  and 45 days for 20d +200 RU. Log 
rank tests: 5d+ 200 RU versus 20d+ 200 RU (p<0.0001). (d) When these survival 
curves are plotted as a percentage of their respective non-RU-treated controls, 
20d +200 RU flies exhibit a significant reduction in relative survival following 
RU treatment (P<0.05, Wilcoxon rank test). 
 
This result was then confirmed using the other equalised Arctic A!42 protein 
expression protocols previously determined (Figure 4.13 and Figure 4.14). 
 
Arctic A!42 protein levels in flies treated with 100#M RU486 from 20-days and 
200#M RU486 from 30-days post eclosion for one week only were equivalent at 
the end of the induction period (Figure 4.13a). As before, suppression of Arctic 
A!42 expression, following a week on RU486-free food, had no effect on Arctic 
A!42 levels in either age group. In both 20-day and 30-day treated flies, survival 
was reduced relative to non-RU-treated controls (Figure 4.13b). This amounted 
to an 8% reduction in median lifespan in 20-day treated flies and remarkably, a 
14% reduction in median lifespan in flies treated at 30 days of age. The 
difference in survival between flies treated at 20-days and 30-days was 
significant (P<0.001, log rank test) and demonstrated that 30-day treated flies 
were more vulnerable to Arctic A!42 toxicity. Further analysis, comparing time 
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to death and relative survival etc., effectively amplified this effect (Figure 4.13c 
and 4.13d).  
 
 
Figure 4.13. Older flies are more vulnerable to Arctic A!42 when comparing 
the effect of equalised Arctic A!42 protein expression in 20-day and 30-day 
treated flies. UAS-Arctic A!42/+;elavGS/+ once-mated females were 
conditionally treated with 100#M RU486 (RU) from 20-days and 200#M RU486 
  159 
from 30-days post-eclosion for one week only, and were maintained on -RU 
prior to and following the RU pulse. (a) A!42 protein expression levels were 
equivalent (non-significantly different) when quantified at the end of the RU 
pulse (0) and 1 week after the switch to –RU (1). Data expressed as means +/- 
SEM (n = 5 for each group). Means compared using Student’s t-test. (b) Survival 
curves of conditionally treated flies. Median lifespans are: 75 days for -RU, 69 
days for 20d +100 RU and 65 days for 30d +200 RU. Log rank test and p values:  
-RU versus 20d+ 100 RU (P<0.0001), -RU versus 30d +200 RU (P<0.0001) and 
20d +100 RU versus 30d +200 RU (p <0.0001). (c) These curves represent the 
survival or time-to-death of conditionally treated flies from the first day of RU 
treatment i.e. 20-days and 30-days, respectively. Median lifespans from RU 
treatment are: 56 days for –RU from 20-days, 46 days for –RU from 30-days, 50 
days for 20d +100 RU and 37 days for 30d +200 RU. Log rank tests: 20d+ 100 
RU versus 30d+ 200 RU (p<0.0001). (d) When these survival curves were 
plotted as a percentage of their respective controls, 30d +200 RU flies exhibited 
a significant reduction in relative survival following RU treatment (P<0.05, 
Wilcoxon rank test). 
 
Next the effect of equivalent Arctic A!42 expression at three different ages was 
assayed (Figure 4.14). In this experiment a two-week RU pulse was used at five, 
20 and 30 days post-eclosion. The results agreed with the two previous one-week 
induction studies. All RU-treated flies showed a reduction in median lifespan 
when compared to non-RU-treated controls: 27% for five-days, 24% for 20-days 
and 14% for 30-days (Figure 4.14b). This progressive reduction was consistent 
with the fact younger flies are exposed to Arctic A!42 for longer. The 
normalised survival from RU treatment was inversely related with age. That is, 
the youngest day-5 treated flies exhibited the longest relative survival following 
RU486 treatment/Arctic A!42 induction (Figure 4.14d). 
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Overall these data clearly show that ageing renders Drosophila more vulnerable 
to a fixed amount of Arctic A!42. In all three equalised protein expression trials, 
the older fly cohort, whether comparing 20-day old flies with 5-day old or 30-
day old flies with 20-day old exhibited a significant reduction in relative 
survival, even after normalising for differences in survival caused by normal 
ageing. The fact this was independently shown in three different experiments 
increased the confidence of the interpretations made. 
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Figure 4.14. Older flies are more vulnerable when comparing the effect of 
equalised Arctic A!42 expression in 5-day, 20-day and 30-day treated flies. 
UAS-Arctic A!42/+;elavGS/+ once-mated females were conditionally treated 
with 100#M RU486 (RU) from 5-days and 200#M RU486 from 20- and 30-days 
post-eclosion for two weeks only, and were maintained on -RU prior to and 
following the RU pulse. (a) A!42 protein expression levels were equivalent 
when quantified at the end of the RU pulse. Data expressed as mean +/- SEM (n 
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= 5 for each group). Means compared using Student’s t-test. (b) Survival curves 
of conditionally treated flies. Median lifespans are: 78 days for -RU, 57 days for 
5d +100 RU, 60 days for 20d +200 RU and 67 days for 30d +200 RU. Log rank 
test and p values: -RU versus 5d+ 200 RU (p<0.0001), -RU versus 20d +200 RU 
(P<0.0001), -RU versus 30d +200 RU (P<0.0001),  5d +100 RU versus 20d +200 
RU. (c) These curves represent the survival or time-to-death of conditionally 
treated flies from the first day of RU treatment i.e. 5-days, 20-days and 30-days, 
respectively. Median lifespans from RU treatment are: 74 days for –RU from 5-
days, 59-days for –RU from 20 days and 49 days for –RU from 30-days. For RU 
treated flies, median lifespans from RU treatment are: 53 days for 5d +100 RU, 
41 days for 20d +200 RU and 38 days for 30d +200 RU. (d) When these survival 
curves are plotted as a percentage of their respective controls, older flies exhibit 
a significant reduction in relative survival following RU treatment (P<0.05 
comparing 20d and 30d with 5d and 20d with 30d, Wilcoxon rank test). 
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4.2.7 Older flies are more vulnerable to chronic Arctic A"42-
mediated toxicity 
To further assess the vulnerability of older flies to A! toxicity, the effect of 
chronic Arctic A!42 expression was also measured in young and old flies. This 
approach made no attempt to neither induce equivalent levels of expression with 
different RU486 concentrations nor ensure RU exposure times were equivalent. 
Simply, UAS-Arctic A!42/+;elavGS/+ flies were chronically treated with 200#M 
RU486 from two-days and 20-days post eclosion. Arctic A!42 protein levels 
were then assayed every 3-5 days until flies started to die (Figure 4.15). Survival 
was again used to measure Arctic A!42 toxicity (Figure 4.16). In essence, this 
experiment was exactly the same as those presented in the previous section. The 
main difference is that by not controlling for the level of toxicity induced at each 
age, Arctic A!42 levels had to be assayed much more frequently.  
 
Two-day treated flies displayed a robust accumulation of Arctic A!42 which 
reached a plateau at around 15-days of age (Figure 4.15a). Arctic A!42 also 
accumulated following induction in older flies, but at a slower rate with the 
concentration continuing to increase at the end of the 25-day assay period (25-45 
days; Figure 4.15a). Arctic A!42 levels were significantly higher in young-
induced compared to old-induced flies at all corresponding time-points assayed 
(P<0.05, Student’s t-test). Thus, the lifetime Arctic A!42 load (calculated from 
the total area under each curve) was higher in flies chronically treated with 
RU486 from two days compared to those treated from 20  days (Figure 4.15b).  
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Survival analysis initially indicated that induction of A!42 in young flies was 
more toxic than induction in older flies (Figure 4.16a), suggesting a positive 
correlation between the lifetime exposure to A!42 and toxicity. In both two-day 
and 20-day treated flies survival was reduced compared to untreated controls, 
with a 45% reduction in young-treated flies and a 25% reduction in older-treated 
flies. Moreover, the difference in survival between two-day and 20-day treated 
flies was significant (P<0.05, log rank test). However, this interpretation did not 
account for the fact that younger flies were exposed to A!42 for longer. I, 
therefore, plotted survival as function of the time from the first day of A!42 
exposure, in other words from two-days in young flies and 20 days in old flies 
(Figure 4.16b). This analysis revealed that older flies were significantly shorter 
lived from the time of induction than young flies (P<0.0001), with median 
lifespans of 40 days and 37 days respectively. However, the median lifespan for 
non-RU-treated flies plotted from two days and 20 days was also reduced using 
this analysis (74 and 56 days respectively). To control for Arctic A!42-
independent effects of normal ageing on lifespan, therefore, the survival of both 
experimental groups were normalised to their respective untreated controls at 
each timepoint (Figure 4.16c). Remarkably, older flies exhibited a significantly 
reduced relative survival when compared to younger flies (P<0.05, Wilcoxin 
rank test).  
 
Overall these results suggest that older flies are more vulnerable to chronic 
Arctic A!42 protein expression, despite a significantly lower lifetime exposure to 
the peptide. However, this approach made no attempt to normalise the level of 
A!42 expression or to ensure equivalent lengths of induction at different ages 
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and so does not provide a direct measure of the effects of ageing on neuronal 
susceptibility to A!42 toxicity.  
 
 
Figure 4.15. Arctic A!42 expression levels in response to chronic RU486 
treatment in young and old flies. UAS-Arctic A!42/+;elavGS/+ once-mated 
females were chronically treated with 200#M RU486 from two-days and 20-days 
post eclosion. (a) Arctic A!42 protein levels were assayed every 3-5 days until 
flies started dying. Data are presented as means +/- SEM (n = 3) with age (days). 
(b) The lifetime Arctic A!42 load was significantly lower in 20-day treated flies. 
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This data is a crude representative of the lifetime Arctic A!42 load in young and 
old flies, and was determined by calculating the area under the curves in (a). 
Data are presented as the mean lifetime Arctic A!42 load (pmoles/g total 
protein*days) +/- SEM (n = 3). *P<0.05 when comparing levels in 20d treated 
flies with that of 2-day treated flies. 
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Figure 4.16. Older flies are more vulnerable to chronic Arctic A!42-
expression. (a) Survival curves of once-mated female UAS-Arctic 
A!42/+;elavGS/+ flies chronically treated with 200uM RU486 from two-days 
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and 20-days post eclosion. Median lifespans are: 75 days for -RU, 41 days for 2d 
+200 RU and 56 days for 20d +200 RU. Log rank test and p values:  -RU versus 
2d+ 200 RU (P<0.0001), -RU versus 20d +200 RU (P<0.0001) and 2d +200 RU 
versus 20d +200 RU (p <0.0001). (b) These curves represent the survival or 
time-to-death of conditionally treated flies from the first day of RU treatment i.e. 
2-days and 20-days, respectively. Median lifespans from RU treatment are: 74 
days for –RU from 2-days, 56 days for –RU from 20-days, 40 days for 2d +200 
RU and 37 days for 20d +200 RU. Log rank tests: 2d+ 200 RU versus 20d+ 200 
RU (p<0.0001). (d) When these survival curves were plotted as a percentage of 
their respective controls, 20d +200 RU flies exhibited a significant reduction in 
relative survival following RU treatment (P<0.05, Wilcoxon rank test). 
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4.3 Discussion 
Many neurodegenerative diseases, including Alzheimer’s disease, share in 
common the accumulation of toxic proteins and a late age of onset (Mattson. 
2006). However, the mechanisms linking protein aggregation and the onset of 
disease symptoms to age remain unclear. Ageing may either represent a measure 
of the time required for the accumulation of damaged proteins to cause 
neuropathology, or the ageing process itself may increase the vulnerability of 
neurons to protein toxicity. This study aimed to address this issue by inducing 
expression of the toxic Arctic A!42 peptide to the same level and duration at 
different ages and to measure the delay to and extent of pathology. 
 
4.3.1 The dynamics of A"42 expression 
Drosophila melanogaster provides a useful model organism for such 
investigations, due to their short lifespan and the availability of inducible 
systems that enable both spatial and temporal control of protein expression 
(Osterwalder et al. 2001). The inducible GeneSwitch (GS) system has been 
widely used to study both ageing (Giannakou et al. 2004; Giannakou et al. 2007; 
Hwangbo et al. 2004) and neurodegeneration (Latouche et al. 2007); however, 
most studies have examined the effects of chronic induction from specific time-
points, during development or adulthood, without reporting on the kinetics and 
subsequent effects of transgene suppression. A further analysis of the dynamics 
of A!42 suppression using my inducible AD model (developed in chapter 3) 
was, therefore, required.  
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It was found that the kinetics of mRNA and protein suppression differed upon 
removal of the inducer mifepristone (RU486). A rapid reduction in mRNA 
expression was observed within 24 hours but the ‘off-response’ at the protein 
level was much slower with A!42 peptide remaining for several weeks after 
suppression of transcription. Importantly, switching-off transgene expression in 
young flies did not reverse A!42 toxicity in this model, since climbing ability 
did not return to control levels following removal of RU486 and even short 
exposure times resulted in slight reductions in median lifespan.  
 
This lack of reversibility is most likely to be due to the high stability of the A!42 
peptide in these flies, which has been reported in other studies. Jankowsky et al. 
(2005) generated a mouse model that mimics the arrest of A! production. These 
mice overexpress mutant APP from a vector that can be regulated by 
doxycycline. Under normal conditions, APP overexpression resulted in amyloid 
pathology. Administration of doxycycline inhibited APP expression by >95% 
and reduced A! production to levels found in non-transgenic mice. Although this 
suppression halted the progression of amyloid pathology, these mice retained a 
considerable A! load 6 months after suppression, with little sign of clearance. 
This result is analogous to the effect seen in Drosophila. Removal of RU486 
effectively halted the further accumulation of Arctic A!42 and worsening of 
climbing ability and lifespan but did not result in a reduction in the Arctic A!42 
load. Furthermore, intracerebral injection of A! antibodies failed to clear pre-
existing amyloid plaques in a mouse model of AD where APP suppression was 
suppressed and only led to a limited reduction of amyloid burden in mice 
constitutively expressing APP (Tucker et al. 2008). In both these studies APP 
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cDNA encoding the Sewdish mutation was expressed. This familial AD-
associated mutation results in increased A! production. It does not increase the 
peptide’s propensity to aggregate as with the Arctic mutation. Therefore, it seems 
the stability of A!42 aggregates is not specific to particular isoforms of the 
peptide.  
 
The high stability of A!42 in this model may be related to the ability of the 
Arctic mutation to promote rapid aggregation (Nilsberth et al. 2001). Indeed 
most of the A!42 present in this model is insoluble (see Figure 3.5). The ZA!3 
Affibody, a conformation-specific A! binding protein that prevents A!42 
aggregation, clears A!42 and rescues toxicity when co-expressed with Arctic 
A!42 in Drosophila neurons (Luheshi et al. 2010). This suggests that the 
aggregation state of A!42 can alter its stability and impact on neuropathological 
phenotypes in the fly. Further analyses of the solubility of A!42 in this model 
over time would be required to elucidate the role of aggregation in altering the 
stability and toxicity of the peptide in this inducible model system.  
 
4.3.2 A"42 toxicity is a dose-dependent in Drosophila 
One possibility for the relationship between protein toxicity and the age of onset 
of AD is that aggregation is a stochastic process requiring many years to 
accumulate toxic proteins to a threshold concentration at which neurons become 
dysfunctional. This study provides some evidence that A!42 toxicity is indeed 
related to the concentration of the peptide produced. A!42 peptide concentration 
correlated with the duration of induction in young flies, and as the peptide 
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remains stable for several weeks, this may be viewed as inducing a dose-
response to A!42 at a given time. This resulted in negative geotaxis and 
shortened lifespan phenotypes in later life that were Arctic A!42 dose-
dependent. Interestingly, survival was found to be more sensitive to changes in 
RU486 dose. A two-day RU486 pulse had no effect on negative geotaxis, when 
compared to controls but did result in small but significant reduction in lifespan. 
This difference could possibly be explained by the fact there is much less noise 
when assaying for survival. The phenotype is easy to score; the fly is dead, alive 
or censored. With negative geotaxis, one must count how many flies there are at 
the top and bottom of 25-ml pipette filled with 15 flies, once 45-seconds has 
passed. The problem with performing this assay manually (as throughout this 
thesis) is that flies can be scored incorrectly, or can change their position in the 
pipette suddenly i.e. falling to the bottom.  
 
The relationship between dose and toxicity is in agreement with previous studies 
in cells showing that toxicity is dependent upon the dose and duration of 
exposure to A!42 (Brewer et al. 1998). Furthermore, in studies where A!42 
mRNA levels were equalised at different ages of induction, it was observed that 
A!42 peptide accumulated to higher levels in older-induced flies compared to 
young-induced flies, and this resulted in a shortened lifespan of older flies. 
Hence, higher concentrations of the peptide do appear to result in stronger 
pathological phenotypes in this model.  
 
However, the association between age and the onset of toxicity does not appear 
to be due to the time required for A!42 to accumulate to a toxic concentration. 
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At equal levels of transgene expression I found that the A!42 peptide 
accumulated more rapidly in older flies compared to young flies. This may 
reflect an alteration in protein turnover, the combined rates of protein synthesis 
and degradation, with age (Niedzwiecki & Fleming. 1990). Measurement of 35S-
methionine incorporation showed that general protein translation was reduced in 
old-induced versus young-induced A!42-expressing flies. This finding is 
consistent with published studies showing that the rate of protein synthesis 
decreases with age in a wide variety of cells, tissues, organs and organisms, 
including humans (reviewed in Rattan. 1996). Particularly, in Drosophila, 
Webster and Webster (1979) showed that the incorporation of radiolabelled 
amino acids in microsomal preparations declines by 70% over the first 14 days of 
adult life and continues to decline thereafter. They also demonstrated that the rate 
of protein synthesis in the thorax declines the most between 1 and 35 days of age 
(96%), followed by the abdomen (33%) and the head (15%). (Webster et al, 
1980). Similar declines in the synthesis of mitochondrial proteins also occur 
between 6 and 38 days of age (Fleming et al, 1986).  
  
As there is no pronounced reduction in protein mass with age (Ryazanov & 
Nefsky. 2002), this reduction in protein synthesis is likely to be accompanied by 
a reduction in protein degradation and this may reflect the increase in A!42 
peptide in aged flies. Interestingly, it has been shown that younger flies show 
faster protein turnover rates than older flies (Niedzwiecki & Fleming, 1990). In 
old flies (35-37 days), labelled proteins reached a peak of radioactivity 5 hours 
following treatment, but no decrease was seen in this peak for up to 30 hours, 
indicating a very low rate of degradation. 
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Since A!42 is highly stable in these flies, directly measuring the rate of its 
degradation with age has proven to be difficult. A further analysis of potential 
A!42 clearance mechanisms, including proteasome activity, autophagy and the 
activity of A!42-degrading enzymes such as insulin degrading enzyme (Farris et 
al. 2003; Miller et al. 2003) and neprilysin (Iwata et al. 2001) may provide an 
indication as to whether the age-related accumulation of the peptide is indeed 
caused by alterations in its degradation. Hence, an intrinsic property of the 
ageing process itself may cause the accumulation of toxic proteins in older 
neurons and subsequently the development of dose-dependent pathologies. 
 
Moreover, the susceptibility of older flies to A!42 toxicity, in comparison to 
young flies, does not appear to be related to the duration of exposure to the 
peptide. Older flies were more vulnerable to chronic induction of Arctic A!42, 
with a shortened relative lifespan from the point of exposure to RU486 compared 
to young flies, despite experiencing a lower lifetime exposure to the A!42 
peptide. Under these chronic induction conditions the lower level of A!42 
accumulated in older flies is likely to reflect a reduction in the level of the 
transcript produced with age as previously observed (see Figure 3.4a).  This is 
probably due to a reduced intake of the inducer RU486 via an age-dependent 
reduction in feeding behaviour (Wong et al. 2010).  
 
4.3.3 Older neurons are more vulnerable to A"42 toxicity 
Together the above data suggest that, although A!42 toxicity is dose-dependent, 
the degree of toxicity with age does not to relate to the length of time required 
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for the protein to accumulate to toxic levels or to the duration of toxic protein 
exposure. Rather the ageing process itself may increase the susceptibility of older 
neurons to A!42 toxicity. To test this hypothesis directly I aimed to induce a 
standard concentration of A!42 peptide at different ages and measure the delay 
to and extent of pathology. This study highlights several technical challenges in 
performing such investigations using inducible models. Firstly, although 
negative geotaxis and lifespan serve as useful markers of A!42 toxicity in the 
fly, they are themselves directly affected by ageing. Hence, the ages of induction 
must be carefully chosen so that (1) peptide over-expression results in 
phenotypes that are significantly different from non-expressing controls at each 
time-point analysed and (2) they are far enough apart to resolve any effect of the 
ageing process. Secondly, the concentration of A!42 is affected by the age of 
induction, as older flies ingest less RU486 due to reduced feeding behaviour, and 
the length of exposure to RU486, with increasing concentrations correlating with 
longer exposures. Moreover, normalising mRNA levels at different ages does not 
result in equivalent levels of protein expression at each time-point of induction. 
Hence, to effectively measure the consequences of proteotoxicity at different 
ages one must systematically equalise protein expression by altering the both 
concentration and the length of exposure to the inducer and measuring the level 
of protein subsequently produced. Using this approach, I achieved normalised 
Arctic A!42 peptide levels across three ages (five, 20 and 30 days) in my 
inducible fly model of AD. This demonstrates that the GeneSwitch system offers 
sufficient flexibility to perform these studies. 
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In three independent trials comparing different ages of induction or different RU 
exposure times, older flies exhibited a faster time to death following RU 
treatment, even when correcting for their decreased life expectancy. This was 
evident by their reduced relative survival following RU486 treatment. As 
described above, chronic over-expression of Arctic A!42 was also more toxic to 
older flies, despite a significantly lower lifetime Arctic A!42 burden. Thus, in all 
instances, either the equivalent or a lower Arctic A!42 load resulted in relatively 
higher levels of toxicity in older flies demonstrating that ageing does increase 
vulnerability to protein-mediated toxicity. These results agree with other studies 
demonstrating that older neurons are more vulnerable to extracellularly applied 
A!42 fibrils both in cell culture (Brewer. 1998) and in the brain of rhesus 
monkeys (Geula et al. 1998). This work builds upon these findings by providing 
the first evidence that this is the case in vivo under physiological conditions of 
A!42 expression and aggregation.  
 
4.3.4 Discussion of the Ling et al. (2011) study 
One other study, using a similar experimental design to investigate the effects of 
ageing on A!42 toxicity in Drosophila (Ling et al. 2011), has reported findings 
that contrast with those in this study. Although Ling et al. (2011) used the 
elavGS driver in conjunction with a UAS-A!42 line and induction via delivery 
of RU486 in the food medium, they reported no difference in A!42 mRNA 
levels between young and old flies when equivalent doses of inducer were used. 
However, higher doses of RU486 were used and experiments performed at a 
higher temperature in comparison to my study, thus inducing higher levels of 
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expression at which subtle differences might not have been observed. Moreover, 
Ling et al. (2011) measured transcript levels during the induction period and I  
measured levels at the end of induction, which may also account for the 
difference in expression observed. At equivalent levels of mRNA expression in 
young-induced and old-induced flies Ling et al. (2011) observed a shorter 
maximum lifespan in young-induced flies compared to old-induced flies, 
concluding that younger flies were more vulnerable to A!42 toxicity. A!42 
protein levels were not measured, however, and so the age-dependent effects of 
protein turnover on toxicity were not controlled for in their study. Moreover, the 
effects of normal ageing on lifespan must be accounted for by analysing the 
survival from the time of induction compared to non-A!42-expressing controls. 
For example, at equivalent protein expression levels I also observed that young-
induced flies displayed a shorter median lifespan compared to older-induced 
flies, but further analysis of the survival from the time of induction revealed that 
in fact older flies were more vulnerable to toxicity than young flies. The varying 
conclusions between these two studies, therefore, highlights the importance of 
controlling for both the effects of protein turnover with age and the effects of 
normal ageing on pathology, when investigating the relationship between ageing 
and protein toxicity. 
 
Overall this study demonstrates that the GeneSwitch system can be effectively 
manipulated to equalise both Arctic A!42 mRNA and protein expression at 
different ages. Thus, this conditional system is flexible enough, through RU486 
dose compensation, to control for age-dependent effects on feeding behaviour 
and protein turnover. This has enabled an investigation, for the first time, in to 
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the effects of ageing on neuronal vulnerability to A!42 toxicity under 
physiological conditions. Although my data demonstrate that A!42 toxicity in 
the fly is dose-dependent, overall these findings strongly suggest that the ageing 
process increases neuronal vulnerability to protein toxicity. 
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Chapter 5 TOR pathway inhibition delays 
ageing but not neuronal dysfunction in an adult-
onset model of Alzheimer’s Disease 
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5.1 Introduction 
The target or rapamycin (TOR) pathway is a highly conserved nutrient-sensory 
pathway that functions in such distinct organisms as yeast and mammals to 
regulate growth and metabolism in response to growth factors, amino acids, 
various stresses and changes in cellular status. It has also been implicated in the 
control of protein translation and ribosome biogenesis – up-regulation of which 
is required for growth (for detailed review see Wullschleger et al. 2006).  
 
Central to the pathway is a serine/threonine protein kinase known as TOR kinase, 
which participates in two different multiprotein complexes known as TORC 
(TOR complex) 1 and TORC2. TORC1 regulates translation and growth via 
phosphorylation of two downstream effectors, the ribosomal subunit S6 kinase 
(S6K) and a repressor protein of the cap-binding eukaryotic initiation factor 4E 
(eIF4E) termed eIF4e-binding protein (4E-BP). Phosphorylated S6K functions to 
promote cellular and organismal growth (Montagne et al. 1999; Um et al. 2006). 
Phosphorylation of 4E-BP disrupts its association with eIF4E, resulting in up-
regulation of cap-dependent translation.  
 
In addition, TORC1 inhibits autophagy, the sole pathway for organelle turnover 
in the cell that is not only vital for reallocation of nutrients and energy, but also 
for degrading normal and aggregated proteins, particularly under stress or injury 
(Nixon. 2007). Thus, under favourable conditions for growth, such as an amino 
acid-rich diet, TORC1 is active and promotes cell growth through up-regulation 
of translation (through activation of S6K and eIF4E) and inhibition of autophagy. 
During times of stress, when nutrients are scarce, TORC1 inactivity results in 
  181 
inhibition of protein translation (by inhibition of S6K and activation of 4E-BP) 
and upregulation of autophagy, which helps to reallocate energy reserves within 
the cell. This is exemplified by the fact S6K-deficient animals are smaller with 
metabolism resembling that on a low-calorie diet (Um et al. 2006). In contrast to 
the many roles of TORC1, the TORC2 complex seems to be mainly involved in 
cytoskeletal remodelling and up-regulating the IIS pathway through 
phosphorylation of Akt, the main kinase in the IIS pathway (Wullschleger et al. 
2006).  
 
TOR kinase is inhibited by rapamycin, a naturally occurring non-antibiotic 
macrolide compound first discovered over 30 years ago as a product of the 
bacterium Streptomyces hygroscopius in a soil sample from Rapa Nui, otherwise 
known as Easter Island (Vézina et al. 1975). Rapamycin is the most specific 
TOR inhibitor known, and acts by forming an inhibitory tri-molecular complex 
with TORC1 and the intracellular protein FKBP12. Inhibition of TORC1 with 
rapamycin reduces phosphorylation of the downstream targets S6K and 4E-BP, 
resulting in a reduction in protein translation (Grolleau et al. 2002; Bjedov et al. 
2010) and up-regulation of autophagy (Ravikumar et al. 2004). On the other 
hand, TORC2 is thought to be rapamycin insensitive (Wullschleger et al. 2006), 
although evidence from cell culture suggests that chronic rapamycin exposure 
can inhibit TORC2 (Sarbassov et al. 2006).  
 
Increasing evidence has pointed to a link between TOR signalling and AD. First, 
studies in a diverse range of model organisms have shown that reducing TOR 
signalling can extend lifespan, a major risk factor for AD. For instance, both 
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chronological (Powers et al. 2006) and replicative (Kaeberlein et al. 2005) 
lifespans are extended in the yeast tor1 mutant. Nematode worms carrying 
mutations in genes encoding the worm homolog of TOR (let-363) and S6K (rsks-
1), along with components of the translational machinery (Vellai et al. 2003; 
Hansen et al. 2007) are long-lived, as are flies over-expressing either a 
dominant-negative form of S6K or negative regulators of the TOR pathway 
(Kapahi et al. 2004). Completing the set of model organisms is the recent study 
showing that genetic deletion of S6K1 in mice also extends lifespan (Selman et 
al. 2009). Furthermore, pharmacological down-regulation of the TOR pathway 
by rapamycin has been shown to increase lifespan in yeast, flies (Bjedov et al. 
2010) and mice (Harrison et al. 2009), which, incredibly, were 600-days-old 
when first treated. This latter study indicated that pharmacological interventions 
initiated in middle age might still be effective in increasing lifespan. 
 
The second major link between TOR signalling and AD is that rapamycin is a 
known activator of autophagy, a process that has been implicated in the 
neurodegeneration of AD (Nixon. 2007). Third, there is some evidence that TOR 
signalling is altered in Alzheimer’s-disease brain tissue and transgenic models of 
AD. However, there is a serious lack of consensus on this issue. For instance, 
studies examining human tissue report increased activation of the TOR pathway 
in affected brain areas in Alzheimer’s-diseased brains compared to non-diseased 
control tissue (Li et al. 2005). Furthermore, it has been recently demonstrated in 
two independent studies that rapamycin can benefit mouse models of AD. In 
3xTG mice (Caccamo et al. 2010)  and PDAPP mice (Spilman et al. 2010) 
rapamycin treatment resulted in a reduction in A! levels and plaque load, which 
  183 
led to reduced pathology and rescue of memory impairments. Both studies 
claimed this rescue was dependent on autophagy upregulation. 
 
Ma et al., (2010) reported a slightly different picture, observing that TOR 
signalling was in fact reduced in the Tg2576 transgenic mouse and that this 
correlated with impaired synaptic plasticity, as measured by long-term 
potentiation in hippocampal slices. By up-regulating TOR signalling via GSK3 
inhibition (with LiCl) they were able to prevent A!-induced impairments in 
synaptic plasticity. They also demonstrated that intraneuronal A!42 co-localises 
with TORC1 and S6K. This study was consistent with the earlier work showing 
that TOR signalling is down-regulated in neuroblastoma cells treated with A!42, 
and also in PSEN mice (Lafay-Chebassier et al. 2005).  
 
In this chapter I set out to investigate the link between TOR signalling and AD 
by using the TOR inhibitor rapamycin in conjunction with a previously 
developed inducible model of AD. The aim was to measure the toxicity 
associated with Arctic A!42 over-expression in response to rapamycin 
administration. 
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5.2 Results 
To determine whether inhibition of the TOR pathway would delay or prevent 
A!42 toxicity in Drosophila, RU486 and rapamycin were simultaneously 
administered to UAS-Arctic A!42/+;elavGS/+ flies. Survival and negative 
geotaxis were then measured following drug treatment, to see whether rapamycin 
would ameliorate A!42-mediated toxicity. To avoid developmental effects, flies 
were reared on normal SY food and then permanently moved to food 
supplemented with both RU486 and rapamycin, from two-days post-eclosion.  
 
In total, four different food combinations were used in all experiments: 
 
-RU486 SY (-RU) 
-RU486 and 200#M rapamycin (-RU/rapa) 
+200#M RU486 (+RU) 
+200#M RU486 and 200#M rapamycin (+RU/rapa)  
 
The different food types were necessary to control for any non-specific or 
synergistic effects of the presence of two different drugs in the fly food. As 
before in chapter 3, RU486 was added to SY to a final concentration of 200#M. 
Similarly, rapamycin was dissolved in SY to a final concentration of 200#M. 
This dose was chosen because it was previously shown to cause the biggest 
increase in median lifespan without toxicity (Bjedov et al. 2010).  
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5.2.1 Rapamycin has no effect on lifespan or neuronal dysfunction 
in UAS-Arctic A!42/+;elavGS/+ flies in the w1118 genetic background. 
As seen previously in Chapter 3, induced A!42 overexpression resulted in a 
significant decline in locomotor function (Figure 5.1) and lifespan (Figure 5.2). 
UAS-Arctic A!42/+;elavGS/+ flies treated with RU486 demonstrated a 
significant decline in climbing ability by day 13, when compared to non-RU-
treated controls. The same flies treated with rapamycin (+RU/Rapa) failed to 
show any relative improvement in climbing ability, when compared to non-RU-
treated flies. Rapamycin also had no effect on the climbing ability of non-RU-
treated flies. 
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Figure 5.1. Rapamycin has no effect on A!42-mediated neuronal 
dysfunction. Negative geotaxis behaviour of w1118 UAS-Arctic A!42;elavGS/+ 
flies treated with RU486 and Rapamycin from two-days post-eclosion. Climbing 
ability was assessed at the indicated time-points. Data are presented as the 
average performance index (PI) +/- SEM (n = 3, number of flies per group = 39-
45) and were compared using two-way ANOVA and Tukey’s honestly 
significant difference (HSD) post-hoc analyses. *P<0.05 comparing PI of +RU 
or +RU/Rapa treatments to that of both –RU and –RU/Rapa control flies at the 
indicated timepoints. No significant difference was seen between –RU and –
RU/Rapa at any timepoint nor was any difference observed between +RU and 
+RU/Rapa. 
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Figure 5.2. Rapamycin treatment may delay ageing in flies overexpressing 
A!42. Survival curves of UAS-Arctic A!42/+;elavGS/+ flies treated with RU486 
and rapamycin from two-days post-eclosion. (a) and (b) represent two individual 
experiments. (a) Median lifespans are as follows: 61 days for –RU and –
RU/Rapa and 30 days for +RU and +RU/Rapa. No significant difference in 
survival was detected between +RU and +RU/Rapa (p = 0.13, log rank test), and 
–RU and –RU/Rapa (P = 0.11). The survival of +RU and +RU/Rapa were 
significantly different to their respective controls (P<0.001 for both 
comparisons).  (b) Median lifespans are as follows: 75 days for –RU and –
RU/Rapa and 40 days for +RU and +RU/Rapa. A significant difference in 
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survival was detected between +RU and +RU/Rapa (p = 0.0006, log rank test) 
but not between –RU and –RU/Rapa (P = 0.57). The survival of +RU and 
+RU/Rapa were significantly different to their respective controls (P<0.001 for 
both comparisons). 
 
In two independent assays, survival was significantly reduced in UAS-Arctic 
A!42/+;elavGS/+ flies treated with RU486 (Figure 5.2). In both trials median 
lifespan was reduced by ~50% compared to non-RU-treated controls. In the first 
trial, rapamycin had no effect the lifespan of RU- and non-RU-treated flies. In 
the second trial rapamycin did slightly increase the survival of RU-treated flies 
but the effect was almost neglibile (median lifespans were the same for these two 
treatments). 
 
5.2.2 Rapamycin delays ageing but has no effect on neuronal 
dysfunction in UAS-Arctic/+;elavGS/+ flies in the wDah genetic 
background 
It has been previously shown that the extension of lifespan seen with rapamycin 
in Drosophila is more robust in the wDah wild-type genetic background (Bjedov 
et al. 2010). This, coupled with the negative results observed in a w1118 prompted 
a parallel study of the effect of rapamycin on A!42-toxicity in the wDah genetic 
background. All transgenes used to develop the inducible model in Chapter 3 
were backcrossed (see methods) into the wDah background for at least 6 
generations. Lifespan and climbing ability were then assayed in wDah;UAS-Arctic 
A!42/+;elavGS/+ flies by repeating the experiments under the same conditions 
as those used previously in w1118. 
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Figure 5.3. Rapamycin extends lifespan in wDah wild-type female flies. 
Survival curves of wDah female flies treated with 200#M rapamycin from two-
days post-eclosion. Median lifespans: 56 days for –RU and 62 days for –
RU/Rapa. The survival of –RU and –RU/Rapa treated flies was significantly 
different (P<0.0001, log rank test).  
 
To ensure rapamycin worked in my hands, I first attempted to repeat the finding 
by Bjedov et al (2010) that wDah wild-type female flies fed 200#M rapamycin 
causes increased lifespan (Figure 5.3). In my hands, rapamycin increased 
median lifespan by ~11%, from 56 days to 62 days. This extension was similar in 
magnitude reported in Bjedov et al (2010). Confident that the rapamycin was 
biologically active, I then treated wDah;UAS-Arctic A!42/+;elavGS/+ flies with 
200#M RU486 and 200#M rapamycin from two-days post eclosion, whilst 
measuring negative geotaxis ( 
Figure 5.4) and survival (Figure 5.5). 
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Figure 5.4. Rapamycin has no effect on A!42-mediated neuronal 
dysfunction but does delay senescent-related decline in locomotor function. 
Negative geotaxis behaviour of wDah;UAS-Arctic A!42;elavGS/+ flies treated 
with RU486 and Rapamycin from two-days post eclosion. Climbing ability was 
assessed at the indicated time-points. Data are presented as the average 
performance index (PI) +/- SEM (n = 3, number of flies per group = 39-45) and 
were compared using two-way ANOVA and Tukey’s honestly significant 
difference (HSD) post-hoc analyses. *P<0.05 comparing PI of +RU or 
+RU/Rapa treatments to that of both –RU and –RU/Rapa control flies at the 
indicated timepoints or comparing PI or –RU treatments to that of –RU/Rapa 
(day 44 and 55 only). No significant difference was seen between +RU and 
+RU/Rapa flies. In addition, no significant difference was seen between –RU and 
–RU/Rapa flies until day 40, from which point, -RU/Rapa treated flies showed a 
higher level of climbing ability compared to –RU treated flies.  
 
Rapamycin did not improve the climbing ability of flies expressing A!42 
suggesting that rapamycin does not improve A!42-mediated neuronal 
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dysfunction in this model. Interestingly, non-RU-treated flies treated with 
rapamycin did have higher negative geotaxis scores at advanced ages (after 40 
days). This supports the fact that rapamycin extended lifespan in these flies. 
 
The effects of rapamycin on A!42 expressing flies were more pronounced and 
robust in the wDah background. In two independent assays, survival was 
significantly reduced in UAS-Arctic A!42/+;elavGS/+ flies treated with RU486 
when compared to non-RU-treated controls. In the first trial, A!42 
overexpression resulted in a 21% decrease in lifespan compared to non-RU-
treated controls. In the second trial, there was a 45% decrease in median lifespan. 
This effect had already been observed many times in w1118 so it was to be 
expected. However, this was the first time it had been seen in the wDah 
background, indicating that the model was compatible with other genetic 
backgrounds, consequently strengthening its reliability.  
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Figure 5.5. Rapamycin treatment delays ageing in flies overexpressing A!42. 
Survival curves of UAS-Arctic A!42/+;elavGS/+ flies treated with RU486 and 
Rapamycin from two-days post-eclosion. (a) and (b) represent two individual 
experiments. (a) Median lifespans are as follows: 63 days for –RU, 78 days for –
RU/Rapa and 50 days for +RU and +RU/Rapa. There was significant difference 
in survival between +RU and +RU/Rapa (p = 0.01, log rank test), and –RU and –
RU/Rapa (P < 0.0001). The survival of +RU and +RU/Rapa were significantly 
different to their respective controls (P<0.001 for both comparisons).  (b) Median 
lifespans are as follows: 72 days for –RU, 75 days for –RU/Rapa, 40 days for 
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+RU and 47 days for +RU/Rapa. A significant difference in survival was 
detected between +RU and +RU/Rapa (P < 0.0001, log rank test) –RU and –
RU/Rapa (P = 0.0016). The survival of +RU and +RU/Rapa were significantly 
reduced when compared to their respective controls (P<0.001 for both 
comparisons). 
  
The differences in lifespan reduction between the trials were unexpected. The 
45% reduction in median lifespan was similar in magnitude seen in w1118. 
However, in the first trial the reduction was only 21%. This could be attributable 
to the fact these stocks had not been recently backcrossed or that there were 
some problems in rearing/development or the quality of the food. Nonetheless, 
rapamycin increased the lifespan of flies treated with RU486 in both trials. In the 
first trial, this effect was very slight (median lifespans between +RU and 
+RU/Rapa) were actually the same) but significant (P = 0.01, log rank test). 
However, in the second trial rapamycin extended median lifespan of RU-treated 
flies by 15%. Of further importance was the fact, in both trials, rapamycin 
extended the lifespan of non-RU-treated UAS-Arctic A"42/+;elavGS/+ flies, by 
19% and 4% respectively. These large differences again could be attributed to 
the reasons given above. It is likely there was something amiss with the first trial, 
quite possibly that for some reason the flies were not feeding as well. This would 
explain the longer lifespan in A!42 over-expressing flies and the smaller 
extension in rapamycin-treated controls. 
 
Because rapamycin inhibits protein translation in Drosophila (Bjedov et al. 
2010), it was important to determine whether the increases in lifespan were 
simply a consequence of reduced Arctic A!42 expression. As has been shown in 
Chapter 4, survival is very sensitive to total Arctic A!42 dose. It was previously 
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shown that rapamycin has no effect on feeding behaviour (Bjedov et al. 2010), 
therefore any differences the amount of A!42 were likely to be due to changes in 
protein turnover. To assess A!42 levels, UAS-Arctic A!42/+;elavGS/+ flies were 
treated with RU486 and rapamycin from two-days post eclosion. Total Arctic 
A!42 was then quantified at 15 days of age (Figure 5.6).   
 
 
 
 
Figure 5.6. Rapamycin has no effect on total A!42 protein levels. Total A!42 
protein levels were quantified at 15-days into-RU486/Rapamycin treatment in 
wDah;UAS-Arctic A!42/+;elavGS/+. Data are presented as means +/- SEM (n = 4 
for each group) and were analysed by Student’s T-test. There was no significant 
difference in total A!42 between +RU and +RU/Rapa groups. Although there 
was a significant different between –RU and –RU/Rapa (P < 0.05, Student’s t-
test) 
 
Both groups of RU-treated flies exhibited significantly elevated levels of Arctic 
A!42 when compared to their respective non-RU-treated controls (P<0.01, 
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Student’s t-test). However, rapamycin appeared to have no effect on the total 
level of Arctic A!42. Arctic A!42 was also detected in non-RU-treated controls, 
confirming again that there is a low level of leaky expression in this system. 
Interestingly, the level of leaky expression was significantly lower in flies treated 
with rapamcyin (P<0.05). 
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5.3 Discussion 
Drosophila melanogaster has proven to be a valuable model organism for 
studying the molecular mechanisms involved in both the ageing process and in 
various neurodegenerative diseases. Increasing evidence suggests a link between 
TOR signalling and AD: down-regulation of TOR signalling extends lifespan, a 
well-established risk factor for AD and upregulates autophagy, which has also 
been implicated in the development of the disease. Furthermore, TOR signalling 
is altered in AD brain tissue and animal models. To investigate the link between 
TOR signalling and AD, I examined the effect of the TOR inhibitor, rapamycin, 
which extends lifespan in wild-type flies and ameliorates AD pathology in mouse 
models of AD, on lifespan and neuronal dysfunction in a previously developed 
inducible Drosophila model of AD (see chapter 3). 
 
5.3.1 The effects of rapamycin were inconclusive in the w1118 
genetic background 
In the w1118 background the effects of rapamycin were inconclusive. Negative 
geotaxis was used as an indirect measure of neuronal dysfunction, and although 
this was compromised by Arctic A!42 overexpression, rapamycin did not 
ameliorate this effect. Arctic A!42 overexpression also resulted in a large 
reduction in lifespan (~50% reduction in median lifespan) as expected in this 
background. However, rapamycin treatment failed to improve the survival of 
Arctic A!42 expressing flies. In one trial rapamycin did extend the lifespan of 
these flies but the effect was very weak (no difference in median lifespan). 
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Furthermore, rapamycin had no effect on non-RU-treated controls. Because of 
these largely negative results further studies were not pursued. 
 
5.3.2 Rapamycin delays ageing but not neuronal dysfunction in the 
wDah genetic background 
Given that rapamycin was shown to have the greatest effect on lifespan in the 
wDah background (Bjedov et al. 2010), the largely negative data seen in w1118 
prompted a repeat in wDah;UAS-Arctic A"42/+;elavGS/+ flies. This necessitated 
backcrossing of the driver and UAS-lines to the wDah background for at least 6 
generations.  
 
In wDah, Arctic A!42 overexpression also resulted in a reduction in negative 
geotaxis and survival relative to non-RU-treated controls. Although these effects 
were to be expected, this was the first time they had been recorded in a different 
background. Hence, this result alone helped to increase the reliability and 
confidence of the inducible model first presented in Chapter 3 because it 
demonstrated that it was viable in more than one genetic background. 
 
Results in wDah were more interesting. As in w1118, rapamycin did not suppress 
the effects of Arctic A!42 overexpression on negative geotaxis, suggesting no 
rescue of neuronal dysfunction in these flies. Interestingly, it did improve the 
performance of non-RU-treated controls at advanced ages (from day 40 
onwards). This effect has also been reported when using genetic interventions to 
increase lifespan. For example, homozygous chico1 mutants exhibited elevated 
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negative geotaxis scores at advanced ages than their isogenic controls (Gargano 
et al. 2005). 
 
 
Figure 5.7. Delayed senescence of negative geotaxis in chico1 homozygous 
mutants. Figure taken from (Gargano et al. 2005). 
 
This effect was seen earlier in this study (by 3 weeks) but they used a much more 
sensitive, automated method that records the height each individual fly climb 
(RING method; see Gargano et al. 2005) and thus, were more likely to detect 
subtle changes in negative geotaxis. What this study and the data presented in 
this chapter demonstrate is that interventions that extend lifespan can also delay 
behavioural senescence (in this case, negative geotaxis). However, this is not a 
general rule applicable to all functions that senesce. For example, studies on 
behavioural senescence in Drosophila methusela mutants, which are long-lived, 
suggest that extension of lifespan does not delay behavioural senescence (Cook-
Wiens & Grotewiel. 2002). Similarly, lifespan in flies that overexpress either the 
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Drosophila insulin receptor (dInR) or its downstream signalling target dFOXO in 
cardiac tissue are indistinguishable, yet cardiac senescence is delayed only in 
flies overexpressing dFOXO (Wessells et al. 2004). 
 
Although rapamycin had no effect on the Arctic A!42-mediated decline in 
negative geotaxis it did extend lifespan of flies expressing Arctic A!42. In one 
trial, a 15% increase in median lifespan was observed. Similarly, rapamycin 
extended the lifespan of non-RU-treated wDah;UAS-Arctic A!42/+;elavGS/+ 
controls and wDah wild-type flies. Thus, rapamycin slowed ageing in all 
treatments and genotypes studied in the wDah background. The magnitude of 
lifespan extension was similar in RU and non-RU-treated wDah;UAS-Arctic 
A!42/+;elavGS/+ flies, suggesting that slowing the ageing process in this 
manner did not ameliorate the reduction in lifespan induced by Arctic A!42. This 
interpretation is consistent with the observation that rapamycin had no effect on 
total Arctic A!42 levels. On the other hand, the fact protein levels were unaltered 
is inconsistent with the fact rapamycin reduces protein translation in Drosophila 
(Bjedov et al. 2010). It might be that the reduction in GeneSwitch expression (if 
translation of this gene is affected by rapamycin) was not significant to result in a 
reduction in UAS-transgene expression. 
 
Given that rapamycin affects all tissues in the fly, but Arctic A!42 is mediating 
its effects predominantly from nervous system, it is likely the extension in 
lifespan seen in Arctic A!42 expressing flies was mediated from tissues outside 
of the nervous system and thus was independent to the effects of Arctic A!42 
toxicity. 
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These results also demonstrate that the processes regulating mortality and 
neurodegeneration can be uncoupled, since rapamycin extended lifespan without 
ameliorating the neuronal dysfunction associated with Arctic A!42 
overexpression. This finding is consistent with other studies. Kerr et al (2009) 
reported that dietary restriction (DR), an intervention known to extend lifespan in 
Drosophila, delays ageing but similarly not neuronal dysfunction in a Drosophila 
model of A!42 toxicity (Kerr et al. 2009). Furthermore, flies expressing a 
mutation in the ADAR (Adenosine Deaminase Acting on RNA) gene display 
severe, progressive neuro-behavioural impairments, but are not short-lived 
(Palladino et al. 2000). 
 
5.3.3 The effects of rapamycin in other AD models 
These findings, particularly the lack of neuronal dysfunction rescue, apparently 
conflict with published studies demonstrating that rapamycin abolishes cognitive 
deficits and reduces A!42 levels and deposition in PDAPP transgenic mice 
(Spilman et al. 2010) and in 3xTg mice (Caccamo et al. 2010). The conflicting 
data in this chapter could be reconciled if rapamycin were acting upstream of A! 
toxicity at the APP processing level since the fly model does not model this 
process. However both mouse studies reported no change in APP, C99, C83 or 
A!40 protein levels ruling out reduced amyloidgenic processing as a mechanism 
of rescue.  
 
Both studies also reported an induction of autophagy in both PDAPP and 3xTg 
mice, and demonstrated that the reduction and disagggregation of A!42 was 
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dependent on this process. Similarly, rapamycin has been shown to reduce levels 
and toxicity of a variety of different aggregation-prone proteins in Drosophila 
including wild-type and mutant human tau (Berger et al. 2006) and Huntington 
protein fragments (with a 120-residue polyglutamine tail) (Ravikumar et al. 
2004). These were also found to be dependent on autophagy. 
 
The level of autophagy was not measured in the fly AD model so it is difficult to 
suggest whether a lack of autophagy induction was to account for the conflicting 
results. However, when using the same rapamycin dose and genetic background, 
Bjedov et al (2010) demonstrated that chronic rapamycin administration does 
indeed induce autophagy in Drosophila. It is a possibility that the high 
concentration of the highly aggregate-prone Arctic A!42 isoform was averse to 
disaggregation, even after autophagy had been apparently induced. This idea is 
consistent with the fact that a small reduction in Arctic A!42 levels was seen in 
the non-RU-treated controls where expression levels are very low, owing to 
leakiness of the UAS-transgene. 
 
Thus, in future work it would be interesting to measure the effects of rapamycin 
on flies expressing lower levels of Arctic A!42. This could be simply achieved 
by lowering the dose of RU486 (chapter 4 demonstrated that a wide range of 
Arctic A!42 expression levels can be achieved by using different RU486 doses 
for varying exposures). Moreover, one could use the wild-type form of A!42, 
which is less aggregation prone and less toxic to Drosophila (Crowther et al. 
2005). The only problem with these approaches is that by lowering the RU486 
dose or the level of toxicity, the phenotypes will become less severe. It might be 
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that a combination of a much higher RU486 dose and wild-type A!42 would be 
more suitable in modelling the subtle effects of rapamycin. However, this could 
be complicated by the fact RU486 is toxic at high doses.  
 
The literature concerning the effects of rapamycin in AD remains very 
controversial. Although this drug has been shown to alleviate toxicity and 
aggregation in mouse AD models, others have demonstrated that rapamycin 
exacerbates A! production and A!-induced cell death (Lafay-Chebassier et al. 
2006), and can promote amyloidogenic processing and A! production via 
ADAM10 inhibition (Zhang et al. 2010). The data presented in this chapter only 
adds to this controversy. It illustrates a rather benign effect of rapamycin on 
A!42-toxicity, and a beneficial effect on lifespan that is likely independent of 
A!42. There appears to be enough evidence to suggest the mTOR pathway is 
certainly affected in AD. However, determining its exact role is confounded by 
the use of different models of AD, different age or developmental stage of the 
organism/cell studied, and most likely, the different concentrations and dosages 
of rapamycin administered. Since these all vary between different studies it is 
very difficult to get a grasp on what actually is going on. The data presented in 
this chapter only serve to highlight this difficulty since even using a different 
genetic background yielded alternative results. Thus, more studies must be done 
to clarify the role of mTOR as well as the potential therapeutic effects of 
rapamycin in AD. This clarification will be aided by the development of an AD 
model that everyone can agree accurately represents the human disease. If this is 
not possible, groups using different models should aim to use similar 
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experimental designs and behavioural paradigms to make comparisons of 
experiments more relevant. 
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Chapter 6 Investigating the interaction between 
reduced insulin signalling and A"42 toxicity in 
chico1 mutants 
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6.1 Introduction 
Because of the strong association between ageing and neurodegenerative disease, 
many studies have investigated whether interventions that reduce ageing might 
also delay neurodegeneration in transgenic disease models (for review see 
(Douglas & Dillin. 2010). In particular, there has been much focus on the 
specific role of the IIS pathway, since this is the most prominent and best-studied 
pathway known to regulate ageing. Results have been mixed and have led to 
what some have labelled the ‘insulin paradox’ (Cohen & Dillin. 2008). This 
paradox concerns the protective nature of IIS signalling, since it has been 
demonstrated that both reduced and increased IIS signalling can be 
neuroprotective.  
 
In worm models of HD and AD it was demonstrated that reduced IIS signalling, 
by AGE-1 and DAF-2 RNAi respectively, ameliorates toxicity, Furthermore, this 
was confirmed in various mouse models of AD, where it was shown that 
deficiencies in IRS-2, neuronal IGF and the neuronal insulin receptor delayed 
pathology (Freude et al. 2009); as did IRS-2 null (Killick et al. 2009) and IGF-1 
receptor heterozygous mice (Cohen et al. 2009). Conversely, infusion of IGF1 
into ageing rats was reported to enhance the clearance of brain A! resulting in 
levels similar to those found in the brains of young rats (Carro et al. 2002). More 
recently, the same group demonstrated that injection of IGF-1 into AD-model 
mice reduced the typical behavioural impairments that are associated with 
increased A! levels. Furthermore, there is now evidence to suggest that IIS 
signalling is compromised in the neurons of patients with AD and that the 
specific neurons that degenerate in AD may, in fact, be resistant to IIS signalling 
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(Moloney et al. 2010). It is unclear, however, whether this represents an active 
neuroprotective response or a secondary manifestation of the neurodegenerative 
process. Nonetheless, these studies point towards the IIS pathway as a major 
mechanistic candidate linking ageing, proteotoxicity and late-onset 
neurodegenerative disease.  
 
This chapter sets out to further explore the link between the IIS pathway and 
proteotoxicity in an inducible model of AD in Drosophila. Interestingly, the 
effect of reduced IIS on a fly model of AD has yet to be reported. This is 
somewhat surprising since there are a variety of AD model reagents and well-
characterised IIS mutants available in Drosophila. To assess the effect of 
reduced IIS on AD phenotypes, Arctic A!42 was pan-neurally expressed in adult 
flies homozygous for chico1, a null mutation in the Drosophila insulin receptor 
substrate gene, chico (Böhni et al. 1999) that has been shown to extend median 
and maximum lifespan in both homozygotes and heterozygotes (Clancy et al. 
2001). 
 
The chico1 mutation was shown to extend life-span by up to 48% in 
homozygotes and 36% in hetereozygotes, when compared to wild-type flies 
(Clancy et al. 2001). In addition, homozygous chico1 flies have a dwarf 
phenotype, owing to fewer and smaller cells despite relatively higher lipid levels 
(Böhni et al. 1999).  
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6.2 Results 
6.2.1 Stock generation 
In previous chapters, the inducible model was established by crossing 
homozygous elavGS flies with homozygous UAS-Arctic A!42 to generate UAS-
Arctic A!42/+;elavGS/+ heterozygotes. These flies were then treated with 
RU486, typically at two-days post-eclosion, to induce Arctic A!42 protein 
expression in adult fly neurons. In this chapter I wished to do the same but in a 
chico1 homozygous background. The cross that was required to achieve this is 
outlined below (Figure 6.1). 
 
 
 
Figure 6.1. Crossing scheme used to establish the inducible AD model in a 
chico1 homozygous genetic background. Note: ‘Arc’ stands for Arctic, Dah 
stands for Dahomey and all females (&) were virgins. 
 
As evident in the above figure, this cross required the generation of new UAS-
Arctic A!42 and elavGS stocks that were heterozygous for the chico1 mutation. 
This ensured a proportion of the resulting offspring would be chico1 
homozygotes, whilst also carrying copies of UAS-Arctic A!42 and elavGS. 
Furthermore, because chico1 homozygotes are sterile (Clancy et al. 2001), chico1 
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had to be maintained in a heterozygous state, otherwise no progeny would be 
generated from this cross. It is also important to note that these stocks were all in 
wDah genetic background. This is because chico1 was originally shown to increase 
lifespan in this background.   
 
Generating the two new stocks outlined above (Figure 6.1) required the use of 
several Drosophila genetic techniques. Generating chico1/CyO;elavGS flies was 
relatively straightforward because these two genes reside on different 
chromosomes; chico1 is located on the second chromosome whereas the elavGS 
insertion is found on the third . However, because the UAS-Arctic A!42 insertion 
is also found on chromosome 2, it was necessary to recombine chromosomes 
carrying chico1 and UAS-Arctic A!42. The crossing schemes for developing 
these two stocks are outlined in Figure 6.2 and Figure 6.3, respectively. 
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Figure 6.2. Crossing scheme used to generate chico1/CyO; elavGS/+ flies. It 
was first necessary to balance elavGS (a) and chico1 (b). These balanced stocks 
were then crossed (c) to generate progeny carrying both genes on chromosomes 
2 and 3, respectively. The wDah;chico1/CyO;elavGS/TM6B progeny were then 
crossed to each other to generate a stock. In subsequent generations, TM6B was 
selected against to make elavGS homozygous. However, because chico1 
homozygotes are sterile, chico1 was kept balanced over CyO. Thus, these flies 
were red-eyed with curly wings. 
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Figure 6.3. Crossing scheme for generating UAS-Arctic A!42, chico1 
recombinants. The first step required crossing UAS-Arctic A!42 homozygotes 
with chico1/cyo (a). All the resulting offspring were either UAS-Arctic 
A!42/chico1 or UAS-Arctic A"42/CyO. Thus, flies with curly wings were 
selected against at this stage. UAS-Arctic A!42/chico1 females were then crossed 
to wDah males (b). It was important to use females in this cross because no 
recombination occurs in male Drosophila (under normal conditions). If the 
insertions were far enough apart on the second chromosome then a number of 
this progeny would have both insertions on the same chromosome following 
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recombination. Because it was impossible to tell the difference between UAS-Arc 
A!42/+ and UAS-Arc A!42,chico1 flies (they both have a red eye colour) all red-
eye male flies from this cross were individually paired with double balancer 
virgins (c). Once these flies had mated, each individual male was subject to 
genomic DNA extraction, after which PCR was used to detect the presence of 
chico1. One ' symbol represents single pair crosses. 
 
Crossing UAS-Arctic A!42,chico1/CyO flies with chico1/CyO;elavGS yielded 
viable UAS-Arctic A!42,chico1/chico1;elavGS/+ offspring. As has been reported 
previously for chico1 homozygotes, development was delayed by approximately 
two-days and they exhibited an obvious dwarf phenotype, which corresponded 
with a 55% reduction in mean body weight. 
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Figure 6.4. Body size reduction in chico1 homozygotes. UAS-Arctic 
A!42,chico1/chico1;elavGS/+ females displayed (a) a visible dwarf phenotype 
that corresponded with (b) reduced body weight at eclosion. In (b) data are 
presented as the mean (n = 10) wet weight (mg) per fly. chico1 homozygotes 
were significantly smaller in body size than wild-type flies.* P<0.05, Student’s t-
test. 
 
6.2.2 Arctic A"42-mediated toxicity is suppressed in chico1 
homozygotes 
Following generation and confirmation of my stocks, my first aim was to 
measure the effect of the loss of chico on A!42-mediated toxicity. In chapter 3, it 
was demonstrated that induced Arctic A!42 overexpression shortens lifespan; 
causes locomotor dysfunction (as measured by negative geotaxis) and neuronal 
dysfunction as measured by Giant Fibre electrophysiology. Although the GFS 
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phenotype offers the most direct marker of A!42 toxicity and neuronal 
dysfunction, it was not a practical method for assaying the effect of the chico1 
mutation on A!42-mediated toxicity because this work was very tiem consuming 
and required a specialised lab (Dr. Hrvoje Augustin). Therefore, lifespan and 
negative geotaxis were chosen as markers of toxicity as they are robust, easy-to-
score phenotypes.  
 
It was important to have a suitable control for the presence of the chico1 
mutation, therefore all experiments were also carried out in UAS-Arctic 
A!42/+;elavGS flies which have normal IIS signalling. It is important to note 
that because of the developmental delay present in chico1 homozygotes, these 
crosses were set up two-days after the chico1 crosses to ensure all progeny 
emerged on the same day.  
 
I first measured the effect of Arctic A!42 expression in chico1 homozygotes by 
measuring negative geotaxis (Figure 6.5). Age-matched UAS-Arctic 
A!42,chico1/chico1;elavGS/+ and UAS-Arctic A!42/+;elavGS/+ females were 
chronically treated with 200#M RU486 from two-days post eclosion. Non-RU-
treated flies of each genotype were used as controls.  
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Figure 6.5. A!42-mediated neuronal dysfunction is ameliorated in flies 
homozygous for chico1. Climbing ability of UAS-Arctic 
A!42,chico1/chico1;elavGS/+ (A!42,chico1/chico1 in figure) and UAS-Arctic 
A!42/+;elavGS/+ (A!42 in figure) females treated with + (200#M) and - RU486 
SY medium was assessed at the indicated time-points, (a) and (b) represent two 
independent experiments. Data are presented as the mean percentage climbing 
performance (ability to climb 5cm in 18s) of flies +/- SEM (n = 3, number of 
flies per group = 45) and were compared using two-way ANOVA and Tukey’s 
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honestly significant difference (HSD) post-hoc analyses. *P<0.05 comparing 
climbing performance of UAS-Arctic A!42/+;elavGS +RU to all other groups at 
the indicated timepoints. A significant difference was seen from day 28 onwards 
in both trials. 
 
It is important to note that a slightly different negative geotaxis assay was used in 
this chapter. Rather than using the 25-ml pipettes, climbing performance was 
measured by the ability of flies to climb 5cm (in a plastic vial with no food) after 
18s. The number of flies reaching the 5cm mark was expressed as a percentage 
of the total number of flies (15 per vial). This is a less stringent version of the 
climbing assay because the ability of flies to climb is distinguished over a much 
shorter distance. Consequently, this assay is less sensitive to subtle differences in 
climbing ability. However, I simply wanted to see whether the climbing 
phenotype could be rescued in a chico1 homozygous background so sensitivity 
was not such a priority. Furthermore, the use of the 25-ml pipette was likely to 
skew the data; due to the fact flies homozygous for chico1 would have to climb 
almost twice the distance, owing to their dwarf phenotype.  
 
In two independent trials, it was found that loss of chico reduced the Arctic A!42 
climbing dysfunction. UAS-Arctic A!42,chico1/chico1;elavGS/+ flies treated 
with RU486 exhibited no relative decline in climbing ability when compared to 
non-RU-treated controls (P<0.05). On the other hand, UAS-Arctic 
A!42/+;elavGS/+ flies treated with RU486 did show a progressive decline in 
climbing ability, that was significantly different to non-RU-treated controls from 
day 28 onwards in both trials. As expected, all flies demonstrated an age-
dependent decline in climbing ability over the assay period. 
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Next the effect of Arctic A(42 overexpression on survival was measured in flies 
homozygous for chico1 (Figure 6.6). As before, age-matched UAS-Arctic 
A!42,chico1/chico1;elavGS/+ and UAS-Arctic A!42/+;elavGS/+ females were 
chronically treated with 200#M RU486 from two-days post eclosion. Non-RU-
treated flies of each genotype were used as controls.  
 
 
 
Figure 6.6. A!42-mediated ageing is delayed in a chico1 homozygous 
background. Survival curves of A!42,chico1/chico1;elavGS/+ and UAS-Arctic 
A!42/+;elavGS females treated with +/-RU486 from two-days post-eclosion. 
Median lifespans: 73 days for Arctic A!42,chico/chico;elavGS/+ -RU and 55 
days for +RU. 70 days for Arctic A!42, chico/+;elavGS/+ -RU and 44 days for 
+RU.  
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RU486 treatment reduced lifespan in both A!42,chico1/chico1;elavGS/+ and 
UAS-Arctic A!42/+;elavGS flies, when compared to their respective non-RU-
treated controls. Interestingly, the extent of this reduction differed between the 
two genotypes. In chico1 homozygotes, RU treatment resulted in a 25% reduction 
in median lifespan from 73 days to 55 days (P<0.001, log rank test). In flies 
expressing A!42 in a wild-type background, there was a larger 37% reduction in 
median lifespan, from 70 days to 44 days. When comparing both RU-treated 
cohorts, chico1 homozygotes exhibited a 20% extension in median lifespan over 
flies solely expressing Arctic A!42 (55 days compared with 44 days, P<0.001). 
A smaller extension in median lifespan of 4% was observed when comparing 
non-RU-treated chico1 homozygotes with controls (73 days compared with 70 
days, P<0.005). These data indicated that although loss of chico could not fully 
rescue the A!42-mediated reduction in lifespan, it could suppress it. 
Furthermore, the difference in median lifespan between the RU-treated groups 
(20%) was greater than that seen between non-RU-treated controls (4%), 
indicating that IIS signalling was playing an active role in modulating A!42-
mediated toxicity rather than extending lifespan through some unrelated 
independent mechanism (as was the case with rapamycin). 
 
6.2.3 Arctic A"42 expression is reduced in chico1 homozygotes  
To further investigate the role of reduced IIS signalling in this model, Arctic 
A!42 protein and mRNA levels were assayed in chico1 homozygotes (Figure 
6.7). Age-matched UAS-Arctic A!42,chico1/chico1;elavGS/+ and UAS-Arctic 
A!42/+;elavGS/+ females were chronically treated with 200#M RU486 from 
two-days post eclosion. Total Arctic A!42 protein and mRNA levels were then 
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assayed 12-days into RU486 treatment using A!42-specific ELISA and Q-PCR, 
respectively.  Non-RU-treated flies were used as controls. 
 
Because chico1 homozygotes are over half the size of wild-type flies it was 
essential to normalize total A!42 levels to the total level of protein in each 
sample. Interestingly, following this normalization, A!42 levels were 
significantly lower in chico1 homozygotes (P<0.05, Student’s t-test). Similarly, 
A!42 mRNA levels were also significantly reduced in chico1 homozygotes 
(P<0.05, Student’s t-test). Thus, these data indicated that the apparent 
amelioration of toxicity, as observed in survival and negative geotaxis assays, 
was actually a consequence of reduced A!42 expression rather than a direct 
consequence of reduced IIS signaling. IIS obviously had an effect but it was not 
acting at the level of Arctic A!42 protein turnover, which has been shown to be 
the case in a worm model of AD (Cohen et al. 2006). 
 
The efficacy of induction with the GeneSwitch system is largely dependent on 
the amount of RU486 ingested during feeding. The fact chico1 homozygotes are 
both dwarves and sterile hinted that these flies were actually feeding less and 
therefore ingesting less RU486. This is because it has been reported that sterile 
ovoD1 flies feed less than fertile flies (Barnes et al. 2008). 
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Figure 6.7. Arctic A!42 expression is reduced in chico1 homozygotes. Total 
Arctic A!42 protein levels (a) and mRNA levels (b) were quantified 12-days 
into-RU486 treatment in A!42,chico1/chico1;elavGS/+ and UAS-Arctic 
A!42/+;elavGS females. Data are presented as means +/- SEM (n = 3 for each 
group). *P<0.05 comparing total A!42 between the two groups (Student’s t-test)   
 
 
This would explain the reduced levels of transcription, which consequently 
would account for the reduced A!42 load and corresponding suppression in 
A!42-mediated toxicity. Therefore, feeding behaviour was assayed at seven days 
post-eclosion in UAS-Arctic A!42,chico1/chico1;elavGS/+ and UAS-Arctic 
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A!42/+;elavGS/+ females using the proboscis extension assay. It has been 
demonstrated that this method is an effective and accurate measure of feeding 
behaviour (Wong et al. 2009). Consequently, chico1 homozygotes exhibited a 
significant reduction in feeding behaviour over the assay period .  
 
 
Figure 6.8. Feeding frequency is reduced in chico1 homozygotes. The 
proportion of time spent feeding of 7-day old UAS-Arctic 
A!42,chico1/chico1;elavGS/+ (A!42,chico1/chico1 in figure) and UAS-Arctic 
A!42/+;elavGS/+ (A!42 in figure) females over a 2-hour period. Data are 
presented as means +/- SEM (N = 10 for each group). *P<0.001 when comparing 
the two genotypes.  
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6.3 Discussion 
The aim of this chapter was to investigate the effect of reduced IIS signalling on 
Arctic A!42-mediated toxicity. This was of particular interest to this thesis since 
reduced IIS signalling extends lifespan in a diverse range of model organisms 
ranging from worms and flies to mice. Moreover, reduced IIS has been shown to 
alleviate toxicity in worm models of AD (and HD) and various mouse models of 
AD. Interestingly, this effect was yet to be observed in a Drosophila model of 
AD. The availability of well-characterised inducible model of A!-toxicity (see 
chapters 3 and 4) and various fly IIS mutants ensured this would be relatively 
straightforward to test. 
 
6.3.1 The suppression of Arctic A"42-mediated toxicity in chico1 
homozygotes is an artefact of reduced feeding 
The generation of wDah;UAS-Arctic A!42, chico/chico;elavGS/+ flies was 
successful and yielded viable, sterile, dwarf flies that were developmentally 
delayed (by ~2 days). This was consistent with previously reported studies on 
wDah;chico1 flies (Böhni et al. 1999; Clancy et al. 2001). RU486 treatment in 
these flies resulted in a robust induction of Arctic A!42 mRNA and protein 
expression. Initially, it appeared that Arctic A!42-mediated toxicity was 
suppressed in chico1 flies since survival and negative geotaxis were both 
improved, although not completely rescued, when compared to flies expressing 
Arctic A!42 in a wild-type background.  
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Comparison of Arctic A!42 mRNA and protein expression levels revealed that 
expression of both mRNA and protein was significantly lower in chico1 
homozygotes when compared to wild-type wDah background controls. Thus, it 
was apparent that the suppression in toxicity was in fact due to a reduction in 
Arctic A!42 expression. This in turn prompted an investigation into the feeding 
behaviour of chico1 homozygotes. The rate of feeding is the major limiting factor 
for UAS-transgene expression when using the RU486 ‘in-food’ delivery method. 
If flies feed less, they ingest less RU486 and UAS-transgene induction is likely 
to be reduced. Using a proboscis-extension assay, it was clear that feeding 
behaviour in chico1 homozygotes was reduced. Interestingly, this disagrees with 
a previous study showing feeding behaviour is unaltered in long-lived chico1 
heterozygotes (Wong et al. 2009). This difference is probably due to the fact 
chico1 homozygotes are sterile. For instance, it has been suggested that females 
feed more than males because of their high nutrient-usage in egg production 
(Wong et al. 2009). Thus, the fact chico1 homozygotes are sterile suggests their 
lower demand for nutrients resulted in reduced feeding and therefore, reduced 
RU486 ingestion, in turn leading to reduced induction. This is consistent with the 
observation that sterile ovoD1 females (in which egg production is arrested) feed 
less during long-term undisturbed conditions than fertile females (feeding also 
measured by proboscis-extension assay in this study) (Barnes et al. 2008). 
 
6.3.2 The pitfalls of the GeneSwitch system and possible future 
resolutions 
Although this study set out to investigate the effects of reduced IIS signalling on 
A!-mediated toxicity in Drosophila, it was more effective in highlighting one of 
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the technical drawbacks of the GeneSwitch system, in particular, the RU486 ‘in-
food’ delivery method. Because UAS-transgene expression is dependent on 
amount of RU486 ingested, controlling for the rate of feeding is essential for 
measuring the equal effects of protein-mediated toxicity in different mutants. 
This is especially so when the level of toxicity in the model is a function of the 
toxic protein dose. This study highlighted that if feeding behaviour is not 
controlled for, data can be misinterpreted. For instance, if feeding behaviour was 
not assayed in this study I may have concluded IIS was affecting the 
transcription of UAS-Arctic A!42, when this evidently was not so. 
 
With the benefit of hindsight it is easy to see how the real effect of chico1 on A! 
toxicity could be measured. This would require controlling for the different level 
of feeding between wild-type and chico1 mutant flies. There are many ways in 
which this could be achieved. One could use different concentrations of RU486 
in wild-type and chico1 flies. This is the same approach used in chapter 4 to 
equalise transcript expression at different ages. Thus, a higher RU486 dose fed to 
chico1 flies would compensate for their reduced feeding. Although this approach 
has been shown to be effective, it is impractical and complex. First, a variety of 
RU486 food concentrations would have to be trialled to find those that result in 
equivalent levels of Arctic A!42 expression. Further complicating this is the fact 
that feeding behaviour declines with age. Hence, the doses might have to be 
changed accordingly (if using chroninc induction). Alternatively, the flies could 
be subject to conditional RU486 treatment as in chapter 4. 
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One approach that would remove the need to control for feeding behaviour 
would be to inject a known dose of RU486 into individual experimental flies. 
Although hardly practical for large experiments this technique has been shown to 
be effective. Bjedov et al. (2010) used this technique to inject a known 
concentration of paraquat, a compound that causes oxidative stress in 
Drosophila, into flies to check that flies are not more/less stress resistant simply 
because they are eating less/more of the paraquat food. Similarly, Cocheme et al. 
(2010)  used the same technique to inject a mitochondrial targeted antioxidant, 
MitoQ, into flies and found that the compound was almost completely cleared 
after 12 hours. Thus, with this approach, wild-type and chico1 Arctic A!42-
expressing flies could be pulsed with an injection of the same dose of RU486 
(after accounting for difference in body weight etc.). In this way, the effect of 
reduced IIS could be measured in the absence of feeding differences. This would 
then reveal if loss of chico really was involved in the suppression of A! toxicity 
in this model system. 
 
A final more radical approach would be to use a different conditional system all 
together. In particular, to use one that does not rely on feeding as a method of 
inducer delivery but still is compatible with the catalogue of existing, well-
characterised GAL4 and UAS transgenic lines. Such a system has recently been 
developed, based on a temperature sensitive GAL80 protein and is called the 
temporal and regional gene expression targeting (TARGET) system (McGuire et 
al. 2003; McGuire et al. 2004. In yeast, GAL80 functions as a repressor of 
GAL4 activity only in the absence of galactose. When galactose is present, 
repression is relieved and GAL4 can activate the transcription of target genes. 
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The TARGET system uses a temperature sensitive variant of GAL80 (GAL80ts) 
that represses GAL4 activity at 18°C, but which is relieved when flies are moved 
to 30°C (Figure 6.9). GAL80ts is ubiquitously expressed under the control of a 
tubulin 1a (Tub) promoter.  
 
 
 
Figure 6.9. The TARGET system. A fly carrying GAL80ts and a promoter-
specific GAL4 is crossed with a fly carrying a UAS-transgene (shown here as 
UAS-A!42). At the permissive temperature (18°C, uninduced) GAL80ts 
suppresses GAL4 activity and prevents transcription of UAS-A!42. When flies 
are moved to the restrictive temperature (30°C, induced) GAL80ts is inactivated 
and GAL4 can activate UAS-A!42 expression. Figure taken from (Iijima & 
Iijima-Ando. 2008). 
 
This system would be ideal for investigating the effect of loss of chico because it 
does not rely on feeding for induction of UAS-Arctic A!42 transgene expression. 
A future study employing this system would be very interesting although it 
would necessitate complete re-characterisation of the inducible model. A 
potential downfall of this system though is that it would require the existence of 
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another insertion (GAL80ts), which would complicate matters, especially when 
using multiple gene insertions as in the case of this chico1 study.  
 
Overall, this study provides a cautionary tale on the limitations and pitfalls of the 
GeneSwitch system, particularly in modelling neurodegenerative disease. 
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Chapter 7 Overall conclusions and future work 
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7.1 Summary of findings 
The overall aims of this thesis were to investigate the role of ageing as a risk 
factor for Alzheimer’s Disease. The fruit fly Drosophila melanogaster is well 
suited for this type of investigation for several reasons. Firstly, fruit flies are 
practical, with short generation times and relatively short lifespans suitable for 
studying age-related neurodegenerative disease. Second, a variety of genetic 
tools are available. Of particular importance to this thesis was the use of the 
conditional GeneSwitch system, that allows UAS-linked transgenes to be turned 
on or off at any time. This system was essential for investigating the effect of A! 
toxicity at different ages because it allowed Arctic A!42 expression to be 
induced at progressively later ages in the adult fly. Third, there are many well-
characterised Drosophila models of AD, with freely available reagents, that 
reproduce many of the features of human disease. Fourth, there are a variety of 
assays available in the fruit fly for measuring toxicity including survival, 
negative geotaxis and Giant Fibre electrophysiology amongst many others not 
used in this thesis. 
 
The data in chapter 3 and 4 demonstrated that the GeneSwitch system is an 
effective platform for developing conditional or adult-onset models of 
neurodegenerative disease. RU486 induction resulted in robust A!42 expression 
and age-dependent accumulation and aggregation of Arctic A!42, which in turn 
resulted in reduced survival, a progressive decline in climbing ability (locomotor 
function) and an impairment of Giant Fibre function. The fact these direct and 
surrogate markers of toxicity presented were consistent and in agreement with 
the literature indicated that they were all modelling the same thing i.e. A! 
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toxicity. Furthermore, the fact no neuronal loss was observed in this model, 
despite using some of the same reagents from studies where Arctic A!42-
mediated neuronal loss was apparent (Crowther et al. 2005), highlighted the 
possible problems with constitutively expressing A! peptides during 
development.  
 
Chapter 4 clearly illustrated the flexibility of the GeneSwitch system and the 
inducible AD model. Modulation of RU486 dose or removing it completely 
allowed the study of the dynamics of A! toxicity and investigation into the direct 
effects of ageing on A! toxicity. These latter experiments required careful 
calibration of A! dose at different ages to control for differences in RU486 
ingestion and protein turnover with age. These calibration steps will be essential 
for studying the effect of ageing in other models neurodegenerative disease 
models. Failure to calibrate could lead to misinterpretation of data, as 
exemplified by the study by Ling et al. (2011).  
 
The switch-off studies in chapter 4 demonstrated that A! is highly resistant to 
degradation in Drosophila. This finding was consistent with studies of A! 
suppression in mouse models of AD (Jankowsky et al. 2005). These studies 
imply that to effectively treat AD with drugs that reduce the A! load it will be 
imperative to treat the plaques as early as possible otherwise they will be very 
difficult to clear. Chapter 4 also demonstrated that ageing increases the 
vulnerability to A! toxicity. This conclusion was reached independently using 
both equalised and chronic A!42 induction in young and old flies and the effect 
was very clear. This was particularly so when measuring the effect of chronic 
  230 
induction in young and old flies where the lifetime Arctic A!42 load was 
considerably lower in older flies. This provided further evidence that older flies 
are more sensitive or vulnerable to A!. The exact mechanism underlying the 
increased vulnerability in older flies is yet to be fully elucidated. This would be 
the main goal of future work and the model developed in this study provides a 
suitable platform to contine from. 
 
This thesis also highlighted the problem of comparing models that are defined by 
different conditions (i.e. temperature, level of expression etc). This was 
exemplified in the study on the effects of rapamycin (chapter 5). This study 
produced results that were inconsistent with the literature. This was likely due to 
the many differences in experimental design such as the type of AD model used 
(APP versus A! overexpression), the dose of rapamycin, the behavioural or 
toxicity markers used, and the age at which the animals were assayed. The data 
in chapter 5 also demonstrated that some toxicity phenotypes such as survival 
and climbing could be uncoupled.  
 
Finally, this thesis draws attention to some of the drawbacks of the GeneSwitch 
system. The first is that UAS-transgene expression occurs in the absence of 
RU486. Thus, this system is not truly inducible. In every experiment measuring 
UAS-linked transgene expression, a low basal level of expression was detected 
in all non-RU86-treated controls. This appears to be an unavoidable feature of 
this and has been reported elsewhere in the literature (Poirier et al. 2008). In the 
case of the experiments presented in this thesis, this leaky expression was not 
important since all comparisons were made to uninduced controls.  
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The other major flaw identified in this thesis is that the GeneSwitch system is 
highly dependent on the level of feeding behaviour, which complicates the study 
of mutations or treatments where feeding behaviour altered. This was especially 
evident in chapter 6 when examining the effects of the chico1 mutation on A! 
toxicity. Although it was shown in chapter 4 that modulating the RU486 dose 
can possibly rectify this problem, other conditional systems such as the 
TARGET system may be more suitable for such experiments. It would be of 
great interest to repeat the chico1 experiments and controlling for reduced 
feeding or using the TARGET system since it remains to be seen whether 
reduced IIS can ameliorate protein-mediated toxicity in Drosophila.  
 
7.2 Future work 
The development and extensive characterisation of this inducible model of AD 
provides a framework from which to develop other models of neurodegenerative 
disease. There are now models of AD, PD, polyglutamine and prion disease in 
the fly. It would be of great interest to see whether older flies were more 
vulnerable to these other forms of proteotoxicity. This could be achieved using 
the same experimental design outlined in this thesis since the experiments and 
protocols used are easily transferrable. This is helped immensely by the 
popularity and universality of the GAL4/UAS system. 
 
This work really only scratches on the surface on the role of ageing in 
neurodegenerative disease. Thus future work focused on the mechanism of 
‘increased vulnerability’ with age would be of much interest. There are several 
ways this could be investigated. It has been suggested that ageing decreases the 
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cell’s ability to degrade aggregates (Cohen & Dillin. 2008). The Arctic A!42 
isoform was incredibly stable so it was difficult to track its degradation following 
Arctic A!42 suppression. Future pulse-chase studies using less aggregatory 
prone proteins such as wild-type A!42 or even A!40 might provide further 
insight into the relative rates of degradation at different ages.  
 
Moreover, one could induce equivalent levels of A!42 expression in young and 
old flies (using the protocols developed in this thesis) and then use microarrays 
to assess the relative changes in gene expression. This could potentially identify 
key targets or pathways that are down-regulated in older flies. Genetic or 
pharmacological upregulation of these target genes could then be used in an 
attempt to rescue the older flies increased vulnerability.  
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Abstract
Ab peptide accumulation is thought to be the primary event in the pathogenesis of Alzheimer’s disease (AD), with
downstream neurotoxic effects including the hyperphosphorylation of tau protein. Glycogen synthase kinase-3 (GSK-3) is
increasingly implicated as playing a pivotal role in this amyloid cascade. We have developed an adult-onset Drosophila
model of AD, using an inducible gene expression system to express Arctic mutant Ab42 specifically in adult neurons, to
avoid developmental effects. Ab42 accumulated with age in these flies and they displayed increased mortality together with
progressive neuronal dysfunction, but in the apparent absence of neuronal loss. This fly model can thus be used to examine
the role of events during adulthood and early AD aetiology. Expression of Ab42 in adult neurons increased GSK-3 activity,
and inhibition of GSK-3 (either genetically or pharmacologically by lithium treatment) rescued Ab42 toxicity. Ab42
pathogenesis was also reduced by removal of endogenous fly tau; but, within the limits of detection of available methods,
tau phosphorylation did not appear to be altered in flies expressing Ab42. The GSK-3–mediated effects on Ab42 toxicity
appear to be at least in part mediated by tau-independent mechanisms, because the protective effect of lithium alone was
greater than that of the removal of tau alone. Finally, Ab42 levels were reduced upon GSK-3 inhibition, pointing to a direct
role of GSK-3 in the regulation of Ab42 peptide level, in the absence of APP processing. Our study points to the need both
to identify the mechanisms by which GSK-3 modulates Ab42 levels in the fly and to determine if similar mechanisms are
present in mammals, and it supports the potential therapeutic use of GSK-3 inhibitors in AD.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia in the
ageing population. Symptoms include, but are not limited to,
memory loss, cognitive decline, and deterioration of language
skills. The pathological hallmarks of AD are the presence of
plaques and neurofibrillary tangles [1]. The tangles are composed
of hyperphosphorylated tau protein while the plaques are
comprised of amyloid beta (Ab) peptides, various species of which
are derived from the amyloid precursor protein (APP), the most
abundant being Ab40 and Ab42 [2]. AD-causing mutations either
increase the level of Ab42 or the ratio of Ab42/Ab40, indicating
that this is the more toxic form of the peptide [2].
The leading candidate explanation for the molecular basis of
AD pathology is the amyloid cascade hypothesis. This states that
the Ab protein initiates the disease process, activating downstream
neurotoxic mechanisms including the dysregulation of tau.
Perhaps the strongest support for the amyloid cascade hypothesis
is that all of the mutations implicated in early-onset, familial AD,
such as the Ab Arctic mutation, increase the aggregation or
production of Ab [1]. Although tau mutations exist, none have
been linked to familial AD, but rather to fronto-temporal
dementia, in which Ab plaques are absent [3,4]. The amyloid
cascade has also been tested experimentally in various ways. For
example, a double transgenic mouse model expressing APP-
V7171 and Tau-P301L, develops amyloid pathology similarly to
mice transgenic for APP-V7171 alone, whereas tauopathy is
dramatically enhanced in the double transgenic compared to mice
transgenic for Tau-P301L alone. This implies that Ab pathology
affects tauopathy but not vice versa [5]. Also, clearance of Ab using
Ab-specific antibodies reduced early tau burden, while elevating
tau burden in transgenic mice had no effect on Ab accumulation
[6,7]. Furthermore, a reduction in tau levels rescued learning and
memory impairment induced by Ab in a mouse model expressing
human APP [8].
Ab increases the phosphorylation of tau protein and concom-
itantly activates glycogen synthase kinase, GSK-3 [9,10]. GSK-3 is
a multi-functional kinase involved in regulating various cellular
processes, including growth and differentiation [9,11]. There are
two isoforms of the protein, GSK-3a and GSK-3b. They share
98% identity within their kinase domain, but are not functionally
identical, although both have been suggested to be involved in AD
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pathogenesis [11]. GSK-3a has been implicated in the amyloido-
genic processing of APP to yield Ab peptides [12], while GSK-3b
has been implicated in the tau-related pathogenesis of AD, by
colocalizing with tau tangles and phosphorylating tau [9]. As yet,
the exact role of GSK-3 in the generation of Ab peptides is not
known. GSK-3 itself is also regulated by phosphorylation.
Phosphorylation at Ser9 of GSK-3b and the equivalent Ser21 of
GSK-3a inhibits activity, while phosphorylation at Tyr216/
Tyr279 of GSK-3b and GSK-3a, respectively, is thought to
increase activity [13].
Remarkable similarities are seen between double transgenic mice
expressing tau either with APP or with GSK-3b. This finding is
consistent with the hypothesis that amyloid acts via activation of
GSK-3 to modulate tau function [5,9,14]. Lithium chloride, which
is used as a mood stabilizing agent in patients with bipolar disorders,
inhibits GSK-3 activity, either by competing with magnesium ions
[15] or by increasing Ser9 phosphorylation [16]. Lithium reduces
amyloid production by altering the role of GSK-3a in APP
processing/cleavage; selective inhibition of GSK-3 by siRNA or
expressing a dominant negative form of GSK-3 also decreases Ab
production in cultured cells and mice [12,17]. Furthermore, lithium
reduces both tau phosphorylation at several GSK-3 epitopes and
tauopathy in a mouse model expressing mutant human tau [12,18].
However, in another study, lithium was seen to reduce tau
phosphorylation but not to affect Ab load in a triple mutant mouse
expressing human APPswe, human tauP301L and with mutant
presenilin 1 PS1M146V knock-in. The differing observations might
be due to variations in the age at which the mice were treated with
lithium, as suggested by the authors [19].
Fruit flies, Drosophila melanogaster, can provide useful invertebrate
models of neurodegeneration because of their complex brains, short
lifespans and relative ease of genetic manipulation. Several fly
models of aspects of AD biology have been made, including ones
that over-express either Drosophila or human tau, and show neuronal
dysfunction phenotypes [20–22]. Co-expression of human tau
protein with Shaggy (Sgg), the Drosophila homologue of GSK-3 [23],
exacerbates these neurotoxic phenotypes and leads to the
appearance of neurofibrillary tangles [22,24,25]. Fly models
expressing Ab peptides have also been generated, and show
neurodegeneration and amyloid deposits [26,28]. Although an
APP orthologue exists in flies, the Ab sequence is not conserved, and
Drosophilamodels directly expressing Ab allow study of Ab toxicity in
the absence of any endogenous amyloid production [29].
In this study we have generated a fly model that expresses Arctic
mutant Ab42 peptide in the nervous system of adult flies, using an
inducible system for gene expression, because we wished to
understand the underlying mechanism of disease progression of
AD in adults, without complications from developmental effects.
We first characterised this model, and then used it to investigate
the amyloid cascade hypothesis, by modulating the levels of
endogenous fly tau and examining the effects on phenotypes
consequent upon expression of Ab. We also investigated the
requirement for GSK-3 in Ab pathology and its role in direct
regulation of Ab peptides.
Results
Arctic Ab42 expression can be induced in adult
Drosophila neurons
To generate an adult-onset fly model of Alzheimer’s disease, we
expressed Arctic mutant Ab42 peptides using an inducible pan-
neuronal driver. An elav GeneSwitch (elavGS) driver line [30–31]
that has been used previously to develop an adult-onset Drosophila
model of spinocerebellar ataxia (SCA) [32] was used to direct
expression of a UAS-Arctic Ab42 transgene [33] both spatially and
temporally, to neurons of the adult fly (Figure 1A). A UAS-Ab40
line [33] was used as a control for over-expression of non-toxic
forms of Ab in fly neurons, since this form of the peptide has
previously been shown to have no detrimental effect in flies [26–28].
We measured expression of Ab peptides in adult neurons when
we treated elavGS;UAS-Arctic Ab42 flies with the activator
mifepristone (RU486;RU) from two days post-eclosion, by measur-
ing RNA and protein levels at 4 and 21 days into treatment
(Figure 1B and 1C). Ab transcripts were clearly elevated in RU-
treated elavGS;UAS-Arctic Ab42 flies in comparison with untreat-
ed (2RU) flies at both time-points (Figure 1B). Moreover, an Ab42-
specific ELISA confirmed that Ab42 protein was elevated in
elavGS;UAS-Arctic Ab42 (+RU) flies compared to untreated
(2RU) flies and that the level of protein increased with age
(Figure 1C). Since RNA transcript level decreased with age, this age-
dependent accumulation of Ab42 protein is most likely to be
attributable to an increased rate of translation of the protein relative
to the rate of protein degradation.
Aggregation of Ab has been shown to be of critical importance
for its pathogenicity [34]. Therefore, we assessed the state of
aggregation of Ab42 in the mutant flies by separating soluble and
insoluble protein fractions from fly brain extracts. At day 15, when
the first signs of pathology were observed in the Arctic Ab42 flies
(see below), we found that most of the Ab42 protein had
accumulated into an insoluble, fibrillar form (Figure 2), consistent
with the aggregation-promoting effects of the Arctic mutation [35].
Overall these results confirm that the elavGS-UAS system used
in this study is sufficient to induce over-expression of Ab peptides
specifically in the adult fly nervous system, and that Arctic mutant
Ab42 protein accumulates with age.
Over-expression of Arctic Ab42 peptide in adult neurons
increases mortality and induces neuronal dysfunction in
Drosophila, without evidence of neuronal cell loss
Previously published studies have shown that constitutive
expression of Arctic Ab42 peptide in fly neurons significantly
shortens lifespan, induces behavioural impairments and causes
neuronal death [26–28]. To determine whether adult-onset
expression of Arctic Ab42 peptide in neurons causes similar
Author Summary
Alzheimer’s disease (AD) is the leading cause of dementia
in the ageing population. Symptoms include memory loss
and decline in understanding and reasoning. Alois
Alzheimer, who reported the first case of AD, observed
plaques and tangles in the brains of patients. The plaques
are made up of amyloid protein, while the tangles are of
tau protein. One of the main scientific ideas about AD is
that it starts with build-up of amyloid, which then alters
tau protein, causing the disease. Another protein, called
GSK-3, also seems to play a part. Simple invertebrates such
as flies are useful for understanding human diseases. We
have created an AD model in the fruit fly Drosophila where
amyloid protein is present in the nerve cells of the adult
fly; this caused the flies to be impaired in their survival,
nerve function, and behavior. We found that amyloid
increased the activity of GSK-3, and so we experimentally
turned down its activity and found that this improved the
survival and behavior of the flies. Importantly, turning
down the activity of GSK-3 in flies that did not have
amyloid did not seem to harm them. GSK-3 could
therefore be a good target for drugs against AD.
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phenotypes, we examined survival, neuronal and behavioural
dysfunction in our inducible Drosophila model of AD.
First, we measured the effects of Arctic Ab42 expression on
lifespan, by treating elavGS;UAS-Arctic Ab42 and elavGS;UAS-
Ab40 flies with RU from two days post-eclosion and recording
their survival. Expression of Arctic Ab42 in adult neurons
shortened median lifespan by about 50% and maximum lifespan
by about 45% in comparison to non-RU-treated flies, and to Ab40
+RU and 2RU control flies (Figure 3), demonstrating a specific
lifespan-shortening effect of Arctic Ab42 compared to the Ab40
form of the peptide.
Next, we determined whether adult-onset expression of Arctic
Ab42 peptide in fly neurons caused neuronal toxicity, by analysing
neuronal function. As a direct measure of physiological activity, we
examined the electrophysiological responses of the Drosophila giant
fibre system (GFS; Figure 4A). Adult elavGS;UAS-Arctic Ab42
flies were fed + or 2 RU486 media from two days post-eclosion,
and GFS activity measured at day 16 and day 28 into treatment.
Giant fibres (GF) were stimulated via electrodes inserted inside the
compound eye, and post-synaptic potentials recorded in the
tergotrochanteral muscle (TTM) and the dorsal longitudinal flight
muscle (DLM) (Figure 4A); parameters measured were the latency
from GF stimulation to muscle response and the stability of the
response to high frequency stimulation. At day 16, response
latencies in the TTM, DLM and the TTM to high frequency
stimulation were comparable between elavGS;UAS-Arctic Ab42
flies on + and2 RU486 food (Figure 4B and Figure S1). However,
at day 28, expression of Arctic Ab42 peptide significantly in-
creased the response latency measured in both the TTM and
DLM, and inhibited the stability of the TTM response to high
frequency stimulation (at 100, 200 and 250 Hz) in comparison to
untreated control flies (Figure 4C and Figure S1). This indicates a
progressive neuronal dysfunction following adult-onset induction
of Arctic Ab42, with young flies exhibiting no dysfunction in the
GFS, while older flies showed obvious defects in response to both a
single stimulus and to high frequency stimuli.
Figure 1. Adult-onset induction of Arctic Ab42 peptide in the Drosophila nervous system. (A) A schematic representation of the
GeneSwitch-UAS expression system (based on [30]). Driver lines expressing the transcriptional activator GeneSwitch under control of the nervous
system-specific elav promoter (elavGS) are crossed to flies expressing an Ab transgene fused to a GAL4-binding upstream activation sequence (UAS-
Ab). In the absence of the activator mifepristone (RU486; 2RU), the GeneSwitch protein is expressed in neurons but remains transcriptionally silent,
so that Ab is not expressed. Following treatment with RU486 (+RU; green) the GeneSwitch protein is transcriptionally activated, binds to UAS and
thus mediates expression of Ab peptide specifically in the fly nervous system. Ab42 RNA (B) and protein (C) levels were quantified at four days and 21
days post-RU486 treatment (see Materials and Methods). Data are presented as means 6 SEM and were analysed by two-way ANOVA and Tukey’s
honestly significant difference (HSD) post-hoc comparisons. P,0.05 comparing Ab RNA expression in RU486-treated UAS-ArcAb42/+;elavGS/+ flies to
their 2RU486 controls at both time-points (Tukey’s HSD). P,0.01 comparing Ab42 protein levels in RU486-treated UAS-ArcAb42/+;elavGS/+ flies to
untreated controls at both time-points.
doi:10.1371/journal.pgen.1001087.g001
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As a behavioural measure of neuronal dysfunction in our
inducible model, locomotor activity was assessed using a negative
geotaxis (climbing) assay that has been used extensively to
characterise fly models of neurodegenerative diseases [33,36].
Drosophila display an age-related decline in climbing behaviour,
and this was apparent in the non-RU-treated and elavGS;UAS-
Ab40 +RU control flies used in the current study (Figure 5). We
found that flies expressing Arctic Ab42 displayed a reduced
negative geotaxis in comparison to their2RU control flies and the
Ab40 +RU and 2RU flies (Figure 5). The climbing behaviour of
the Arctic Ab42 flies had declined to a level by day 15 that was
reached by the control flies only by day 28.
Finally, we quantified neuronal loss, as measured by the number
of cell bodies in one hemisphere, in flies over-expressing Arctic
Ab42 peptide in adult neurons compared to non-expressing
controls. No neuronal loss was evident in the brains of these flies
(Figure S2).
Collectively, these data demonstrate that expression of Arctic
Ab42 specifically in the neurons of the adult fly leads to early death
and progressive neuronal dysfunction, in the apparent absence of
neuronal loss. Hence we have successfully developed an inducible
Drosophila model of AD that will provide a useful system in which
to further investigate the potential mechanisms underlying
pathogenesis in Alzheimer’s disease, without any confounding
effects on neuronal development.
Adult-onset expression of Ab42 increases the activity of
Shaggy in the adult nervous system
Because of the described role of GSK-3 in Alzheimer’s disease,
we investigated the activity of the fly orthologue of GSK-3, Sgg, in
the Ab42-expressing flies. Phosphorylation at Ser9 of Sgg is
important in suppressing its kinase activity. We found that
expression of Arctic Ab42 in the adult nervous system decreased
the Ser9 phosphorylation level of Sgg, indicating an up-regulation
of the activity of the kinase (see Figure 6). This increase in Sgg
activity could have contributed to the toxicity we observed in our
Ab42 expressing flies. Lithium is a GSK-3 inhibitor, and we
therefore tested its effect on Ser9 phosphorylation in the Ab42 flies
and, indeed, we found an increase in Ser9 phosphorylation
compared to untreated controls (Figure 6).
Inhibition of Shaggy activity in the adult nervous system
suppresses the toxicity of Arctic Ab42
We next investigated if the increase in Sgg activity that we
observed in the Artic Ab42-expressing flies contributed to Ab42
toxicity. To do this, we co-expressed in adult neurons a dominant
negative form of Sgg, the S9E mutant, which mimics an inhibited
state of the kinase [37,38] and renders it inactive. Expression of this
dominant-negative Sgg increased the median and maximum
lifespan of flies expressing Arctic Ab42. Flies co-expressing Arctic
Ab42 and the dominant negative mutant S9E lived significantly
longer than control flies co-expressing Arctic Ab42 and GFP
(Figure 7), to control for any titration effect of GAL4 in the presence
of a secondUAS-transgene. Furthermore, inactivation of Sgg, either
by expressing the dominant negative mutant S9E or feeding the flies
lithium in adulthood, significantly suppressed the climbing deficit of
the Arctic Ab42-expressing flies (Figure 8). Two different doses of
lithium (30mM and 100mM) both rescued the climbing deficit of
the Ab42-expressing flies. These data demonstrate that inhibiting
the activity of Sgg in neurons in adults suppresses the adult onset
Arctic Ab42 induced toxicity, and demonstrate experimentally a
functional role of GSK-3 in mediating Ab42 toxicity.
Figure 2. Arctic Ab42 peptide in the adultDrosophila nervous system ismostly in an insoluble fibrillar state. In the absence of the activator
mifepristone (RU486; 2RU), a negligible amount of soluble protein is observed at day 15. Following treatment with RU486 (+RU; dark green) the Ab
peptide expression is seen in both soluble and insoluble fractions with a significant proportion observed in the insoluble fraction. Data are presented as
means 6 SEM and were analysed by ANOVA, P,0.01 when protein levels of soluble and insoluble fractions of Ab42 expressing flies were compared.
doi:10.1371/journal.pgen.1001087.g002
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Arctic Ab42 toxicity, and protection by Shaggy inhibition,
is not mediated predominantly through alterations in tau
phosphorylation
Since GSK-3 is a well-established tau kinase, and tau is
abnormally phosphorylated in AD, we next investigated whether
the protective effect of Sgg inhibition on Ab42 toxicity in our fly
model is mediated via alterations in tau phosphorylation. Hence,
we examined the phosphorylation of Drosophila tau in flies over-
expressing Arctic Ab42 peptide in the absence or presence of
lithium-treatment (Figure 9).
We analysed tau phosphorylation using Phos-tag acrylamide gels, a
technique for separating phosphorylated protein isoforms [39], which
has been employed previously to investigate the phosphorylation of
fly proteins [40]. Phos-tag is a phosphate-binding compound which,
when incorporated into polyacrylamide gels, can result in an
exaggerated mobility shift for phosphorylated proteins, dependent
on the degree of phosphorylation. When heat-stable fly head
homogenates were run on Phos-tag gels, several prominent tau
bands were detected, implying that endogenous tau is phosphorylated
at multiple sites in WT tissue (Figure 9A). De-phosphorylation using
l-protein phosphatase confirmed that the high molecular weight
bands were due to tau phosphorylation, and that non-phosphorylated
fly tau runs as a doublet (Figure 9A). This method is thus capable of
detecting at least some phosphorylation changes on the endogenous
fly tau. Using this method, no difference in the level of tau
phosphorylation was observed in flies over-expressing Arctic Ab42
compared to non-expressing controls or to Arctic Ab42 flies treated
with lithium chloride (Figure 9A and Figure S3A).
The phosphorylation sites on fly tau have not yet been
extensively characterized. Drosophila-specific phosphorylation-de-
pendent antibodies are hence not available for the examination of
specific sites. However, several GSK-3 specific sites [41,42], and
sites reported to be altered by Ab42 peptide [43–45], on human
tau appear to be conserved in the Drosophila tau sequence (Figure
S4). Of these, Ser262, and Ser356 phosphorylation-dependent
human tau antibodies were found to detect fly tau protein
specifically (Figure 9B and Figure S3B). We therefore used these
antibodies to examine the effects on tau phosphorylation at these
sites. Arctic Ab42 over-expression, or treatment of Ab42-
expressing flies with lithium, did not modify phosphorylation at
the Ser262 or Ser356 homologous tau epitopes (Figure 9B). This
suggests that neither Ab42 nor GSK-3 are predominant in vivo
regulators of the phosphorylation of these sites on fly tau.
Loss of Tau reduces adult-onset Ab42 toxicity
Although we could not uncover a role for tau phosphorylation
in Ab42 toxicity, we investigated whether the presence of tau
modulates Ab42 pathology. We found that loss of tau reduced the
Arctic Ab42 climbing dysfunction. UAS-ArcAb42/+;elavGS tau
EP3203/tau deficiency (dfc) flies, which express Arctic Ab42 in a
genetic background homozygous mutant for tau (see Figure 10A
for tau expression levels; tau antibody has previously been
described [46]), had improved locomotor ability compared to
UAS-ArcAb42/+;elavGS tau EP2303/TM6 flies, which express a
much greater level of tau (P,0.0001, two-way ANOVA;
Figure 10A) and UAS-ArcAb42/+;elavGS/+ flies, which express
Figure 3. Expression of Arctic Ab42 specifically in the adult nervous system shortens lifespan. Lifespans were determined as described in
materials & methods. Survival curves are depicted and data were compared using the log-rank test. P,0.01 comparing median lifespan of UAS-
ArcAb42/+;elavGS/+ +RU flies to their 2RU controls. P,0.01 comparing UAS-ArcAb42/+;elavGS/+ +RU flies to UAS-Ab40/+;elavGS/+ +RU controls.
Induction of Ab40 in the adult nervous system did not alter lifespan in comparison to non-RU486-treated controls.
doi:10.1371/journal.pgen.1001087.g003
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wild-type tau levels (P=0.0002, two-way ANOVA; Figure 10B),
on +RU food. It is important to note, however, that tau loss of
function flies themselves displayed some locomotor dysfunction
compared to controls (Figure 10B; P,0.0001 comparing UAS-
ArcAb42/+;elavGS/+ to UAS-ArcAb42/+;elavGS tau EP3203/
tau dfc on 2RU486, two-way ANOVA), thus potentially reducing
the apparent protective effect of removing tau on Ab42 pathology.
These data parallel observations in mammals, where loss of
murine Tau rescued Ab-induced behavioural deficits in a mouse
AD model [8].
We further investigated interactions between Drosophila tau and
GSK-3 in the protection against Ab42 pathology, to determine if
they might act in the same biochemical pathway (Figure 10B).
Lithium treatment alone had a greater protective effect against
Ab42 toxicity than did loss of tau function alone, although this
may have been confounded by the reduced climbing ability of flies
with reduced tau. Moreover, lithium treatment rescued Ab42-
induced climbing dysfunction to the same extent in the presence or
absence of tau, (P=0.692 comparing UAS-ArcAb42/+;elavGS/+
and UAS-ArcAb42/+;elavGS tau EP3203/tau dfc flies on +RU, +
lithium food, two-way ANOVA) suggesting that endogenous tau is
not required for the lithium effect. This suggests that a large
proportion of the protective effect of GSK-3 inhibition on Ab42
toxicity is mediated via non-tau-dependent mechanisms. We also
show that tau is required for the manifestation of Ab42 effects.
Our experimental design does not address, neither excludes, the
possibility that a direct interaction of GSK-3 and tau may also
affect Ab42 toxicity.
Inhibition of Shaggy in the adult nervous system reduces
Ab load in Arctic Ab42-expressing flies
Because the amelioration of Ab42 toxicity by reduced GSK-3
activity did not appear to be mediated mainly through tau, we
next examined the direct effect of GSK-3 inhibition on Ab42
levels. Interestingly, we found by ELISA analysis that Ab peptide
was significantly reduced in flies expressing Arctic Ab42 when Sgg
activity was reduced. Adult flies that co-expressed Arctic Ab42 and
the inactive dominant negative mutant Sgg S9E, or adult flies that
expressed Arctic Ab42 and were fed lithium, showed a major
reduction in total Ab42 levels in comparison to flies expressing
Arctic Ab42 alone and reared on food without lithium
(Figure 11A). The transcript levels of Ab42 in the presence of
functional or inhibited Sgg activity were not significantly different
Figure 4. Arctic Ab42 peptides induce progressive, adult-onset neuronal defects in Drosophila. (A) A schematic illustration of the
Drosophila giant fibre system (GFS; adapted from [74]). Giant fibres (GFs; blue) relay signals from the brain to the thoracic musculature via mixed
electrochemical synapses with the motorneurons (TTMn, red) of the tergotrancheral muscle (TTM; left), and the peripherally synapsing interneuron
(PSI; green), which subsequently forms chemical synapses with the motorneurons (DLMn; orange) of the dorsal longitudinal muscles (DLM; right).
Note only one of the TTMn axons is shown exiting the nervous system and contacting the muscle on the left hand side and one set of the DLMns and
corresponding neuromuscular junctions are depicted on the right hand side. GFS activity was measured in UAS-ArcAb42;elavGS flies at (B) 16 days
and (C) 28 days post-RU486 treatment (see Materials and Methods); parameters measured were the latencies from GF stimulation to muscle response
(response latency DLM and TTM) and the stability of the response to high frequency stimulation at 100, 200 and 250 Hz (high frequency stimulation
TTM). Data are presented as the mean response 6 SEM and were analysed by student’s t-test, at each time point, on log-derived data. *P,0.05,
**P,0.01 comparing response latency or response to high frequency stimulation of UAS-ArcAb42/+;elavGS/+ +RU flies to 2RU controls at 28 days
post-induction.
doi:10.1371/journal.pgen.1001087.g004
Figure 5. Expression of Arctic Ab42 peptides in the adult fly nervous system causes locomotor dysfunction. Climbing ability of UAS-
ArcAb42/+;elavGS/+ and UAS-Ab40/+;elavGS/+ flies on + and 2 RU486 SY medium was assessed at the indicated time-points (see Materials and
Methods). Data are presented as the average performance index (PI) 6 SEM and were compared using two-way ANOVA and Tukey’s honestly
significant difference (HSD) post-hoc analyses (number of independent tests (n) = 3, number of flies per group (nt) = 39–45). *P,0.05 comparing PI of
UAS-ArcAb42/+;elavGS/+ +RU486 flies to that of untreated and Ab40 over-expressing controls at the indicated time points (Tukey’s HSD).
doi:10.1371/journal.pgen.1001087.g005
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(Figure 11B), suggesting that Sgg does not affect transgene
expression, but rather acts directly or indirectly on Ab degrada-
tion/sequestration. These data demonstrate for the first time a role
of GSK-3 in determining the level of Ab42 peptide, in the absence
of effects on APP processing. Furthermore, this reduction in the
levels of Ab42 peptide by GSK-3 inhibition is most likely not
mediated by tau, since loss of tau function partially rescued Ab
toxicity, but did not affect Ab42 levels (Figure 10A and Figure S5).
These data again suggest that GSK-3 can modify Ab42 toxicity via
tau-independent mechanisms.
Discussion
Glycogen synthase kinase-3 is increasingly thought to play a
pivotal role in the pathogenesis of Alzheimer’s disease, both as a
regulator of the accumulation of Ab peptide [12,17,47] and
through its well-established role as a tau kinase [48–52]. Although
previous studies in mice have suggested that GSK-3 alters Ab
levels via modulation of APP processing [12,17], the direct effects
of the enzyme on Ab toxicity, and in the adult nervous system,
have not been examined. We therefore performed a more direct
analysis of the specific role of GSK-3 in regulating Ab42 toxicity in
adult neurons in vivo, by modulating its activity in an adult-onset
Drosophila model of Alzheimer’s disease. Our study shows for the
first time that GSK-3 inhibition ameliorates Ab42 toxicity in adult
flies, and also highlights a novel mechanism of protection by which
GSK-3 directly regulates Ab42 levels in the absence of any effects
on APP processing.
We have generated an inducible Drosophila model of Alzheimer’s
disease. Over-expression of the Arctic Ab42 peptide in adult fly
neurons led to shortened lifespan, neuronal dysfunction and
behavioural impairments. However, no neuronal loss was evident
Figure 6. Flies expressing Ab42 in adult neurons show a decrease in Shaggy inhibitory Ser9 phosphorylation. (A) Western blot analyses
for pan-Sgg and phospho Ser9 Sgg revealed a decrease in Ser9 phosphorylation in flies expressing Ab42 by RU induction for 15 days (UAS-ArcAb42/
+;elavGS/+ or UAS-ArcAb42/GFP;elavGS/+) in comparison to their 2RU controls, while an increase in Ser9 phosphorylation was observed when the
Ab42 expressing flies were fed lithium (+RU +Li). Flies over expressing Sgg were used as positive control. (B) Quantification of the western blot
analysis in (A), n = 3, is depicted in the bar chart, with significant differences seen between ArcAb42/+;elavGS/+ +RU flies to 2RU controls (P,0.01),
and between ArcAb42/+;elavGS/+ +RU +Li flies to +RU controls (P,0.001).
doi:10.1371/journal.pgen.1001087.g006
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Figure 7. Expression of the dominant negative mutant Shaggy S9E in the adult nervous system extends the median and maximum
lifespan of Arctic Ab42 flies. (A). Survival curves of flies co-expressing Arctic Ab42 and SggS9E are depicted and data were compared using the
log-rank test. P,0.001 comparing UAS-ArcAb42/+;elavGS/UAS-SggS9E +RU flies to UAS-ArcAb42/UAS-gfp;elavGS/+ +RU controls. No significant
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in the brains of these flies. This finding contrasts with previous
reports that flies over-expressing Arctic Ab42, using a constitutive
neuronal driver, develop vacuoles [28,33], These contrasting
results could be reconciled if neuronal loss upon Ab42 over-
expression is a consequence of developmental abnormalities in the
Drosophila brain or if neuronal loss represents an end-stage event in
response to Ab42 toxicity, since vacuolation has been reported
only under the most extreme conditions of expression, age and
temperature, while neuronal toxicity in these models is already
apparent under less stringent conditions [33]. Importantly, our
findings agree with those of other studies demonstrating that
neuronal loss is generally not evident in murine models of
amyloidosis, such as in mice transgenic for the amyloid precursor
protein [53]. Moreover, our study has provided direct evidence of
neuronal dysfunction in response to Ab42, by electrophysiological
methods, at a timepoint more suitable to understanding the early
events that lead to neuronal decline in AD.
GSK-3 activity was increased in our flies upon Arctic Ab42
over-expression, as measured by reductions in phosphorylation of
endogenous Sgg at the inhibitiory Ser9 site. This is consistent with
previous observations showing that Ab42 alters GSK-3 phosphor-
ylation in cells [54] and in mice [14]. Contrary to these findings,
difference was seen in the 2RU controls. (B). Expression of Shaggy S9E alone did not affect control lifespan. No significant difference was observed
comparing elavGS/UAS-SggS9E +RU to either elavGS/UAS-SggS9E 2RU, or UAS-gfp/elavGS/+ +RU control lifespans.
doi:10.1371/journal.pgen.1001087.g007
Figure 8. Inhibition of Shaggy, either by expression of SggS9E in the adult nervous system or treatment with lithium, suppresses
the locomotor dysfunction phenotype of Arctic Ab42 flies. (A) Climbing ability of UAS-ArcAb42/UAS-gfp;elavGS/+ and UAS-ArcAb42/
+;elavGS/UAS-SggS9E flies on +RU486 SY medium was assessed at the indicated time-points (see Materials and Methods). Data are presented as the
percentage climbing performance of flies 6 SD. P,0.001 when UAS-ArcAb42/UAS-gfp;elavGS/+ and UAS-ArcAb42/+;elavGS/UAS-SggS9E flies are
compared at day 21 (one-way ANOVA, number of independent tests (n) = 3). Graph shows one representative data of repeated experiments. (B)
Expression of Shaggy S9E alone does not reduce climbing ability of control flies. elavGS/UAS-SggS9E +RU flies display a similar locomotor function
compared to both elavGS/UAS-SggS9E 2RU and UAS-gfp/+;elavGS/+ +RU control flies. (C) Climbing ability of UAS-ArcAb42/+;elavGS/+ and UAS-
ArcAb42/UAS-gfp;elavGS/+ on +RU486 SY medium was assessed in the presence and absence of lithium chloride (30mM and 100mM). P,0.001 when
UAS-ArcAb42 flies were fed lithium and compared to flies not fed lithium at day 18 (one-way ANOVA, n = 3). Graph shows one representative data of
repeated experiments. (D) Lithium had no effect on negative geotaxis of control flies. UAS-gfp/+;elavGS/+ +RU and UAS-gfp/+;elavGS/+ +RU in the
presence of lithium had similar locomotor function. The crosses were performed at 27uC.
doi:10.1371/journal.pgen.1001087.g008
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Figure 9. Flies expressing Ab42 in adult neurons show no changes in total tau phosphorylation and at Ser 262 and Ser 356 specific
epitopes. (A) Western blot analyses for total tau phosphorylation using phos-tag gels and (B) phospho Ser262 and Ser356. Tau showed no changes in
phosphorylation in flies expressing Ab42 (UAS-ArcAb42/GFP;elavGS/+) in comparison to their 2RU controls, and when the Ab42 expressing flies were
fed lithium (+RU +Li). Flies were collected 17 days post RU induction, andmaintained at 27uC. Quantification of the western blot analysis in (A), phospho-
tau or non-phospho-tau normalised to total tau per sample (n= 4), and in (B) n = 4 for total tau and n=3 for the Ser sites depicted in the bar chart,
showed no significant differences between ArcAb42/+;elavGS/+ +RU flies to 2RU controls or to ArcAb42/+;elavGS/+ +RU +Li flies (one-way ANOVA).
doi:10.1371/journal.pgen.1001087.g009
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however, one other study has shown that WT Ab42 expression
does not alter phosphorylation of Sgg in flies [55]. These
differences may reflect varying mechanisms by which Arctic
mutant Ab42 and WT Ab42 peptides modulate GSK-3 activity, or
a distinction in the effect of expressing Ab42 throughout
development compared to adult-only expression. Hence, our
observed increase in Sgg activity may reflect an age-dependent
effect. We aimed, therefore, to further investigate the functional
role of this kinase in mediating Ab toxicity in our adult-onset AD
model.
GSK-3 plays an important role in neuronal development
[56,57]. Previous analyses of the role of GSK-3 in amyloid toxicity
Figure 10. Lithium treatment alone has a greater protective effect against Ab42 toxicity than loss of tau function alone. (A) Loss of
tau partially suppressed the locomotor dysfunction phenotype of Arctic Ab42 flies. Expression of Arctic Ab42 peptide in a tau heterozygous
background in the adult fly nervous system caused locomotor dysfunction. This phenotype was suppressed when Arctic Ab42 peptide was expressed
in a homozygous tau mutant background. Climbing ability of UAS-ArcAb42/+;elavGS Tau EP3203/TM6 and UAS-ArcAb42/+;elavGS Tau EP3203/Tau
Dfc flies on +RU486 SY medium was assessed at the indicated time-points (see Materials and Methods). Data are presented as the average
performance index (PI)6 SEM (number of independent tests (n) = 3, number of flies per group (nt) = 45). P,0.0001 comparing the PI of UAS-ArcAb42/
+;elavGS Tau EP3203/Tau Dfc to UAS-ArcAb42/+;elavGS Tau EP3203/TM6 flies (two-way ANOVA). The crosses were performed at 27uC. Western
blotting analysis, using a non-phosphorylation dependent antibody to Drosophila tau, confirmed that endogenous tau protein levels were greatly
reduced in UAS-ArcAb42/+;elavGS tau EP3203/tau Dfc flies in comparison to tau heterozygous flies (UAS-ArcAb42/+;elavGS tau EP3203/TM6) and
control w1118 flies. (B) Arctic Ab42 toxicity was suppressed when the peptide was expressed in a homozygous tau mutant background or when flies
were treated with lithium. Lithium treatment alone had a greater protective effect against Ab42 toxicity than did loss of tau function alone, and was
not dependent on tau. Climbing ability of UAS-ArcAb42/+;elavGS/+ and UAS-ArcAb42/+;elavGS tau EP3203/tau Dfc flies on 2 or +RU486 SY medium,
in the presence or absence of lithium, was assessed at the indicated time-points. Data are presented as the average PI 6 SEM and were analysed by
two-way ANOVA (number of independent tests (n) = 4, number of flies per group (nt) = 60). Comparing PI of UAS-ArcAb42/UAS-gfp;elavGS/+ and
UAS-ArcAb42/+;elavGS tau EP3203/tau Dfc flies on2RU, significant differences between genotypes (P,0.0001) were observed. P= 0.0002 comparing
PI of UAS-ArcAb42/UAS-gfp;elavGS/+ and UAS-ArcAb42/+;elavGS tau EP3203/tau Dfc flies on +RU food. No significant differences were observed
comparing UAS-ArcAb42/+;elavGS/+ and UAS-ArcAb42/+;elavGS tau EP3203/tau Dfc flies on +RU +lithium (P=0.692).
doi:10.1371/journal.pgen.1001087.g010
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using constitutive expression systems may, therefore, represent
abnormal neuronal development in addition to the response to AD
pathology in the adult period. Hence, we confined GSK-3
inhibition to the adult neurons of Arctic Ab42-expressing flies,
by over-expressing a dominant negative form of the Drosophila
orthologue Sgg, using our inducible expression system, or we
treated whole adult flies with the GSK-3 inhibitor, lithium. GSK-3
inhibition extended lifespan of Arctic Ab42-expressing flies and
suppressed the locomotor dysfunction caused by expression of the
peptide in adult neurons. This is an important finding because it
demonstrates a definitive role for GSK-3 in Ab42 pathogenesis in
adult flies. Moreover, we found that inhibiting Sgg in adulthood
had no adverse effect on wild type flies. Hence, our study provides
further support for the therapeutic potential of GSK-3 inhibitors
in treating Alzheimer’s disease. Further studies are required to test
this potential in mammalian models, firstly to confirm the
relevance of GSK-3 for direct regulation of Ab42 toxicity and
secondly to establish a therapeutic index for GSK-3 inhibition in
the treatment of AD.
Ab42 has been shown previously to increase tau phosphoryla-
tion in cells [45] and in mice [5,43]. Correlative evidence has
suggested that GSK-3 may mediate the effects of Ab on tau
Figure 11. Inhibiting Shaggy activity reduces amyloid levels of Arctic Ab42 flies. (A) Protein levels of UAS-ArcAb42/UAS-gfp;elavGS/+ and
UAS-ArcAb42/+;elavGS/UAS-SggS9E flies on +RU486 SY medium, and UAS-ArcAb42/UAS-gfp;elavGS/+ flies on +RU +Lithium (Li), were measured by
ELISA at 15 days post-induction (see Materials and Methods). Data were compared using one-way ANOVA, number of independent tests (n) = 3.
P,0.01, and P,0.0001 when comparing UAS-ArcAb42/UAS-gfp;elavGS/+ to UAS-ArcAb42/+;elavGS/UAS-SggS9E flies on +RU486 SY medium, and
UAS-ArcAb42/UAS-gfp;elavGS/+ +RU to UAS-ArcAb42/UAS-gfp;elavGS/+ +RU +Li respectively. (B) RNA levels of UAS-ArcAb42/UAS-gfp;elavGS/+, UAS-
ArcAb42/+;elavGS/UAS-SggS9E +RU486 SY medium and UAS-ArcAb42/UAS-gfp;elavGS/+ +RU + lithium flies were measured at day 5. No significant
difference was seen in the levels of RNA expression, number of independent tests (n) = 3.
doi:10.1371/journal.pgen.1001087.g011
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phosphorylation, since Ab increases GSK-3 activity [10]. Fur-
thermore, GSK-3 and APP cause similar increases in tau
phosphorylation and aggregation in tau over-expressing mice
[14]. Because both tau and GSK-3 appeared to play a causal role
in Arctic Ab42 toxicity in our flies, we examined whether the
protective effect of GSK-3 inhibition on Ab toxicity might be
mediated via alterations in phosphorylation of endogenous
Drosophila tau. We found that Arctic Ab42 over-expression and
lithium treatment of Ab42-expressing flies did not have an
observable effect on overall tau phosphorylation, as revealed both
by generic measures, and at two specific sites by examination of
phosphorylation of fly tau at Ser262 and Ser356 epitopes.
However, because the Ser 262 and 356 sites are also predominant
in vivo substrates for MARK (microtubule-associated protein
(MAP)-microtubule affinity regulating kinase) [58,59], further
investigation of more specific GSK-3 sites on Drosophila tau, using
mass spectrometric methods, would provide a more definitive
analysis of the role of tau phosphorylation by GSK-3 in mediating
Ab42 toxicity in the fly.
Our data suggest that tau phosphorylation may not be the only
mechanism by which Ab42 exerts its toxic effect in Drosophila, since
phosphorylation sites thought to be important for mediating Ab42
effects on tau (Thr212/Ser214 [43], Thr231 [45], Ser422, Ser262
[44]) are predominantly not conserved in the fly, or are not altered
by Ab42 over-expression in our AD model. These findings seem to
contradict previous studies showing that Ab42 increases phos-
phorylation of human tau in Drosophila [55,60], and indicating that
particular sites, such as Ser262, are important in mediating Ab
toxicity in the fly [60]. This disparity could reflect a lack of
conservation of the mechanisms through which Ab42 regulates
human and Drosophila tau proteins. However, the endogenous fly
tau does appear to be an important downstream mediator of Ab42
toxicity, since loss of tau function partially reduced Ab42
pathology in our study. This protective effect of tau against
Ab42 toxicity, however, may have been masked by the locomotor
dysfunction from reducing levels of tau itself in flies that do not
over-express the Ab42 peptide. As a previous study has reported
similar tau-dependent neuropathological phenotypes in an APP-
overexpressing mouse model of AD [8], our findings suggest that
the role of tau in amyloid toxicity is conserved over large
evolutionary distances.
We further examined the epistatic interaction between GSK-3
inhibition and tau loss of function in protecting against Ab42
toxicity in our fly model. Lithium alone had a greater protective
effect against Ab42 toxicity than loss of tau function alone, and
lithium could prevent Ab42-induced dysfunction in the presence
or absence of tau. This suggests that a large proportion of the
protective effect of GSK-3 inhibition on Ab42 toxicity is mediated
via non-tau-dependent mechanisms and that tau is not required
for this effect. We observed no additive effect of combining lithium
treatment and tau loss of function in protection against Ab42-
induced pathology; however, this could have been a consequence
either of toxicity of loss of tau in the absence of Ab42 or of the level
of protection afforded by lithium, which could have produced a
ceiling effect. Our findings agree with other recently published
studies, showing that loss of tau only partially protects against
GSK-3-induced neuronal degeneration in adult mice [61],
suggesting that other non-tau-dependent mechanisms of GSK-3
neuro-toxicity exist.
Previous studies have shown a reduction in Ab load in mice as a
result of GSK-3 inhibition, but this has been explained mainly by
dysregulation of APP processing, either by increasing c-secretase
activity [12] or by increasing the phosphorylation of APP and
therefore directing its subcellular location to sites of secretase
activity [17]. Our inducibleDrosophilamodel, however, expresses the
Arctic Ab42 peptide directly, thus circumventing the requirement
for APP processing. We found that inhibition of GSK-3 caused a
reduction in the level of Ab42 peptide, but not in RNA transcript
levels. Hence, although previous studies have indicated that GSK-3
does not affect Ab degradation [17], our findings demonstrate a
novel effect of GSK-3 in Ab metabolism, irrespective of APP
processing, in the adult nervous system. Furthermore, this
observation may, partially, explain the non-tau-dependent effect
of GSK-3 in protecting against Ab toxicity in our flies.
Our study, therefore, implies that GSK-3 may increase Ab
degradation or clearance. Candidate in vivo Ab degrading enzymes
include neprilysin (NEP) [62], insulin degrading enzyme (IDE)
[63–64] and to a lesser extent endothelin converting enzymes
(ECE-1,2) [65] and plasmin [66]. Mice deficient in IDE [63,64] or
NEP [62] display increased levels of Ab peptides in the brain.
Conversely, increasing expression and activity of NEP or IDE
reduces the cerebral amyloid plaque burden observed in APP
over-expressing mice [67], further implying that these are
predominant in vivo Ab degrading enzymes. Direct interactions
between GSK-3 and IDE or neprilysin activities in relation to Ab
degradation, however, have not been extensively investigated.
Studies examining the effects of reduced insulin signalling on
amyloid toxicity in APP over-expressing mice have reported either
increased GSK-3 activity, reduced IDE activity and increased
amyloidosis [68] or decreased GSK-3 activity, increased IDE
expression and reduced amyloidosis [69] in the brain, suggesting
an inverse correlation between GSK-3 and IDE activities in
relation to Ab metabolism. Other studies have reported no
correlation between inhibition of GSK-3 activity and neprilysin
levels in relation to reduced Ab load in mice [17], but NEP activity
was not measured and may provide a more accurate indication of
the role of this enzyme in Ab metabolism downstream of GSK-3.
As most information from mouse models is correlative, however,
further work is required to determine whether these degrading
enzymes are direct mediators of Ab degradation in response to
GSK-3 inhibition, by modulating their activities in our inducible
Drosophila model. Drosophila homologues of both IDE and NEP
exist, and over-expression of both NEP [26,70] and IDE [71] have
been shown to reduce Ab induced neurotoxicity in flies. This
suggests that these degradation mechanisms may be generally
conserved, and that the fly is a valuable model for the direct
analysis of these genetic interactions with respect to the role of
GSK-3 in AD.
The more general proteosome degradation pathway could also
play a role in regulating Ab degradation or sequestration. Heat
shock protein 90 (Hsp90), a protein chaperone involved in the
proteosome degradation pathway, is thought to phosphorylate
GSK-3 and regulate its activity [13]. In addition, an increase in
levels of GSK-3 down-regulates the transcriptional activity of Heat
shock factor-1 (HSF-1) and Hsp70 [72]; thus a decrease in GSK-3
activity could lead to an increase in levels/activity of these
chaperone molecules and augment the levels of Ab. In a
Caenorhabdits elegans worm model of AD, the aggregation-mediated
Ab42 toxicity was regulated by modulating the levels of hsf-1; a
reduction in hsf-1 increased paralysis in these worms, suggesting a
role of hsf-1 in the dis-aggregation of Ab toxic oligomers [73].
Thus, any of these pathways/molecules could play a role in
affecting Ab load in our fly model and will require detailed
exploration in the future.
Our data highlight that this fly model is suitable for the study of
AD pathology, since we observe neuronal dysfunction and toxicity
that are particular to the expression of Ab42 peptide. Further-
more, we have been able to test the amyloid cascade hypothesis in
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part, to show that tau is acting downstream of Ab pathology. This
inducible model of AD will also open the way to understanding the
role of events at different ages and of the ageing process itself in the
biological pathway leading to this ageing related disease. We have
shown the involvement of GSK-3, particularly in adulthood, in
AD pathogenesis, and also uncover a novel mechanism by which
GSK-3 could be acting directly or indirectly on Ab, by reducing
Ab load. These results raise new potential therapeutic benefits of
GSK-3 in AD pathology.
Materials and Methods
Fly stocks and maintenance
All fly stocks were maintained at 25uC or 27uC on a 12:12-h
light:dark cycle at constant humidity on a standard sugar-yeast
(SY) medium (15gl21 agar, 50 gl21 sugar, 100 gl21 autolysed
yeast, 100gl21 nipagin and 3ml l21 propionic acid). Adult-onset
neuronal-specific expression of Arctic mutant Ab42 peptide or
constitutively active Sgg was achieved by using the elav
GeneSwitch (elavGS)-UAS system [GAL4-dependant upstream
activator sequence; [30]]. ElavGS was derived from the original
elavGS 301.2 line [30] and obtained as a generous gift from Dr H.
Tricoire (CNRS, France). UAS-ArcAb42 and UAS-SggS9E were
obtained from Dr D. Crowther (University of Cambridge, UK)
and the Bloomington Drosophila Stock Centre respectively. Tau
dfc (9530) and EP line 3203 (17098) were received from
Bloomington Drosophila stock centre. The EP line orientation is
opposite to tau expression and causes a reduction in tau expression
[46]. elavGS and UAS-lines used in all experiments were
backcrossed six times into the w1118 genetic background. Male
flies expressing UAS-constructs were crossed to female flies
expressing elavGS, and adult-onset neuronal expression induced
in female progeny by treatment with mifepristone
(RU486;200mM) added to the standard SY medium.
Lithium treatment protocol
Lithium Chloride was made at 1M concentration and added to
200mM RU486 standard SY medium at a final concentration of
30mM or 100mM.
Lifespan analyses
For all experiments, flies were raised at a standard density on
standard SY medium in 200 mL bottles. Two days after eclosion
once-mated females were transferred to experimental vials
containing SY medium with or without RU486 (200mM) at a
density of 10 flies per vial. Deaths were scored almost every other
day and flies were transferred to fresh food three times a week.
Statistical analyses were performed using JMP (version 7.0)
software (SAS Institute, Cary, NC, USA). Data are presented as
survival curves and analysis was performed using log-rank tests to
compare between groups.
Negative Geotaxis Assays
To characterise the adult-onset behavioural effects of Arctic
Ab42 peptide on neuronal function, climbing assays were initially
performed at 25uC according to previously published methods [75].
Climbing ability was analysed every 2–3 days post-RU486
treatment. Briefly, 15 adult flies were placed in a vertical column
(25cm long, 1.5cm diameter) with a conic bottom end, tapped to the
bottom of the column, and their subsequent climb to the top of the
column was analysed. Flies reaching the top and flies remaining at
the bottom of the column after a 45 sec period were counted
separately, and three trials were performed at 1 min intervals for
each experiment. Scores recorded were the mean number of flies at
the top (ntop), the mean number of flies at the bottom (nbottom) and
the total number of flies assessed (ntot). A performance index (PI)
defined as K(ntot+ntop2nbottom)/ntot) was calculated. Data are
presented as the mean PI 6 SEM obtained in three independent
experiments for each group, and analysis of variances (ANOVA)
and post hoc analyses were performed using JMP 7.0 software.
To assess various modifiers of the adult-onset neuronal
dysfunction in Arctic Ab42 over-expressing flies, a less stringent
climbing assay was performed at 27uC. Thirty flies expressing Arctic
Ab42 with or without co-expressing modifiers in the neurons (elav-
GAL4GS) were used for the climbing assay, adapted fromGanetzky
et al. [76]. Climbing performance (ability to climb past a 5cm mark
in 18s) was assessed after eclosion post RU486 treatment.
Electrophysiology
Recordings from the GFS of adult flies were made essentially as
described in [77]; a method based on those described by Tanouye
and Wyman (1980) [78] and Gorczyca and Hall (1984) [79]. Flies
were anaesthetized by cooling on ice and secured in wax, ventral
side down, with the wings held outwards in the wax. A tungsten
earth wire (ground electrode) was placed into abdomen; tungsten
electrodes were pushed through the eyes and into the brain to
deliver a 40V pulse for 0.03ms using a Grass S48 stimulator.
Recordings were made from the TTM and contralateral DLM
muscle using glass microelectrodes (resistance: 40–60 MV). The
electrodes were filled with 3M KCl and placed into the muscles
through the cuticle. Responses were amplified using Getting 5A
amplifiers (Getting Instruments, USA) and the data digitized using
an analogue-digital Digidata 1320 and Axoscope 9.0 software
(Axon Instruments, USA). For response latency recordings, at least
5 single stimuli were given with a 5s rest period between each
stimulus; trains of 10 stimuli, at either 100Hz, 200 Hz or 250Hz,
were given a 5s rest interval between each train.
Histology
For neuronal cell loss, adult heads were fixed, dehydrated and
transverse sections were stained with Toluidine blue. Cell bodies
were then counted blind for each genotype.
Quantitative RT–PCR
Total RNA was extracted from 20–25 fly heads using Trizol
(GIBCO) according to the manufacturers’ instructions. The
concentration of total RNA purified for each sample was
measured using an eppendorf biophotometer. 1mg of total RNA was
then subjected to DNA digestion using DNAse I (Ambion),
immediately followed by reverse transcription using the Super-
script II system (Invitrogen) with oligo(dT) primers. Quantitative
PCR was performed using the PRISM 7000 sequence-detection
system (Applied Biosystems), SYBR Green (Molecular Probes),
ROX Reference Dye (Invitrogen), and Hot Star Taq (Qiagen,
Valencia, CA) by following manufacturers’ instructions. Each
sample was analysed in triplicate with both target gene (Arctic
Ab42) and control gene (RP49) primers in parallel. The primers
for the Ab transgenes were directed to the 59 end and 39 end of the
Ab coding sequence: forward GATCCTTCTCCTGCTAACC;
reverse CACCATCAAGCCAATAATCG. The RP49 primers
were as follows: forward ATGACCATCCGCCCAGCATCAGG;
reverse ATCTCGCCGCAGTAAACG.
Quantification of total, soluble, and aggregated Ab42
To extract total Ab42, five fly heads were homogenised in 50 ml
GnHCl extraction buffer (5 M Guanidinium HCl, 50 mM Hepes
pH 7.3, protease inhibitor cocktail (Sigma, P8340) and 5mM
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EDTA), centrifuged at 21,000 g for 5 min at 4uC, and cleared
supernatant retained as the total fly Ab42 sample. Alternatively,
soluble and insoluble pools of Ab42 were extracted using a protocol
adapted from previously published methods [80]: 200 fly heads
were homogenised in 200 ml tissue homogenisation buffer (250mM
sucrose, 20mM Tris base, 1mM EDTA, 1mM EGTA, protease
inhibitor cocktail (Sigma) then mixed further with 200ml DEA buffer
(0.4%DEA, 100mMNaCl and protease inhibitor cocktail). Samples
were centrifuged at 135,000 g for 1 hour at 4uC (Beckman Optima
Max centrifuge, TLA120.1 rotor), and supernatant retained as the
cytosolic, soluble Ab42 fraction. Pellets were further resuspended in
400ml ice-cold formic acid (70%), and sonicated for 2630 sec on ice.
Samples were re-centrifuged at 135,000 g for 1 hour at 4uC, then
210 ml of supernatant diluted with 4ml FA neutralisation buffer (1M
Tris base, 0.5M Na2HPO4, 0.05% NaN3) and retained as the
insoluble, formic acid-extractable Ab42 fraction.
Total, soluble or insoluble Ab42 content was measured in Arctic
mutant Ab42 flies and controls using the hAmyloid b42 ELISA kit
(HS) (The Genetics Company, Switzerland). Total Ab42 samples
were diluted 1:100, and soluble versus insoluble Ab42 samples
diluted 1:10 in sample/standard dilution buffer, then ELISA
performed according to the manufacturers’ instructions. Protein
extracts were quantified using the Bradford protein assay (Bio-Rad
protein assay reagent; Bio-Rad laboratories Ltd (UK)) and the
amount of Ab42 in each sample expressed as a ratio of the total
protein content (pmoles/g total protein). Data are expressed as the
mean 6 SEM obtained in three independent experiments for each
genotype. ANOVAs and Tukey’s-HSD post-hoc analyses were
performed using JMP 7.0 software.
Analysis of tau phosphorylation by Phos-tag SDS-PAGE
Fly heads were homogenised in Mes buffer (100 mM Mes,
pH 6.5, 1 M NaCl, 0.5 mM MgCl2, 1 mM EGTA, 10 mM NaF,
Protease inhibitor cocktail [Sigma, P8340] and Phosphatase
inhibitor cocktail 2 [Sigma, P5726]), centrifuged at 20,000 g for
30 minutes at 4uC, then supernatants adjusted to 0.5% b-
mercaptoethanol, boiled for 5 minutes and re-centrifuged. Cleared
supernatants were then retained as heat-stable soluble tau. Control
samples were dephosphorylated by incubating with l-protein
phosphatase (NEB, P0753) for 3 hours at 30uC.
To detect phosphorylated and non-phosphorylated tau, samples
were separated by SDS-PAGE, using Phos-tag AAL-107 (FMS
laboratory) according to the manufacturers’ instructions. Western
blotting was then performed using a non-phosphorylation
dependent Drosophila rabbit anti-tau antibody (1:5000). Quantita-
tion was performed using Image J software (National Institutes of
Health). Phosphorylated and non-phosphorylated tau was ex-
pressed as a percentage of the total amount of tau present in each
sample. ANOVA and Tukey’s-HSD post-hoc analyses were
performed using JMP 7.0 software.
Western blotting
Drosophila heads were pooled and homogenised in 26Laemmli
sample buffer containing b-mercaptoethanol and boiled for
10 mins. Proteins were separated on SDS polyacrylamide gels
and blotted onto nitrocellulose. Membranes were incubated in a
blocking solution containing 5% milk proteins either in TBST for
1hr at room temperature for Tau blot or in PBST for 20 min for
Sgg blot, then probed with primary antibodies overnight at 4uC.
Mouse anti-actin antibody (Santacruz) was used at a 1 in 1000
dilution. Tau antibody (rabbit) was a kind gift from Nick Lowe,
and used at a 1 in 2000 dilution. Rabbit anti-phospho S262 and
S356 (Abcam) were used at a dilution of 1:1000 in 5% BSA TBST.
Quantitation was performed using Image J software. Rabbit anti-
phospho S9/S21 GSK-3 antibody (AB 9331 Cell Signaling) at a 1
in 250 dilution was detected using an anti-rabbit 800 nm
flourophore conjugate (Rockland, USA). Monoclonal antibody,
pan Sgg mouse monoclonal (4G1G) at a 1 in 2000 dilution was a
kind gift from Marc Bourouis, which was subsequently detected
using a 680 nm anti-mouse flourophore conjugate (Invitrogen,
UK). Membranes were sequentially scanned at 700 and 800 nm
using a Licor Odyssey infrared scanner. Densitometric measure-
ments were taken in both wavelengths. Relative phospho-serine 9
Sgg levels were determined by dividing the signal at 800 nm by
that obtained at 700 nm. Details of secondary antibodies and
Odyssey analysis have been previously described in [69].
Supporting Information
Figure S1 Neuronal electrophysiology of flies over-expressing
Arctic Ab42 peptide in adulthood. Representative traces for (A)
TTM and DLM response latencies and (B) TTM responses to high
frequency stimulation (100 Hz) measured in elavGS/+;UAS-
ArcAb42/+ flies fed with + or 2 RU486 medium at days 16
and 28. TTM and DLM response latency was increased in Arctic
Ab42 over-expressing flies at day 28, but not at day 16 (marked
with arrows). Vertical scale bars, 50 mV (TTM) and 60mV (DLM)
for response latencies, 20 mV for following at 100Hz; horizontal,
2 ms for response latencies, 20ms for following at 100 Hz.
Found at: doi:10.1371/journal.pgen.1001087.s001 (0.11 MB
DOC)
Figure S2 Neuronal cell loss is not evident in flies over-
expressing Arctic Ab42 peptide in adulthood. Cell loss was
quantified at day 21 in elavGS/+;UAS-ArcAb42/+ flies, fed with
+ or 2 RU486 medium and maintained at 27 degrees, by
counting the number of cell bodies per brain hemisphere. No
significant difference was observed when the two genotypes were
compared (student’s t-test), N= 7 per genotype.
Found at: doi:10.1371/journal.pgen.1001087.s002 (0.22 MB
DOC)
Figure S3 Investigating tau phosphorylation. (A) Western blot
analyses of tau phosphorylation using phos-tag polyacrylamide
gels. Tau showed no changes in phosphorylation in flies expressing
Ab42 (UAS-ArcAb42/GFP;elavGS/+) in comparison to their
2RU controls, and when the Ab42 expressing flies were fed
lithium (+RU +Li). (B) Phospho-Ser262 and Ser356 human tau
antibodies specifically detect tau in fly head homogenates. The
55 kDa tau band is reduced in tau lof/TM6 and absent in tau lof/
tau lof flies compared to w1118 controls.
Found at: doi:10.1371/journal.pgen.1001087.s003 (1.23 MB
DOC)
Figure S4 Full-length Tau (P10636), the longest CNS Tau
isoform (P10636-8) and Drosophila Tau were aligned by Clustal W
alignment. *Shaded in sky and light blue are sites conserved between
human and Drosophila tau that are phosphorylated by GSK-3 in
vitro. The two Ser sites 262 and 356 (light blue) had available human
tau antibodies that detect those conserved sites in Drosophila.
** Shaded in red are likely GSK-3 sites and Abeta sites (212 and
214 for Abeta) that we had available antibodies for and tested in
Drosophila, but did not work since they are not conserved. ***Shaded
in yellow is an Abeta site (Ser 422) that is conserved in Drosophila,
which we had an antibody for; Ser 262 is also a likely Abeta site.
Found at: doi:10.1371/journal.pgen.1001087.s004 (0.03 MB
DOC)
Figure S5 Reduction in tau levels does not affect amyloid levels
of Arctic Ab42 flies. Protein levels of UAS-ArcAb42/+;elavGS
Tau EP3203/Tau Dfc to UAS-ArcAb42/+;elavGS Tau EP3203/
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TM6 flies flies on +RU486 SY medium, were measured by ELISA
at 21 days post-induction. Data are presented as the average
protein concentration, 6 standard error of mean, data were
compared using one-way ANOVA and student t-test, number of
independent tests (n) = 3. No significant difference was seen in the
levels of Ab42.
Found at: doi:10.1371/journal.pgen.1001087.s005 (0.08 MB
DOC)
Acknowledgments
We thank Dr. D. Crowther (University of Cambridge) for helpful
discussions and kind donation of UAS-Ab42 fly stocks, Dr. H. Tricoire
(CNRS, France) for kind donation of elavGS fly stocks, Dr. N. Lowe
(University of Cambridge) for the Drosophila tau antibody, Dr. M. Bourouis
(CNRS, France) for the pan-Sgg antibody, and Dr. J. Fitzgerald (Institute
of Neurology, UCL) for advice on using the phos-tag methods.
Author Contributions
Conceived and designed the experiments: OS FK IR SL LP. Performed
the experiments: OS FK IR RK HA CG MJA. Analyzed the data: OS FK
IR RK HA CG MJA. Contributed reagents/materials/analysis tools: OS
FK MJA. Wrote the paper: OS FK IR JH SL LP.
References
1. Spires TL, Hyman BT (2005) Transgenic models of Alzheimer’s disease:
learning from animals. NeuroRx 2: 423–437.
2. Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding
predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:
545–584.
3. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. (1998) Association
of missense and 59-splice-site mutations in tau with the inherited dementia
FTDP-17. Nature 393: 702–705.
4. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, et al. (1999) High
prevalence of mutations in the microtubule-associated protein tau in a
population study of frontotemporal dementia in the Netherlands. Am J Hum
Genet 64: 414–421.
5. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. (2001) Enhanced
neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Science 293: 1487–1491.
6. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta
immunotherapy leads to clearance of early, but not late, hyperphosphorylated
tau aggregates via the proteasome. Neuron 43: 321–332.
7. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, et al. (2007) Genetically
augmenting tau levels does not modulate the onset or progression of Abeta
pathology in transgenic mice. J Neurochem 102: 1053–1063.
8. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007)
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an
Alzheimer’s disease mouse model. Science 316: 750–754.
9. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, et al. (2008)
Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
Genes Brain Behav 7 Suppl 1: 57–66.
10. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, et al. (2006) Effects of endogenous
beta-amyloid overproduction on tau phosphorylation in cell culture.
J Neurochem 98: 1167–1175.
11. Forde JE, Dale TC (2007) Glycogen synthase kinase 3: a key regulator of cellular
fate. Cell Mol Life Sci 64: 1930–1944.
12. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates
production of Alzheimer’s disease amyloid-beta peptides. Nature 423: 435–439.
13. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, et al. (2006) A
chaperone-dependent GSK-3beta transitional intermediate mediates activation-
loop autophosphorylation. Mol Cell 24: 627–633.
14. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, et al. (2008)
Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.
Am J Pathol 172: 786–798.
15. Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by
competition for magnesium. Biochem Biophys Res Commun 280: 720–725.
16. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/
threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1
activity in neurons. Proc Natl Acad Sci U S A 96: 8745–8750.
17. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, et al. (2007)
Neuroprotective effects of regulators of the glycogen synthase kinase-3beta
signaling pathway in a transgenic model of Alzheimer’s disease are associated with
reduced amyloid precursor protein phosphorylation. J Neurosci 27: 1981–1991.
18. Noble W, Planel E, Zehr C, Olm V, Meyerson J, et al. (2005) Inhibition of
glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and
degeneration in vivo. Proc Natl Acad Sci U S A 102: 6990–6995.
19. Caccamo A, Oddo S, Tran LX, LaFerla FM (2007) Lithium reduces tau
phosphorylation but not A beta or working memory deficits in a transgenic
model with both plaques and tangles. Am J Pathol 170: 1669–1675.
20. Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, et al. (2004)
Learning and memory deficits upon TAU accumulation in Drosophila
mushroom body neurons. Learn Mem 11: 277–287.
21. Ubhi KK, Shaibah H, Newman TA, Shepherd D, Mudher A (2007) A
comparison of the neuronal dysfunction caused by Drosophila tau and human
tau in a Drosophila model of tauopathies. Invert Neurosci 7: 165–171.
22. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, et al. (2001)
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.
Science 293: 711–714.
23. Ruel L, Bourouis M, Heitzler P, Pantesco V, Simpson P (1993) Drosophila
shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and
act downstream of Notch. Nature 362: 557–560.
24. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, et al. (2002)
Human wild-type tau interacts with wingless pathway components and produces
neurofibrillary pathology in Drosophila. Neuron 34: 509–519.
25. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, et al. (2004) GSK-
3beta inhibition reverses axonal transport defects and behavioural phenotypes in
Drosophila. Mol Psychiatry 9: 522–530.
26. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M (2004) A model for studying
Alzheimer’s Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell
Neurosci 26: 365–375.
27. Crowther DC, Page R, Chandraratna D, Lomas DA (2006) A Drosophila model
of Alzheimer’s disease. Methods Enzymol 412: 234–255.
28. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, et al. (2004) Dissecting
the pathological effects of human Abeta40 and Abeta42 in Drosophila: a
potential model for Alzheimer’s disease. Proc Natl Acad Sci U S A 101:
6623–6628.
29. Rosen DR, Martin-Morris L, Luo LQ, White K (1989) A Drosophila gene
encoding a protein resembling the human beta-amyloid protein precursor. Proc
Natl Acad Sci U S A 86: 2478–2482.
30. Osterwalder T, Yoon KS, White BH, Keshishian H (2001) A conditional tissue-
specific transgene expression system using inducible GAL4. Proc Natl Acad
Sci U S A 98: 12596–12601.
31. McGuire SE, Mao Z, Davis RL (2004) Spatiotemporal gene expression targeting
with the TARGET and gene-switch systems in Drosophila. Sci STKE 2004: pl6.
32. Latouche M, Lasbleiz C, Martin E, Monnier V, Debeir T, et al. (2007) A
conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a
reversible adult phenotype suitable for identifying modifier genes. J Neurosci 27:
2483–2492.
33. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, et al. (2005)
Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a
Drosophila model of Alzheimer’s disease. Neuroscience 132: 123–135.
34. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG (2009)
Abeta aggregation and possible implications in Alzheimer’s disease pathogenesis.
J Cell Mol Med 13: 412–421.
35. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K,
et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by
enhanced Abeta protofibril formation. Nat Neurosci 4: 887–893.
36. Feany MB, Bender WW (2000) A Drosophila model of Parkinson’s disease.
Nature 404: 394–398.
37. Papadopoulou D, Bianchi MW, Bourouis M (2004) Functional studies of
shaggy/glycogen synthase kinase 3 phosphorylation sites in Drosophila
melanogaster. Mol Cell Biol 24: 4909–4919.
38. Bourouis M (2002) Targeted increase in shaggy activity levels blocks wingless
signaling. Genesis 34: 99–102.
39. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T (2006) Phosphate-
binding tag, a new tool to visualize phosphorylated proteins. Mol Cell
Proteomics 5: 749–757.
40. Oh H, Irvine KD (2008) In vivo regulation of Yorkie phosphorylation and
localization. Development 135: 1081–1088.
41. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, et al. (2007) Novel
phosphorylation sites in tau from Alzheimer brain support a role for casein
kinase 1 in disease pathogenesis. J Biol Chem 282: 23645–23654.
42. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the
therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:
112–119.
43. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary
tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:
1491–1495.
44. Perez M, Ribe E, Rubio A, Lim F, Moran MA, et al. (2005) Characterization of
a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and
aggregation. Neuroscience 130: 339–347.
GSK-3 Inhibition Ameliorates Ab Pathology
PLoS Genetics | www.plosgenetics.org 17 September 2010 | Volume 6 | Issue 9 | e1001087
45. Pennanen L, Gotz J (2005) Different tau epitopes define Abeta42-mediated tau
insolubility. Biochem Biophys Res Commun 337: 1097–1101.
46. Doerflinger H, Benton R, Shulman JM, St Johnston D (2003) The role of PAR-1
in regulating the polarised microtubule cytoskeleton in the Drosophila follicular
epithelium. Development 130: 3965–3975.
47. Su Y, Ryder J, Li B, Wu X, Fox N, et al. (2004) Lithium, a common drug for
bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
Biochemistry 43: 6899–6908.
48. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen
synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau:
generation of paired helical filament epitopes and neuronal localisation of the
kinase. Neurosci Lett 147: 58–62.
49. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, et al. (1992)
Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-
associated protein tau. FEBS Lett 314: 315–321.
50. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, et al. (1994)
Alzheimer’s disease-like phosphorylation of the microtubule-associated protein
tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4:
1077–1086.
51. Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, et al. (1997) Tau
phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta
transgenes. Neuroreport 8: 3251–3255.
52. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, et al. (2001)
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegener-
ation in GSK-3beta conditional transgenic mice. Embo J 20: 27–39.
53. McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer’s
disease in transgenic mice. Trends Genet 22: 281–289.
54. Magrane J, Rosen KM, Smith RC, Walsh K, Gouras GK, et al. (2005)
Intraneuronal beta-amyloid expression downregulates the Akt survival pathway
and blunts the stress response. J Neurosci 25: 10960–10969.
55. Folwell J, Cowan CM, Ubhi KK, Shiabh H, Newman TA, et al. Abeta
exacerbates the neuronal dysfunction caused by human tau expression in a
Drosophila model of Alzheimer’s disease. Exp Neurol 223: 401–409.
56. Joutel A, Tournier-Lasserve E (1998) Notch signalling pathway and human
diseases. Semin Cell Dev Biol 9: 619–625.
57. Dierick H, Bejsovec A (1999) Cellular mechanisms of wingless/Wnt signal
transduction. Curr Top Dev Biol 43: 153–190.
58. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E (1997) MARK,
a novel family of protein kinases that phosphorylate microtubule-associated
proteins and trigger microtubule disruption. Cell 89: 297–308.
59. Nishimura I, Yang Y, Lu B (2004) PAR-1 kinase plays an initiator role in a
temporally ordered phosphorylation process that confers tau toxicity in
Drosophila. Cell 116: 671–682.
60. Iijima K, Gatt A, Iijima-Ando K (2010) Tau Ser262 phosphorylation is critical
for A{beta}42-induced tau toxicity in a transgenic Drosophila model of
Alzheimer’s disease. Hum Mol Genet. epub ahead of print.
61. Gomez de Barreda E, Perez M, Gomez Ramos P, de Cristobal J, Martin-
Maestro P, et al. Tau-knockout mice show reduced GSK-3-induced hippocam-
pal degeneration and learning deficits. Neurobiol Dis 37: 622–629.
62. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, et al. (2001) Metabolic
regulation of brain Abeta by neprilysin. Science 292: 1550–1552.
63. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, et al. (2003) Insulin-
degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the
beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad
Sci U S A 100: 4162–4167.
64. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, et al. (2003)
Amyloid-beta peptide levels in brain are inversely correlated with insulysin
activity levels in vivo. Proc Natl Acad Sci U S A 100: 6221–6226.
65. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003)
Alzheimer’s disease beta-amyloid peptide is increased in mice deficient in
endothelin-converting enzyme. J Biol Chem 278: 2081–2084.
66. Melchor JP, Pawlak R, Strickland S (2003) The tissue plasminogen activator-
plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation
and inhibits Abeta-induced neurodegeneration. J Neurosci 23: 8867–8871.
67. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, et al. (2003) Enhanced
proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation,
secondary pathology, and premature death. Neuron 40: 1087–1093.
68. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, et al. (2004) Diet-induced insulin
resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s
disease. Faseb J 18: 902–904.
69. Killick R, Scales G, Leroy K, Causevic M, Hooper C, et al. (2009) Deletion of
Irs2 reduces amyloid deposition and rescues behavioural deficits in APP
transgenic mice. Biochem Biophys Res Commun 386: 257–262.
70. Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, et al. (2008)
Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-
induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction
in cAMP-responsive element-binding protein-mediated transcription, age-
dependent axon pathology, and premature death in Drosophila. J Biol Chem
283: 19066–19076.
71. Tsuda M, Kobayashi T, Matsuo T, Aigaki T Insulin-degrading enzyme
antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in
Drosophila. FEBS Lett.
72. He B, Meng YH, Mivechi NF (1998) Glycogen synthase kinase 3beta and
extracellular signal-regulated kinase inactivate heat shock transcription factor 1
by facilitating the disappearance of transcriptionally active granules after heat
shock. Mol Cell Biol 18: 6624–6633.
73. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing
activities protect against age-onset proteotoxicity. Science 313: 1604–1610.
74. Allen MJ, Godenschwege TA, Tanouye MA, Phelan P (2006) Making an escape:
development and function of the Drosophila giant fibre system. Semin Cell Dev
Biol 17: 31–41.
75. Rival T, Soustelle L, Strambi C, Besson MT, Iche M, et al. (2004) Decreasing
glutamate buffering capacity triggers oxidative stress and neuropil degeneration
in the Drosophila brain. Curr Biol 14: 599–605.
76. Ganetzky B, Flanagan JR (1978) On the relationship between senescence and
age-related changes in two wild-type strains of Drosophila melanogaster. Exp
Gerontol 13: 189–196.
77. Allen MJ, Shan X, Caruccio P, Froggett SJ, Moffat KG, et al. (1999) Targeted
expression of truncated glued disrupts giant fiber synapse formation in
Drosophila. J Neurosci 19: 9374–9384.
78. Tanouye MA, Wyman RJ (1980) Motor outputs of giant nerve fiber in
Drosophila. J Neurophysiol 44: 405–421.
79. Gorczyca M, Hall JC (1984) Identification of a cholinergic synapse in the giant
fiber pathway of Drosophila using conditional mutations of acetylcholine
synthesis. J Neurogenet 1: 289–313.
80. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, et al. (2003) Presenilin
redistribution associated with aberrant cholesterol transport enhances beta-
amyloid production in vivo. J Neurosci 23: 5645–5649.
GSK-3 Inhibition Ameliorates Ab Pathology
PLoS Genetics | www.plosgenetics.org 18 September 2010 | Volume 6 | Issue 9 | e1001087
